

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION Cumulative

Supplement 11

November 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION CUMULATIVE

**SUPPLEMENT 11
November 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 35th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543	16824	
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	
NUMBER OF APPLICANTS	927	935	957	975	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION; IV (INFUSION)
ACETAMINOPHEN

FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Oct NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL

>A> ALLZITAL

>A> LARKEN LABS INC 325MG; 25MG A203484 001 Dec 04, 2015 Nov NEWA

BUTALBITAL AND ACETAMINOPHEN

>A> AA LARKEN LABS INC 325MG; 50MG A203484 002 Dec 04, 2015 Nov NEWA

AA TEDOR PHARMA INC 325MG; 50MG A205120 001 Oct 30, 2015 Oct NEWA

BUTAPAP

AA + MIKART 325MG; 50MG A089987 001 Oct 26, 1992 Oct CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG; 50MG; 40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG; 50MG; 40MG; 30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG; 30MG A085868 001 Apr CAHN

AA 300MG; 60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG; 2.5MG A040846 001 Jun 09, 2010 Feb CTEC

@ SUN PHARM INDS LTD 325MG; 10MG A040826 001 Aug 16, 2007 Apr CAHN

NORCO

AA ACTAVIS LABS FL INC 325MG; 2.5MG A040148 004 Jul 07, 2014 Feb NEWA

AA 325MG; 5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

DIAMOX

AB + TEVA BRANDED PHARM 500MG N012945 001 Jun CAHN

TABLET; ORAL

ACETAZOLAMIDE

>D> @ MUTUAL PHARM 250MG A089753 001 Jun 22, 1988 Nov CAHN

>A> @ SUN PHARM INDS 250MG A089753 001 Jun 22, 1988 Nov CAHN

ACETOHEXAMIDE

TABLET; ORAL

ACETOHEXAMIDE

@ ANI PHARMS INC 250MG A070869 001 Feb 09, 1987 Jul CAHN

@ 500MG A070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Jun NEWA

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

AN ALVOGEN INC 10% A204674 001 Feb 11, 2014 Sep CAHN

AN 20% A203853 001 Jun 21, 2012 Sep CAHN

ACITRETINCAPSULE;ORAL
ACITRETIN

AB	MYLAN PHARMS INC	10MG	A202148	001	Sep 10, 2015	Aug NEWA
AB		17.5MG	A203707	001	Sep 10, 2015	Aug NEWA
AB		22.5MG	A203707	002	Sep 10, 2015	Aug NEWA
AB		25MG	A202148	002	Sep 10, 2015	Aug NEWA
AB	SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA
AB		17.5MG	A204633	002	May 22, 2015	May NEWA
AB		22.5MG	A204633	003	May 22, 2015	May NEWA
AB		25MG	A204633	004	May 22, 2015	May NEWA

ACLIDINIUM BROMIDEPOWDER, METERED;INHALATION
TUDORZA PRESSAIR

+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN
+		0.4MG/INH	N202450	001	Jul 23, 2012	Aug CPOT

ACYCLOVIRTABLET;ORAL
ACYCLOVIR

AB	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN
AB		800MG	A074980	002	Sep 30, 1998	Apr CAHN

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep NEWA
	EPIDUO					
AB	+ GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep CFTG
	EPIDUO FORTE					
	+ GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug CAHN
	+ GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul NEWA

ADENOSINEINJECTABLE;INJECTION
ADENOSINE

AP	EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Sep CAHN
	@ WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

ALBENDAZOLETABLET, CHEWABLE;ORAL
ALBENZA

+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun NEWA
---	-------------------	-------	---------	-----	--------------	----------

ALBUTEROL SULFATEPOWDER, METERED;INHALATION
PROAIR RESPICLICK

+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

SYRUP;ORAL

ALBUTEROL SULFATE

AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr CAHN
----	------------------	-----------------	---------	-----	--------------	----------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDEAEROSOL, METERED;INHALATION
COMBIVENT

@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May DISC
---	----------------------	--------------------------------	---------	-----	--------------	----------

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
ALFUZOSIN HYDROCHLORIDE

	@ WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb DISC
	UROXATRAL					
AB	+ CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

@ NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May DISC
@	EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May DISC
@	EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May DISC
@	EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

@ NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May DISC
@	EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May DISC
@	EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May DISC
@	EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May DISC
@	EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May DISC

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB	MYLAN PHARMS INC	EQ 6.25MG BASE	A205171	001	Nov 09, 2015	Oct NEWA
AB		EQ 12.5MG BASE	A205171	002	Nov 09, 2015	Oct NEWA
AB	TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun NEWA
AB		EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun NEWA
	AXERT					
AB	JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun CFTG
AB	+	EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB	ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr NEWA
AB		EQ 1MG BASE	A200652	002	May 04, 2015	Apr NEWA
	LOTRONEX					
AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr CFTG
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr CFTG

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

	@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul CAHN
	@	0.5MG	A074085	002	Feb 16, 1994	Jul CAHN
	@	1MG	A074085	003	Feb 16, 1994	Jul CAHN
	@	2MG	A074085	004	Feb 26, 1996	Jul CAHN
AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul NEWA
AB		0.5MG	A203346	002	Jul 31, 2015	Jul NEWA
AB		1MG	A203346	003	Jul 31, 2015	Jul NEWA
AB		2MG	A203346	004	Jul 31, 2015	Jul NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Sep CAHN
AB		1MG	A078489	002	Oct 17, 2008	Sep CAHN
AB		2MG	A078489	003	Oct 17, 2008	Sep CAHN
AB		3MG	A078489	004	Oct 17, 2008	Sep CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

AMANTADINE HYDROCHLORIDE

AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan CAHN
----	----------------------	-------	---------	-----	--------------	----------

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May CAHN
@ SILARX	50MG/5ML	A076352	001	Sep 10, 2004	Oct DISC
@ VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006	Oct DISC

AMIKACIN SULFATE

INJECTABLE;INJECTION
AMIKACIN SULFATE

>A>	AP	FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015	Nov	NEWA
>A>	AP		EQ 250MG BASE/ML	A205604	001	Dec 09, 2015	Nov	NEWA
		@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
		@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN

AMILORIDE HYDROCHLORIDE

TABLET;ORAL
AMILORIDE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA
----	--	----------------------	-----	---------	-----	--------------	-----	------

AMINO ACIDS

INJECTABLE;INJECTION
BRANCHAMIN 4% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC
---	-----------------	----------------	---------	-----	--------------	-----	------

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION
TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC
---	-----------------	--	---------	-----	--------------	-----	------

AMINOCAPROIC ACID

SYRUP;ORAL
AMINOCAPROIC ACID

AA		VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

TABLET;ORAL
AMINOCAPROIC

AB		VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL
AMITRIPTYLINE HYDROCHLORIDE

@	ANI PHARMS INC	10MG	A084910	003		Aug	CAHN
@		25MG	A085031	001		Aug	CAHN
@		50MG	A085032	001		Aug	CAHN
@		75MG	A085030	001		Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL
LIMBITROL

@	HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001		Jul	CAHN
---	---------------------	--------------------	---------	-----	--	-----	------

LIMBITROL DS

@	HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002		Jul	CAHN
---	---------------------	-------------------	---------	-----	--	-----	------

AMLODIPINE BESYLATE

TABLET;ORAL
AMLODIPINE BESYLATE

>A>	AB	ASCENT PHARMS INC	EQ 2.5MG BASE	A206367	001	Dec 10, 2015	Nov	NEWA
>A>	AB		EQ 5MG BASE	A206367	002	Dec 10, 2015	Nov	NEWA
>A>	AB		EQ 10MG BASE	A206367	003	Dec 10, 2015	Nov	NEWA
	AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011	Mar	CAHN
	AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Mar	CAHN
	AB	MYLAN PHARMS INC	EQ 2.5MG BASE	A078224	001	Feb 27, 2008	Sep	CAHN
	AB		EQ 5MG BASE	A078224	002	Feb 27, 2008	Sep	CAHN
	AB		EQ 10MG BASE	A078224	003	Feb 27, 2008	Sep	CAHN
	AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015	Jul	NEWA
	AB		EQ 5MG BASE	A204900	002	Jul 23, 2015	Jul	NEWA
	AB		EQ 10MG BASE	A204900	003	Jul 23, 2015	Jul	NEWA
	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007	Apr	CAHN
	AB		EQ 5MG BASE	A077974	002	Jul 09, 2007	Apr	CAHN
	AB		EQ 10MG BASE	A077974	003	Jul 09, 2007	Apr	CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015	May	NEWA
AB			5MG;25MG;160MG	A200797	002	Jun 03, 2015	May	NEWA
AB			10MG;12.5MG;160MG	A200797	003	Jun 03, 2015	May	NEWA

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015	May NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015	May NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015	May NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015	May NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015	May NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015	May NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015	May NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	May CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012	May CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	May CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012	May CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012	May CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 03, 2015	Sep CMS1
AB		5MG;12.5MG;160MG	A201593	001	Jun 04, 2015	May NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 03, 2015	Sep CMS1
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015	May NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 03, 2015	Sep CMS1
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015	May NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 03, 2015	Sep CMS1
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015	May NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 03, 2015	Sep CMS1
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015	May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015	Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015	Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	3D IMAGING DRUG	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203779	001	Oct 19, 2015	Oct NEWA
AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr NEWA
>D>	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Nov DISC
>A>	@	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Nov DISC
		3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun NEWA

INJECTABLE; INTRAVENOUS
AMMONIA N 13

AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan NEWA
AP	PETNET	30mCi-300mCi (3.75-37.5mCi/ML)	A204510	001	Nov 02, 2015	Oct NEWA
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr NEWA

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr CAHN

FOR SUSPENSION; ORAL
AMOXICILLIN

	@ SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr CAHN
	@	400MG/5ML	A065113	002	Nov 29, 2002	Apr CAHN

TABLET; ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr CAHN

TABLET, CHEWABLE; ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML; EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr CAHN
AB		400MG/5ML; EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr CAHN
AB		600MG/5ML; EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr CAHN

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

	@ SUN PHARM INDS LTD	500MG; EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr CAHN
AB		875MG; EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr CAHN

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG; EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr CAHN
AB		400MG; EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr CAHN

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE; ORAL

DYANAVAL XR

+	TRIS PHARMA INC	EQ 2.5MG BASE/ML	N208147	001	Oct 19, 2015	Oct NEWA
---	-----------------	------------------	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG; 1.875MG; 1.875MG; 1.875MG	A040444	005	Nov 03, 2014	May NEWA
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A040444	006	Nov 03, 2014	May NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A040444	007	Nov 03, 2014	May NEWA
>D> AB	MUTUAL PHARM	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040480	001	Sep 09, 2003	Nov CAHN
>D> AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A040480	002	Sep 09, 2003	Nov CAHN
>D> AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A040480	003	Sep 09, 2003	Nov CAHN
>D> AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A040480	004	Sep 09, 2003	Nov CAHN
>D> AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A040480	005	Sep 09, 2003	Nov CAHN
>D> AB		5MG; 5MG; 5MG; 5MG	A040480	006	Sep 09, 2003	Nov CAHN
>D> AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A040480	007	Sep 09, 2003	Nov CAHN
AB	MYLAN PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206721	001	Nov 10, 2015	Oct NEWA
AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A206721	002	Nov 10, 2015	Oct NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206721	003	Nov 10, 2015	Oct NEWA
AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A206721	004	Nov 10, 2015	Oct NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206721	005	Nov 10, 2015	Oct NEWA
AB		5MG; 5MG; 5MG; 5MG	A206721	006	Nov 10, 2015	Oct NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206721	007	Nov 10, 2015	Oct NEWA
>A> AB	SUN PHARM INDS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A040480	001	Sep 09, 2003	Nov CAHN
>A> AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A040480	002	Sep 09, 2003	Nov CAHN
>A> AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A040480	003	Sep 09, 2003	Nov CAHN

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003	Nov CAHN
>A>	AB	3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003	Nov CAHN
>A>	AB	5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003	Nov CAHN
>A>	AB	7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003	Nov CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Aug NEWA	
AP		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Aug NEWA	
AP		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Aug NEWA	
AP		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Aug NEWA	
AP		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Aug NEWA	
>A>	AP	SAGENT PHARMS	EQ 125MG BASE/VIAL	A090583	001	Nov 27, 2015	Nov NEWA
>A>	AP		EQ 250MG BASE/VIAL	A090583	002	Nov 27, 2015	Nov NEWA
>A>	AP		EQ 500MG BASE/VIAL	A090583	003	Nov 27, 2015	Nov NEWA
>A>	AP		EQ 1GM BASE/VIAL	A090583	004	Nov 27, 2015	Nov NEWA
>A>	AP		EQ 2GM BASE/VIAL	A090583	005	Nov 27, 2015	Nov NEWA
AP		EQ 10GM BASE/VIAL	A090581	001	Oct 20, 2015	Oct NEWA	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

>A>	AP	ANTIBIOTICS SA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A201406	001	Dec 07, 2015	Nov NEWA
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A201406	002	Dec 07, 2015	Nov NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

	@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN
--	--------------------	---------------------------	---------	-----	--	----------

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

	@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar CAHN
--	------------------------	-----	---------	-----	--------------	----------

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr CDFR	
AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug CTNA

INJECTABLE;IV (INFUSION)

ARGATROBAN

AP	FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar NEWA
----	--------------------	------------------------	---------	-----	--------------	----------

ARIPIRAZOLE

SOLUTION;ORAL

ARIPIRAZOLE

AA	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Aug NEWA
AA	APOTEX INC	1MG/ML	A204094	001	Sep 30, 2015	Sep NEWA
AA	SILARX PHARMS INC	1MG/ML	A204171	001	Aug 14, 2015	Aug NEWA

TABLET;ORAL

ABILIFY

AB	OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
AB	+	5MG	N021436	005	Nov 15, 2002	Apr CFTG
AB	+	10MG	N021436	001	Nov 15, 2002	Apr CFTG
AB		15MG	N021436	002	Nov 15, 2002	Apr CFTG
AB		20MG	N021436	003	Nov 15, 2002	Apr CFTG
AB		30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIRAZOLE

AB	ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
AB		5MG	A202101	002	Apr 28, 2015	Apr NEWA
AB		10MG	A202101	003	Apr 28, 2015	Apr NEWA

TABLET;ORAL

ARIPIPIRAZOLE

AB		15MG	A202101	004	Apr 28, 2015	Apr NEWA
AB		20MG	A202101	005	Apr 28, 2015	Apr NEWA
AB		30MG	A202101	006	Apr 28, 2015	Apr NEWA
AB	APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul NEWA
AB		5MG	A078583	002	Jul 24, 2015	Jul NEWA
AB		10MG	A078583	003	Jul 24, 2015	Jul NEWA
AB		15MG	A078583	004	Jul 24, 2015	Jul NEWA
AB		20MG	A078583	005	Jul 24, 2015	Jul NEWA
AB		30MG	A078583	006	Jul 24, 2015	Jul NEWA
AB	AUROBINDO PHARMA LTD	2MG	A203908	001	Oct 08, 2015	Sep NEWA
AB		5MG	A203908	002	Oct 08, 2015	Sep NEWA
AB		10MG	A203908	003	Oct 08, 2015	Sep NEWA
AB		15MG	A203908	004	Oct 08, 2015	Sep NEWA
AB		20MG	A203908	005	Oct 08, 2015	Sep NEWA
AB		30MG	A203908	006	Oct 08, 2015	Sep NEWA
AB	HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
AB		5MG	A205064	002	Apr 28, 2015	Apr NEWA
AB		10MG	A205064	003	Apr 28, 2015	Apr NEWA
AB		15MG	A205064	004	Apr 28, 2015	Apr NEWA
AB		20MG	A205064	005	Apr 28, 2015	Apr NEWA
AB		30MG	A205064	006	Apr 28, 2015	Apr NEWA
AB	TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
AB		5MG	A078607	002	Apr 28, 2015	Apr NEWA
AB		10MG	A078608	001	Apr 28, 2015	Apr NEWA
AB		15MG	A078708	001	Apr 28, 2015	Apr NEWA
AB		20MG	A078708	002	Apr 28, 2015	Apr NEWA
AB		30MG	A078708	003	Apr 28, 2015	Apr NEWA
AB	TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
AB		10MG	A201519	003	Apr 28, 2015	Apr NEWA
AB		5MG	A201519	002	Apr 28, 2015	Apr NEWA
AB		15MG	A201519	004	Apr 28, 2015	Apr NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr NEWA
AB		30MG	A201519	006	Apr 28, 2015	Apr NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

AB	+ OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr CFTG
AB		15MG	N021729	003	Jun 07, 2006	Apr CFTG
ARIPIPIRAZOLE						
AB	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr NEWA
AB		15MG	A202102	002	Apr 28, 2015	Apr NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015	Oct NEWA
		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015	Oct NEWA
+		882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015	Oct NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

@	IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
---	--------------	--	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

@	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug CTNA
---	----------------	---	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun CAHN

ASPIRINCAPSULE, EXTENDED RELEASE;ORAL
DURLAZA

+ NEW HAVEN PHARMS 162.5MG N200671 001 Sep 04, 2015 Sep NEWA

ASPIRIN; BUTALBITAL; CAFFEINECAPSULE;ORAL
FIORINAL

AA + ACTAVIS LABS UT INC 325MG;50MG;40MG N017534 005 Apr 16, 1986 Jan CAHN

TABLET;ORAL

FIORINAL

@ ACTAVIS LABS UT INC 325MG;50MG;40MG N017534 003 Apr 16, 1986 Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

AB COASTAL PHARMS 325MG;50MG;40MG;30MG A203335 001 Oct 30, 2015 Oct NEWA

FIORINAL W/CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N019429 003 Oct 26, 1990 Jan CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

+ SUN PHARM INDS 356.4MG;30MG;16MG N011483 004 Sep 06, 1983 Aug CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ 385MG;30MG;25MG A074654 001 Dec 31, 1996 Mar CTEC

+ 770MG;60MG;50MG A074654 002 Dec 31, 1996 Mar CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA ACTAVIS LABS FL INC 325MG;4.8355MG A090084 001 Mar 22, 2011 Mar CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+ BRISTOL MYERS SQUIBB EQ 300MG BASE;150MG N206353 001 Jan 29, 2015 Jan NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB ALVOGEN IPCO SARL 25MG A073646 001 Jul 31, 1992 Jul CAHN

AB 50MG A072303 001 Jul 15, 1988 Jul CAHN

AB 100MG A072304 001 Jul 15, 1988 Jul CAHN

@ DAVA PHARMS INC 25MG A074099 001 Apr 28, 1992 Jun DISC

>D> AB MUTUAL PHARM 25MG A074499 001 Jul 30, 1997 Nov CAHN

>D> AB 50MG A073475 001 Mar 30, 1993 Nov CAHN

>D> AB 100MG A073476 001 Mar 30, 1993 Nov CAHN

>A> AB SUN PHARM INDS 25MG A074499 001 Jul 30, 1997 Nov CAHN

>A> AB 50MG A073475 001 Mar 30, 1993 Nov CAHN

>A> AB 100MG A073476 001 Mar 30, 1993 Nov CAHN

TENORMIN

AB ALVOGEN IPCO SARL 25MG N018240 004 Apr 09, 1990 Feb CAHN

AB 50MG N018240 001 Feb CAHN

AB + 100MG N018240 002 Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB ALVOGEN IPCO SARL 50MG;25MG A072301 001 May 31, 1990 Jul CAHN

AB 100MG;25MG A072302 001 May 31, 1990 Jul CAHN

TENORETIC 100

AB + ALVOGEN IPCO SARL 100MG;25MG N018760 001 Jun 08, 1984 Feb CAHN

TENORETIC 50

AB ALVOGEN IPCO SARL 50MG;25MG N018760 002 Jun 08, 1984 Feb CAHN

TABLET;ORAL
AZITHROMYCIN

AB		EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA
----	--	---------------	---------	-----	--------------	----------

BALSALAZIDE DISODIUM

CAPSULE;ORAL
COLAZAL

AB	+	VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN
----	---	---------------------	-------	---------	-----	--------------	----------

TABLET;ORAL
BALSALAZIDE DISODIUM

AB		PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Aug NEWA
----	--	---------------	-------	---------	-----	--------------	----------

		GIAZO					
AB	+	VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
AB	+		1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB			10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB			20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB			40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB		SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB			10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB			20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB			40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
AB			10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
AB			20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
AB			20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL
BENZONATATE

AA		APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA			200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA		BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN
AA		CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
AA		STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
AA			200MG	A091133	002	Jul 30, 2015	Jul NEWA
AA		STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
AA			200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL
ACANYA

AB	+	DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG
		CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB		ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
AB		PERRIGO ISRAEL	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	Sep NEWA
		ONEXTON					
	+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL
ERYTHROMYCIN AND BENZOYL PEROXIDE

AB		LYNE	5%;3%	A065385	001	Sep 18, 2015	Sep NEWA
----	--	------	-------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL
BENZPHETAMINE HYDROCHLORIDE

>A>	AA	EPIC PHARMA LLC	50MG	A090346	001	Dec 15, 2015	Nov NEWA
	AA	+	KVK TECH	A090968	001	Jul 20, 2010	Jun CRLD
>A>	AA	TEDOR PHARM	25MG	A040747	002	Nov 20, 2015	Nov NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar	NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar	NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar	NEWA

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr	CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr	CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

+	LEO PHARMA AS	0.064%; 0.005%	N207589	001	Oct 16, 2015	Oct	NEWA
---	---------------	----------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION; TOPICAL

TACLONEX

>A>	+	LEO PHARMA AS	0.064%; 0.005%	N022185	002	Oct 29, 2015	Nov	NEWA
-----	---	---------------	----------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS LTD	EQ 0.05% BASE; 1%	A202894	001	Oct 30, 2015	Oct	NEWA
----	---------------------	-------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct	CAHN
----	------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar	CAHN
AA		10MG	A091256	002	May 04, 2010	Mar	CAHN
AA		25MG	A091256	003	May 04, 2010	Mar	CAHN
AA		50MG	A091256	004	May 04, 2010	Mar	CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb	CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb	CMFD

DUVOID

AA	WELLSPRING PHARM	10MG	A086262	001		Jan	CMFD
AA		25MG	A086263	001		May	CMFD
AA		50MG	A085882	003		May	CMFD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun	CMFD
	@	75MG	A203174	001	Aug 12, 2014	Jan	CAHN
AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun	CTEC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May	NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May	NEWA

BIMATOPROSTSOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BIPERIDEN HYDROCHLORIDETABLET;ORAL
AKINETON
@ ABBVIE

2MG

N012003 001

Aug DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

+ FOREST LABS LLC 140MG;125MG;125MG

N050786 001 Sep 28, 2006 Jul CAHN

BIVALIRUDININJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP	HOSPIRA INC	250MG/VIAL
AP		250MG/VIAL

A090811	001	Jul 14, 2015	Jun NEWA
A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATETABLET;ORAL
BOSULIF+ WYETH PHARMS INC EQ 100MG BASE
EQ 500MG BASE

N203341	001	Sep 04, 2012	Jun CRLD
N203341	002	Sep 04, 2012	Jun CRLD

BREXPIPIRAZOLETABLET;ORAL
REXULTI

OTSUKA PHARM CO LTD	0.25MG
	0.5MG
	1MG
	2MG
	3MG
+	4MG

N205422	001	Jul 10, 2015	Jul NEWA
N205422	002	Jul 10, 2015	Jul NEWA
N205422	003	Jul 10, 2015	Jul NEWA
N205422	004	Jul 10, 2015	Jul NEWA
N205422	005	Jul 10, 2015	Jul NEWA
N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMFENAC SODIUM

AT2	APOTEX INC	EQ 0.09% ACID
AT1	+ COASTAL PHARMS	EQ 0.09% ACID
AT2	HI-TECH PHARMACAL	EQ 0.09% ACID
AT1	PADDOCK LLC	EQ 0.09% ACID

A202620	001	Jun 23, 2014	May CTEC
A201211	001	May 11, 2011	May CRLD
A203395	001	Jan 22, 2014	May CTEC
A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDEAEROSOL, FOAM;RECTAL
UCERIS+ VALEANT PHARMS INTL 2MG/ACTUATION
SPRAY, METERED;NASAL
BUDESONIDE

APOTEX INC 0.032MG/INH

A078949 001 May 12, 2014 Mar CTEC

TABLET, EXTENDED RELEASE;ORAL
UCERIS

+ VALEANT PHARMS INTL 9MG

N203634 001 Jan 14, 2013 Aug CAHN

BUMETANIDEINJECTABLE;INJECTION
BUMETANIDE

AP	EUROHLTH INTL SARL	0.25MG/ML
----	--------------------	-----------

A079196 001 Apr 30, 2008 Jun CAHN

TABLET;ORAL
BUMEX

AB	VALIDUS PHARMS INC	0.5MG
AB		1MG
AB		2MG

N018225	002	Feb 28, 1983	Oct CMFD
N018225	001	Feb 28, 1983	Oct CMFD
N018225	003	Jun 14, 1985	Oct CMFD

BUPRENORPHINE HYDROCHLORIDEFILM;BUCCAL
BELBUCA

>A>	ENDO PHARMS INC	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Nov CPOT
>A>		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Nov CPOT
>A>		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Nov CPOT
>A>		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Nov CPOT
>A>		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Nov CPOT
>A>		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Nov CPOT
>A>	+	EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Nov CPOT
>D>		75MCG	N207932	001	Oct 23, 2015	Nov CPOT
		75MCG	N207932	001	Oct 23, 2015	Oct NEWA
>D>		150MCG	N207932	002	Oct 23, 2015	Nov CPOT
		150MCG	N207932	002	Oct 23, 2015	Oct NEWA
>D>		300MCG	N207932	003	Oct 23, 2015	Nov CPOT
		300MCG	N207932	003	Oct 23, 2015	Oct NEWA
>D>		450MCG	N207932	004	Oct 23, 2015	Nov CPOT
		450MCG	N207932	004	Oct 23, 2015	Oct NEWA
>D>		600MCG	N207932	005	Oct 23, 2015	Nov CPOT
		600MCG	N207932	005	Oct 23, 2015	Oct NEWA
>D>		750MCG	N207932	006	Oct 23, 2015	Nov CPOT
		750MCG	N207932	006	Oct 23, 2015	Oct NEWA
>D>		900MCG	N207932	007	Oct 23, 2015	Nov CPOT
		900MCG	N207932	007	Oct 23, 2015	Oct NEWA

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul NEWA
	TABLET;SUBLINGUAL					
	BUPRENORPHINE HYDROCHLORIDE					
AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

SUBOXONE

	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep CDFR
		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep CDFR
		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep CDFR
	+	EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep CDFR
	TABLET;SUBLINGUAL					
	BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE					
AB	ETHYPHARM USA CORP	EQ 2MG BASE;EQ 0.5MG BASE	A204431	001	Oct 16, 2015	Oct NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A204431	002	Oct 16, 2015	Oct NEWA
	ZUBSOLV					
	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
		348MG	N022108	002	Apr 23, 2008	Feb CAHN
	+	522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May NEWA
AB1		150MG	A202304	002	May 26, 2015	May NEWA
AB1		200MG	A202304	003	May 26, 2015	May NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar CAHN
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May DISC
	@	150MG	A201331	002	Aug 30, 2012	May DISC
	@	200MG	A201331	003	Aug 30, 2012	May DISC

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB	EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Sep NEWA
AB		10MG	A204582	002	Sep 18, 2015	Sep NEWA
AB		15MG	A204582	003	Sep 18, 2015	Sep NEWA
AB		30MG	A204582	004	Sep 18, 2015	Sep NEWA
>A> AB	ORION CORP ORION	5MG	A202087	001	Dec 16, 2015	Nov NEWA
>A> AB		10MG	A202087	002	Dec 16, 2015	Nov NEWA
>A> AB		15MG	A202087	003	Dec 16, 2015	Nov NEWA
>A> AB		30MG	A202087	004	Dec 16, 2015	Nov NEWA

BUTABARBITAL SODIUM

ELIXIR; ORAL

BUTISOL SODIUM

@ MEDA PHARMS

30MG/5ML

A085380 001

Jul DISC

TABLET; ORAL

BUTISOL SODIUM

@ MEDA PHARMS

50MG

N000793 003

May DISC

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

@ ELAN PHARMA INTL LTD

2%

N019881 001 Feb 07, 1997 May CTNA

GYNAZOLE-1

+ PERRIGO ISRAEL

2%

A200923 001 May 18, 2012 Jun CTNA

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

AP AUROBINDO PHARMA LTD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A205013 001 Sep 22, 2015 Sep NEWA

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB GLENMARK PHARMS LTD

0.005%

A205772 001 Jun 09, 2015 May NEWA

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMON

@ IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995 Mar CAHN

MIACALCIN

@ MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986 Aug CAHN

+

200 IU/ML

N017808 002 Mar 29, 1991 Aug CAHN

SPRAY, METERED; NASAL

MIACALCIN

AB + MYLAN IRELAND LTD

200 IU/SPRAY

N020313 002 Aug 17, 1995 Aug CAHN

CALCITRIOL

CAPSULE; ORAL

CALCITRIOL

AB BANNER LIFE SCIENCES

0.25MCG

A091174 001 May 24, 2013 Jan CAHN

AB

0.5MCG

A091174 002 May 24, 2013 Jan CAHN

AB

STRIDES PHARMA

0.25MCG

A091356 001 Dec 12, 2014 Jan CAHN

AB

0.5MCG

A091356 002 Dec 12, 2014 Jan CAHN

INJECTABLE; INJECTION

CALCIJEX

@ ABBVIE

0.001MG/ML

N018874 001 Sep 25, 1986 Jun DISC

@

0.002MG/ML

N018874 002 Sep 25, 1986 Jun DISC

CALCITRIOL

@ AKORN

0.002MG/ML

A078066 002 Jan 29, 2008 Jun DISC

@ FRESENIUS KABI USA

0.001MG/ML

A075836 001 Dec 31, 2002 Jun DISC

@

0.002MG/ML

A075836 002 Dec 31, 2002 Jun DISC

@ FRESENIUS MEDCL

0.001MG/ML

A075766 001 Feb 20, 2003 Jun DISC

@

0.002MG/ML

A075766 002 Feb 20, 2003 Jun DISC

@ LUITPOLD

0.001MG/ML

A075746 001 Sep 26, 2003 Jun DISC

@

0.002MG/ML

A075746 002 Sep 26, 2003 Jun DISC

@ SAGENT PHARMS

0.001MG/ML

A077102 001 Feb 08, 2006 Jun DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep CAHN
AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
AB	NOSTRUM LABS INC	EQ 169MG CALCIUM	A203179	001	Oct 26, 2015	Oct NEWA
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA

TABLET;ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep CAHN
AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct CAHN
---	-----------------	---	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

@	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct CAHN
---	-----------------	---	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct CAHN
---	-----------------	---	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT
---	--------------------	--	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct CAHN
-------------------	---	---------	-----	--------------	----------

@ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT
----------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct CAHN
-------------------	---	---------	-----	--------------	----------

+ GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT
----------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct CAHN
-------------------	--	---------	-----	--------------	----------

+ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT
----------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Oct CAHN
-------------------	--	---------	-----	--------------	----------

@ GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT
----------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct CAHN
-------------------	--	---------	-----	--------------	----------

@ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT
----------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct CAHN
-------------------	--	---------	-----	--------------	----------

+ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT
----------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct CAHN
-------------------	---	---------	-----	--------------	----------

+ GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT
----------------------	---	---------	-----	--------------	----------

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct CAHN
-------------------	---	---------	-----	--------------	----------

@ GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT
----------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3 .05GM/1000ML;0.314GM/1000ML;2.21GM /1000ML;6.95GM/1000ML;0.187GM/1000 ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA
---	---------------	---	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000M L;3.05GM/1000ML;0.314GM/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187 GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA
---	---------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.18 4MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/M L;0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC
---	------------------	---	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;11 9MG/100ML;161MG/100ML;94MG/100ML;1 38MG/100ML	N017390	001		Mar DISC
---	-----------------	--	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/1 00ML;640MG/100ML;496MG/100ML;89.6M G/100ML	N017438	001		Mar DISC
---	-----------------	---	---------	-----	--	----------

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1 000ML;2.21GM/1000ML;6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Oct CAHN
---	-----------------	---	---------	-----	--------------	----------

+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1 000ML;2.21GM/1000ML;6.95GM/1000ML; 0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Feb CAIN
---	---------------	---	---------	-----	--------------	----------

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314G M/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187	N207026	001	Jan 13, 2015	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314G M/1000ML ;3.09GM/1000ML;6.34GM/1000ML;0.187	N207026	001	Jan 13, 2015	Feb CAIN
---	---------------	--	---------	-----	--------------	----------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N019933	001	Aug 29, 1989	Sep DISC
---	-----------------	---	---------	-----	--------------	----------

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

	@ G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074462	001	Feb 13, 1996	Apr CAHN
	@	12.5MG	A074483	001	Feb 13, 1996	Jul CAHN
	@	12.5MG	A074590	004	Aug 30, 1996	Apr CAHN
	@	25MG	A074433	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074462	002	Feb 13, 1996	Apr CAHN
	@	25MG	A074483	002	Feb 13, 1996	Jul CAHN
	@	25MG	A074590	002	Aug 30, 1996	Apr CAHN
	@	50MG	A074433	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074462	003	Feb 13, 1996	Apr CAHN
	@	50MG	A074483	003	Feb 13, 1996	Jul CAHN
	@	50MG	A074590	001	Aug 30, 1996	Apr CAHN
	@	100MG	A074433	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr CAHN
	@	100MG	A074483	004	Feb 13, 1996	Jul CAHN
	@	100MG	A074590	003	Aug 30, 1996	Apr CAHN
AB	+ MYLAN	100MG	A074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

IMPAX LABS INC

		23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION; ENTERAL

DUOPA

	+ ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
--	--------------	-------------------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

FOREST RES INST INC

		EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep NEWA
		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep NEWA
		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep NEWA
		EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
>D> AA	MUTUAL PHARM	350MG	A089346	001	Oct 17, 1991	Nov CAHN
AB	SHASUN PHARMS LTD	250MG	A205513	001	Nov 12, 2015	Oct NEWA
AA		350MG	A205513	002	Nov 12, 2015	Oct NEWA
>A> AA	SUN PHARM INDS	350MG	A089346	001	Oct 17, 1991	Nov CAHN
	SOMA					
AB	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET; ORAL
CARVEDILOL

	@ HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep CAHN
	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug NEWA

CEFIXIME

FOR SUSPENSION; ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

	@ IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN

CEFOTAN IN PLASTIC CONTAINER

	@ IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
	@	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFOXITIN SODIUM

POWDER; IV (INFUSION)

CEFOXITIN IN PLASTIC CONTAINER

>A>	SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015	Nov NEWA
-----	--------------	---------------	---------	-----	--------------	----------

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET; ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIMEINJECTABLE; INJECTION
FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN
AP	+	IGI LABS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Oct CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Oct CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Oct CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Oct CAHN

CEFTAZIDIME SODIUMINJECTABLE; INJECTION
FORTAZ IN PLASTIC CONTAINER

	@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
+			EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
+			EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN
	@	IGI LABS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct CAHN
+			EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct CAHN
+			EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Oct CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUMPOWDER; IV (INFUSION)
ZERBAXA

+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN
---	-------------------	--------------------------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUMINJECTABLE; INJECTION
CEFTRIAXONE

AP		FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN
		INJECTABLE; INTRAMUSCULAR, INTRAVENOUS					
		CEFTRIAXONE					
	@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
	@	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFUROXIME AXETIL

AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET; ORAL

CEFUROXIME AXETIL

AB		ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUMINJECTABLE; INJECTION
CEFUROXIME SODIUM

AP		FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN

ZINACEF

AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN

ZINACEF IN PLASTIC CONTAINER

	@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
+			EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM

AB		FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIBCAPSULE;ORAL
CELECOXIB

AB	ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
AB		100MG	A204519	002	Aug 21, 2015	Aug NEWA
AB		200MG	A204519	003	Aug 21, 2015	Aug NEWA
AB		400MG	A204519	004	Aug 21, 2015	Aug NEWA
AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
AB		100MG	A204197	002	Jun 02, 2015	May NEWA
AB		200MG	A204197	003	Jun 02, 2015	May NEWA
AB	CIPLA LTD	50MG	A207446	001	Sep 23, 2015	Sep NEWA
AB		100MG	A207446	002	Sep 23, 2015	Sep NEWA
AB		200MG	A207446	003	Sep 23, 2015	Sep NEWA
AB		400MG	A207446	004	Sep 23, 2015	Sep NEWA
AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
AB		200MG	A202240	003	Jun 09, 2015	May NEWA
AB		400MG	A202240	004	Jun 09, 2015	May NEWA
AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB		EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN
	FOR SUSPENSION;ORAL					
	CEPHALEXIN					
	@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
Zyrtec

AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN
----	------------------------	---------	---------	-----	--------------	----------

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP	SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
----	---------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATETABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
SPRIASO LLC 8MG;54.3MG

N206323	001	Jun 22, 2015	Jun NEWA
---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATESOLUTION;ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
	VITUZ					
AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA
----	----------------	--------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREXSUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@ CYCLE PHARMS LTD 30MG/ML

A088157 001 Apr 27, 1983 Jun CAHN

@ 100MG/ML

A088158 001 Apr 27, 1983 Jun CAHN

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

+ EUROHLTH INTL SARL 25MG/ML

A083329 001 Feb CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ CYCLE PHARMS LTD 10MG

A085331 001 Jun CAHN

@ 25MG

A085331 002 Jun CAHN

@ 50MG

A085331 003 Jun CAHN

@ 100MG

A085331 004 Jun CAHN

@ 200MG

A085331 005 Jun CAHN

@ SANDOZ 10MG

A080439 001 May DISC

@ 25MG

A080439 002 May DISC

@ 50MG

A080439 003 May DISC

@ 100MG

A080439 004 May DISC

@ 200MG

A080439 005 May DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

@ G AND W LABS INC 50MG

A088651 001 May 30, 1985 Apr CAHN

>D> AB MUTUAL PHARM 50MG

A089286 001 Jul 21, 1986 Nov CAHN

AB 50MG

A089286 001 Jul 21, 1986 Mar CMFD

AB + MYLAN 50MG

A086831 001 Jun CTEC

>A> AB SUN PHARM INDS 50MG

A089286 001 Jul 21, 1986 Nov CAHN

THALITONE

@ CITRON PHARMA LLC 15MG

N019574 001 Dec 20, 1988 Jun DISC

CHLORZOXAZONE

TABLET; ORAL

PARAFON FORTE DSC

>D> AA + JANSSEN R AND D 500MG

N011529 002 Jun 15, 1987 Nov DISC

>A> @ 500MG

N011529 002 Jun 15, 1987 Nov DISC

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

@ ANI PHARMS INC EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996 Aug CAHN

@ EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996 Aug CAHN

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

ASKLEPION PHARMS LLC 50MG

N205750 001 Mar 17, 2015 Mar NEWA

+ 250MG

N205750 002 Mar 17, 2015 Mar NEWA

RTRX 50MG

N205750 001 Mar 17, 2015 Apr CAHN

+ 250MG

N205750 002 Mar 17, 2015 Apr CAHN

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

>A> AP GLOBAL ISOTOPES LLC 4-33.1mCi/ML

A206319 001 Nov 13, 2015 Nov NEWA

AP + MCPRF 4-33.1mCi/ML

N203155 001 Sep 12, 2012 Oct CFTG

AP UNIV TX MD ANDERSON 4-33.1mCi/ML

A205690 001 Oct 29, 2015 Oct NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB ACTAVIS ELIZABETH EQ 45MG FENOFIBRIC ACID

A200920 001 Oct 07, 2015 Sep NEWA

AB EQ 135MG FENOFIBRIC ACID

A200920 002 Oct 07, 2015 Sep NEWA

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

AT APOTEX INC 8%

A078172 001 Sep 18, 2007 Sep CMFD

CIDOFOVIRINJECTABLE;INJECTION
CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May CRLD
----	---	---------------------	-----------------	---------	-----	--------------	----------

CIMETIDINE HYDROCHLORIDESOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

		@ G AND W LABS INC	EQ 300MG BASE/5ML	A074176	001	Jun 01, 1994	Apr CAHN
--	--	--------------------	-------------------	---------	-----	--------------	----------

CIPROFLOXACININJECTABLE;INJECTION
CIPROFLOXACIN

AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A078062	001	Apr 29, 2008	Apr CAHN
----	--	----------------------	----------------------	---------	-----	--------------	----------

AP			400MG/40ML (10MG/ML)	A078062	002	Apr 29, 2008	Apr CAHN
----	--	--	----------------------	---------	-----	--------------	----------

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		CLARIS PHARMASERVICE	200MG/100ML	A078024	001	Mar 18, 2008	Apr CAHN
----	--	----------------------	-------------	---------	-----	--------------	----------

AP			400MG/200ML	A078024	002	Mar 18, 2008	Apr CAHN
----	--	--	-------------	---------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT		RISING PHARMS INC	EQ 0.3% BASE	A077689	001	Dec 13, 2006	Oct CAHN
----	--	-------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A075747	001	Jun 09, 2004	Apr CAHN
----	--	--------------------	---------------	---------	-----	--------------	----------

AB			EQ 500MG BASE	A075747	002	Jun 09, 2004	Apr CAHN
----	--	--	---------------	---------	-----	--------------	----------

AB			EQ 750MG BASE	A075747	003	Jun 09, 2004	Apr CAHN
----	--	--	---------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATEINJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203183	001	Feb 26, 2015	Feb NEWA
----	--	--------------------	----------------	---------	-----	--------------	----------

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A203182	001	Feb 26, 2015	Feb NEWA
----	--	--------------------	----------------	---------	-----	--------------	----------

AP			EQ 10MG BASE/ML	A203182	002	Feb 26, 2015	Feb NEWA
----	--	--	-----------------	---------	-----	--------------	----------

CISPLATININJECTABLE;INJECTION
CISPLATIN

AP		ACCORD HLTHCARE	1MG/ML	A206774	001	Aug 18, 2015	Aug NEWA
----	--	-----------------	--------	---------	-----	--------------	----------

CITALOPRAM HYDROBROMIDESOLUTION;ORAL
CITALOPRAM HYDROBROMIDE

>A>	AA	HETERO LABS LTD III	EQ 10MG BASE/5ML	A201450	001	Dec 15, 2015	Nov NEWA
-----	----	---------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr CAHN
----	--	------------------	--------------	---------	-----	--------------	----------

AB			EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr CAHN
----	--	--	--------------	---------	-----	--------------	----------

AB			EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr CAHN
----	--	--	--------------	---------	-----	--------------	----------

CLARITHROMYCINFOR SUSPENSION;ORAL
CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A065382	001	Aug 30, 2007	Apr CAHN
----	--	--------------------	-----------	---------	-----	--------------	----------

AB			250MG/5ML	A065382	002	Aug 30, 2007	Apr CAHN
----	--	--	-----------	---------	-----	--------------	----------

TABLET;ORAL

CLARITHROMYCIN

AB		HEC PHARM USA INC	250MG	A203584	001	Sep 28, 2015	Sep NEWA
----	--	-------------------	-------	---------	-----	--------------	----------

AB			500MG	A203584	002	Sep 28, 2015	Sep NEWA
----	--	--	-------	---------	-----	--------------	----------

AB		SUN PHARM INDS LTD	250MG	A065174	001	Sep 24, 2004	Apr CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

AB			500MG	A065174	002	Sep 24, 2004	Apr CAHN
----	--	--	-------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

AB		LUPIN LTD	500MG	A202532	001	Sep 15, 2015	Aug NEWA
----	--	-----------	-------	---------	-----	--------------	----------

AB	+	TEVA	500MG	A065154	001	May 18, 2005	Jan CRLD
----	---	------	-------	---------	-----	--------------	----------

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A062691	001	Dec 19, 1986	May DISC
@		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	001	Apr 01, 1985	May DISC
@		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
	TIMENTIN IN PLASTIC CONTAINER					
@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

@	ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul CAHN
---	----------------	--------	---------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	ALVOGEN INC	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep CAHN
AP		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep CAHN
AP		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep CAHN
	@ IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	@ BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan CAHN
AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun NEWA
	ZIANA					
AB	+ MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	+ FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May CRLD
	CORMAX					
AB1	+ HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun CRLD

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	+ FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May CRLD
----	------------------	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb CAHN
----	------------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar CMFD
>A> AT	NOVEL LABS INC	0.05%	A206075	001	Nov 23, 2015	Nov NEWA

CLOMIPHENE CITRATE

TABLET; ORAL

SEROPHENE

@	EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun DISC
---	------------	------	---------	-----	--------------	----------

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL
CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@ DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May DISC
	@	0.2MG	A071784	001	Apr 05, 1988	May DISC
	@	0.3MG	A071785	001	Apr 05, 1988	May DISC
>D> AB	MUTUAL PHARM	0.1MG	A070925	001	Sep 04, 1987	Nov CAHN
>D> AB		0.2MG	A070924	001	Sep 04, 1987	Nov CAHN
>D> AB		0.3MG	A070923	001	Sep 04, 1987	Nov CAHN
>A> AB	SUN PHARM INDS	0.1MG	A070925	001	Sep 04, 1987	Nov CAHN
>A> AB		0.2MG	A070924	001	Sep 04, 1987	Nov CAHN
>A> AB		0.3MG	A070923	001	Sep 04, 1987	Nov CAHN

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB2	ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May NEWA
AB1		0.1MG	A203320	001	May 15, 2015	May NEWA
	@	0.2MG	A202792	002	May 15, 2015	Aug DISC
AB2		0.2MG	A202792	002	May 15, 2015	May NEWA
	@	0.2MG	A203320	002	May 15, 2015	Aug DISC
AB1		0.2MG	A203320	002	May 15, 2015	May NEWA
	@ ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Aug DISC
AB2		0.1MG	A202983	001	Apr 02, 2014	May CTEC
	@	0.2MG	A202983	002	Apr 02, 2014	Aug DISC
AB2		0.2MG	A202983	002	Apr 02, 2014	May CTEC
	CLONIDINE HYDROCHLORIDE					
AB1	ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
	@	0.2MG	A202984	002	Sep 30, 2013	Aug DISC
AB1		0.2MG	A202984	002	Sep 30, 2013	May CTEC
	KAPVAY					
AB1 +	CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
AB1		0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
AB1 +		0.1MG	N022331	003	Sep 28, 2010	May CTEC
	@	0.2MG	N022331	004	Sep 28, 2010	Aug DISC
AB1 +		0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
AB1		0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

AB	SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
AB		7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
AB		15MG	A076911	003	Sep 29, 2004	Apr CAHN

CLOZAPINE

TABLET;ORAL

CLOZAPINE

>A> AB	ACCORD HLTHCARE	25MG	A202873	001	Nov 25, 2015	Nov NEWA
>A> AB		100MG	A202873	002	Nov 25, 2015	Nov NEWA
AB	ACTAVIS LABS FL INC	25MG	A203807	001	Sep 17, 2015	Sep NEWA
AB		100MG	A203807	002	Sep 17, 2015	Sep NEWA
	CLOZARIL					
AB	HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989	Aug CAHN
AB +		100MG	N019758	002	Sep 26, 1989	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

CLOZAPINE

>A> AB	BARR LABS INC	25MG	A090308	001	Nov 25, 2015	Nov NEWA
>A> AB		100MG	A090308	002	Nov 25, 2015	Nov NEWA
AB	MYLAN PHARMS INC	25MG	A201824	002	Sep 15, 2015	Aug NEWA
AB		100MG	A201824	003	Sep 15, 2015	Aug NEWA
>A> AB	TEVA PHARMS USA	150MG	A203039	001	Nov 25, 2015	Nov NEWA
>A> AB		200MG	A203039	002	Nov 25, 2015	Nov NEWA
	FAZACLO ODT					
AB	JAZZ PHARMS III	25MG	N021590	001	Feb 10, 2004	Aug CFTG
AB +		100MG	N021590	002	Feb 10, 2004	Aug CFTG

TABLET, ORALLY DISINTEGRATING;ORAL
FAZACLO ODT

>D>		150MG	N021590	005	Jul 09, 2010	Nov CTEC
>A>	AB	150MG	N021590	005	Jul 09, 2010	Nov CTEC
>D>		200MG	N021590	006	Jul 09, 2010	Nov CTEC
>A>	AB	200MG	N021590	006	Jul 09, 2010	Nov CTEC

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA
---	---------------	---------------------	---------	-----	--------------	----------

>A> COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

>A> TABLET;ORAL
>A> GENVOYA

>A>	+	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE	N207561	001	Nov 05, 2015	Nov NEWA
-----	---	---------------------	--------------------------------	---------	-----	--------------	----------

>A> COBIMETINIB FUMARATE

>A> TABLET;ORAL
>A> COTELLIC

>A>	+	GENENTECH INC	EQ 20MG BASE	N206192	001	Nov 10, 2015	Nov NEWA
-----	---	---------------	--------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

		PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE					
AA		AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	A200963	001	Aug 26, 2015	Aug NEWA

CODEINE SULFATE

SOLUTION;ORAL
CODEINE SULFATE
@ ROXANE

30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC
----------	---------	-----	--------------	----------

COLCHICINE

CAPSULE;ORAL
MITIGARE

HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN
-------------------	-------	---------	-----	--------------	----------

COLCHICINE; PROBENECID

TABLET;ORAL
PROBENECID AND COLCHICINE
@ ANI PHARMS INC

0.5MG;500MG	A083734	001		Aug CAHN
-------------	---------	-----	--	----------

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION
COLISTIMETHATE SODIUM

AP		XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA
----	--	-------------------	--------------------	---------	-----	--------------	----------

CORTICOTROPIN

INJECTABLE;INJECTION
H.P. ACTHAR GEL

@ MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Aug CAHN
+	80 UNITS/ML	N008372	008		Aug CAHN

CYANOCOBALAMIN

INJECTABLE;INJECTION
CYANOCOBALAMIN

>A>	AP	@ EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN
		GAVIS PHARMS LLC	1MG/ML	A206503	001	Dec 11, 2015	Nov NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET;ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>D>	AB	MUTUAL PHARM	5MG	A073541	002	Apr 06, 2006	Nov CAHN
>D>	AB		10MG	A073541	001	May 23, 1995	Nov CAHN
	AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
>A>	AB	SUN PHARM INDS	5MG	A073541	002	Apr 06, 2006	Nov CAHN
>A>	AB		10MG	A073541	001	May 23, 1995	Nov CAHN
	AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
	AB		7.5MG	A078722	002	May 12, 2008	Apr CAHN
	AB		10MG	A078722	003	May 12, 2008	Apr CAHN

CYCLOPENTOLATE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
CYCLOGYL

>D>	+	ALCON	0.5%	A084109	001		Nov	CFTG
>A>	AT	+	0.5%	A084109	001		Nov	CFTG
>A>		CYCLOPENTOLATE HYDROCHLORIDE						
>A>	AT	AKORN INC	0.5%	A205937	001	Dec 09, 2015	Nov	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		MIRROR PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Sep	NEWA
----	--	-------------------	-----	---------	-----	--------------	-----	------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

PRADAXA

>A>		BOEHRINGER INGELHEIM	EQ 110MG BASE	N022512	003	Nov 20, 2015	Nov	NEWA
-----	--	----------------------	---------------	---------	-----	--------------	-----	------

DABRAFENIB MESYLATE

CAPSULE;ORAL

TAFINLAR

		NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar	CAHN
	+		EQ 75MG BASE	N202806	002	May 29, 2013	Mar	CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET;ORAL

DAKLINZA

		BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul	NEWA
	+		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul	NEWA

DALTEPARIN SODIUM

INJECTABLE;INJECTION

FRAGMIN

@ PFIZER INC 7,500 IU/0.75ML

N020287 008 Apr 04, 2002 Jun CAHN

@ PHARMACIA AND UPJOHN 7,500 IU/0.75ML

N020287 008 Apr 04, 2002 Apr CAHN

INJECTABLE;SUBCUTANEOUS

FRAGMIN

		PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun	CAHN
			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun	CAHN
			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun	CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun	CAHN
			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun	CAHN
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun	CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun	CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun	CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun	CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun	CAHN
		PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr	CAHN
			5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr	CAHN
			7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr	CAHN
	@		10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr	CAHN
			10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr	CAHN
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr	CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr	CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr	CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr	CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr	CAHN

DANTROLENE SODIUM

CAPSULE;ORAL

DANTROLENE SODIUM

AB		ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May	CAHN
AB			50MG	A076686	002	Oct 24, 2005	May	CAHN
AB			100MG	A076686	003	Oct 24, 2005	May	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar	NEWA
AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar	NEWA

TABLET, EXTENDED RELEASE;ORAL							
ENABLEX							
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar	CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar	CFTG
<u>DASATINIB</u>							
TABLET;ORAL							
SPRYCEL							
+	BRISTOL MYERS SQUIBB	100MG	N021986	004	May 30, 2008	Sep	CRLD
		140MG	N021986	006	Oct 28, 2010	Sep	CRLD
<u>DECITABINE</u>							
INJECTABLE;INTRAVENOUS							
DACOGEN							
AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
<u>DEFERASIROX</u>							
TABLET;ORAL							
JADENU							
	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar	NEWA
		180MG	N206910	002	Mar 30, 2015	Mar	NEWA
+		360MG	N206910	003	Mar 30, 2015	Mar	NEWA
<u>DEFERIPRONE</u>							
SOLUTION;ORAL							
FERRIPROX							
+	APOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015	Sep	NEWA
<u>DEMECLOCYCLINE HYDROCHLORIDE</u>							
TABLET;ORAL							
DEMECLOCYCLINE HYDROCHLORIDE							
AB	EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug	NEWA
AB		300MG	A065447	002	Aug 18, 2015	Aug	NEWA
<u>DEOXYCHOLIC ACID</u>							
SOLUTION;SUBCUTANEOUS							
KYBELLA							
+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr	NEWA
<u>DESIPRAMINE HYDROCHLORIDE</u>							
TABLET;ORAL							
DESIPRAMINE HYDROCHLORIDE							
	ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Sep	CMS1
		50MG	A071803	003	Dec 08, 1987	Sep	CMS1
		75MG	A071803	004	Dec 08, 1987	Sep	CMS1
		150MG	A071803	005	May 29, 1997	Sep	CMS1
<u>DESIRUDIN RECOMBINANT</u>							
INJECTABLE;SUBCUTANEOUS							
IPRIVASK							
+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May	CAHN
<u>DESLORATADINE</u>							
SOLUTION;ORAL							
CLARINEX							
AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
DESLORATADINE							
AA	TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun	NEWA
<u>DESMOPRESSIN ACETATE</u>							
TABLET;ORAL							
DDAVP							
AB	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan	CAHN
AB	+	0.2MG	N019955	002	Sep 06, 1995	Jan	CAHN
DESMOPRESSIN ACETATE							
AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May	NEWA
AB		0.2MG	A201831	002	May 28, 2015	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOLTABLET; ORAL-28
BEKYREE

AB	LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul NEWA
	CYCLESSA					
AB	+ ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N021090	001	Dec 20, 2000	Aug CAHN
	ISIBLOOM					
AB	SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul NEWA
	KARIVA					
AB	+ BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr CTEC
	KIMIDESS					
AB	VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr NEWA

DESONIDECREAM; TOPICAL
DESONIDE

AB	TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May CMFD
----	-------------	-------	---------	-----	--------------	----------

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug NEWA
AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun NEWA

OINTMENT; TOPICAL
DESOXIMETASONE

AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr NEWA
----	------------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATETABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun NEWA
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun NEWA
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun NEWA
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun NEWA
	PRISTIQ					
AB	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun CFTG
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun CFTG

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Nov NEWA
	AP	BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep NEWA
		@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar CAHN
	AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATEOINTMENT; OPHTHALMIC
MAXITROL

AT	+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar CAHN
----	------------------	---------------------------------------	---------	-----	--	----------

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar CAHN
----	------------------	---------------------------------------	---------	-----	--	----------

DEXMEDETOMIDINE HYDROCHLORIDEINJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep NEWA
AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug NEWA
	PRECEDEX					
	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan NEWA

SOLUTION; IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

+	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Oct	NEWA
		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Oct	NEWA

DESMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug	NEWA
AB		10MG	A204266	002	Aug 25, 2015	Aug	NEWA
AB		15MG	A204266	003	Aug 25, 2015	Aug	NEWA
AB		40MG	A204266	007	Aug 25, 2015	Aug	NEWA
AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul	NEWA
AB		10MG	A079108	002	Aug 05, 2015	Jul	NEWA

TABLET; ORAL

DESMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	ABHAI INC	2.5MG	A206931	001	Dec 04, 2015	Nov	NEWA
>A>	AB		5MG	A206931	002	Dec 04, 2015	Nov	NEWA
>A>	AB		10MG	A206931	003	Dec 04, 2015	Nov	NEWA
>A>	AB	NOVEL LABS INC	2.5MG	A204534	001	Dec 04, 2015	Nov	NEWA
>A>	AB		5MG	A204534	002	Dec 04, 2015	Nov	NEWA
>A>	AB		10MG	A204534	003	Dec 04, 2015	Nov	NEWA
	AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep	NEWA
	AB		5MG	A201231	002	Sep 24, 2015	Sep	NEWA
	AB		10MG	A201231	003	Sep 24, 2015	Sep	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

>A>	AA	AVANTHI INC	5MG	A203548	001	Nov 23, 2015	Nov	NEWA
>A>	AA		10MG	A203548	002	Nov 23, 2015	Nov	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

>D>		@ G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Nov	CMFD
>A>	AA		15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Nov	CMFD
		@	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	May	CAHN

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50% IN PLASTIC CONTAINER

>D>	AP	+	HOSPIRA	50GM/100ML	N019894	001	Dec 26, 1989	Nov	DISC
>A>		@		50GM/100ML	N019894	001	Dec 26, 1989	Nov	DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 36 8MG/100ML; 526MG/100ML; 502MG/100ML	N017451	001		Mar	DISC
--	---	-----------------	---	---------	-----	--	-----	------

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP	+	LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Feb	CAHN
----	---	------------------	----------	---------	-----	--------------	-----	------

SOLUTION; ORAL, RECTAL

MD-GASTROVIEW

AA		LIEBEL-FLARSHEIM	66%; 10%	A087388	001		Jan	CAHN
----	--	------------------	----------	---------	-----	--	-----	------

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

	TARO	50MG	N011366	002	Aug 07, 2015	Aug	NEWA
--	------	------	---------	-----	--------------	-----	------

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

>A>	AB	ACTAVIS MID ATLANTIC	3%	A206493	001	Dec 02, 2015	Nov	NEWA
		VOLTAREN						
	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug	CAHN
		SOLUTION;TOPICAL						
		DICLOFENAC SODIUM						
	AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun	NEWA
	AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug	NEWA
>A>	AT	NOVEL LABS INC	1.5%	A205878	001	Dec 09, 2015	Nov	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		DICLOFENAC SODIUM						
>A>	AT	ALTAIRE PHARMS INC	0.1%	A203383	001	Nov 16, 2015	Nov	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		DICLOFENAC SODIUM						
	AB	VPNA	100MG	A075492	001	Feb 11, 2000	Oct	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		TENUATE DOSPAN						
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN
		TABLET;ORAL						
		DIGOXIN						
AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
AB			0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD
		LANOXIN						
		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
AB			0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
AB	+		0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
	@		0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
	@		0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILT-CD

@ APOTEX

@

@

@

DILTIAZEM HYDROCHLORIDE

			120MG	A076151	001	May 20, 2004	Oct	DISC
			180MG	A076151	002	May 20, 2004	Oct	DISC
			240MG	A076151	003	May 20, 2004	Oct	DISC
			300MG	A076151	004	May 20, 2004	Oct	DISC
AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD
		TIAZAC						
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE; INJECTION									
DILTIAZEM HYDROCHLORIDE									
AP	EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008		Jun	CAHN	
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
DIPHENHYDRAMINE HYDROCHLORIDE									
AP	+ EUROHLTH INTL SARL	50MG/ML	A080817	002			Jun	CAHN	
<u>DIPYRIDAMOLE</u>									
INJECTABLE; INJECTION									
DIPYRIDAMOLE									
AP	EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996		Jun	CAHN	
<u>DISULFIRAM</u>									
TABLET; ORAL									
DISULFIRAM									
AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015		Feb	NEWA	
AB		500MG	A203916	002	Mar 04, 2015		Feb	NEWA	
<u>DIVALPROEX SODIUM</u>									
TABLET, EXTENDED RELEASE; ORAL									
DIVALPROEX SODIUM									
AB	AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015		May	NEWA	
AB		EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015		May	NEWA	
	@ G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009		Jul	CAHN	
<u>DOBUTAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
DOBUTAMINE HYDROCHLORIDE									
	@ IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995		Mar	CAHN	
<u>DOCETAXEL</u>									
INJECTABLE; INJECTION									
DOCETAXEL									
AP	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015		Aug	NEWA	
AP		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015		Aug	NEWA	
<u>DONEPEZIL HYDROCHLORIDE</u>									
TABLET; ORAL									
DONEPEZIL HYDROCHLORIDE									
AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015		Jan	NEWA	
AB		10MG	A203034	002	Jan 30, 2015		Jan	NEWA	
AB	LUPIN LTD	23MG	A202782	001	Oct 30, 2015		Oct	NEWA	
AB	MYLAN PHARMS INC	23MG	A202656	001	Oct 22, 2015		Oct	NEWA	
AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010		Apr	CAHN	
AB		10MG	A076786	002	Nov 26, 2010		Apr	CAHN	
AB		23MG	A204293	001	Jun 05, 2015		May	NEWA	
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
NAMZARIC									
	FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014		Mar	CAHN	
	+	10MG; 28MG	N206439	002	Dec 23, 2014		Mar	CAHN	
<u>DOPAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
DOPAMINE HYDROCHLORIDE									
	@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985		Mar	CAHN	
	@	40MG/ML	N018656	001	Jun 28, 1983		Mar	CAHN	
	@	80MG/ML	A070089	001	Oct 23, 1985		Mar	CAHN	
	@	80MG/ML	A070090	001	Oct 23, 1985		Mar	CAHN	
	@	80MG/ML	A070091	001	Oct 23, 1985		Mar	CAHN	
	@	160MG/ML	A070092	001	Oct 23, 1985		Mar	CAHN	
	@	160MG/ML	A070093	001	Oct 23, 1985		Mar	CAHN	
	@	160MG/ML	A070094	001	Oct 23, 1985		Mar	CAHN	

DOXAPRAM HYDROCHLORIDEINJECTABLE; INJECTION
DOPRAM

AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

DOXEPIN HYDROCHLORIDECAPSULE; ORAL
DOXEPIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM; TOPICAL
ZONALON

	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN
--	---	-------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROLINJECTABLE; INJECTION
DOXERCALCIFEROL

AP		AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
----	--	-----------	--------------------	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

>D>	AP		ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Nov	CRLD
>A>	AP	+		2MG/ML	A203622	001	Jun 27, 2014	Nov	CRLD
>A>	AP	+		200MG/100ML	A203622	002	Jun 27, 2014	Nov	NEWA
>D>	AP	+	EUROHLTH INTL SARL	2MG/ML	A062975	001	Mar 17, 1989	Nov	CRLD
>A>	AP			2MG/ML	A062975	001	Mar 17, 1989	Nov	CRLD
>D>	AP	+		200MG/100ML	A064097	001	Sep 13, 1994	Nov	CRLD
>A>	AP			200MG/100ML	A064097	001	Sep 13, 1994	Nov	CRLD
	AP	+	PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	Oct	CMFD
		@		2MG/ML	N050629	001	Dec 23, 1987	Oct	CTNA
		@		10MG/VIAL	N050467	001		Oct	CTNA
		@		20MG/VIAL	N050467	003	May 20, 1985	Oct	CTNA
		@		50MG/VIAL	N050467	002		Oct	CTNA
		@		150MG/VIAL	N050467	004	Jul 22, 1987	Oct	CTNA
				150MG/75ML	N050629	003	Mar 28, 2011	Oct	NEWA
	AP	+		200MG/100ML	N050629	002	May 03, 1988	Oct	CMFD
		@		200MG/100ML	N050629	002	May 03, 1988	Oct	CTNA

DOXYCYCLINECAPSULE; ORAL
DOXYCYCLINE

AB		NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB			EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB			EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB			EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB			EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET; ORAL
DOXYCYCLINE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB			EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB			EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN

DOXYCYCLINE HYCLATEINJECTABLE; INJECTION
DOXYCYCLINE

	@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
	@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN

DRONABINOLCAPSULE; ORAL
DRONABINOL

>D>	AB		INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011	Nov	DISC
>A>		@		2.5MG	A078501	001	Aug 19, 2011	Nov	DISC
>D>	AB			5MG	A078501	002	Aug 19, 2011	Nov	DISC
>A>		@		5MG	A078501	002	Aug 19, 2011	Nov	DISC
>D>	AB			10MG	A078501	003	Aug 19, 2011	Nov	DISC
>A>		@		10MG	A078501	003	Aug 19, 2011	Nov	DISC

DROPERIDOLINJECTABLE; INJECTION
DROPERIDOL

@ IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
@	2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
@	2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug NEWA
AB	JAI PHARMA LTD	3MG;0.02MG	A202594	001	Oct 22, 2015	Oct NEWA

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS; ORAL
DULOXETINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug NEWA
AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug NEWA
AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug NEWA
AB	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Oct NEWA
AB		EQ 30MG BASE	A090780	002	Oct 28, 2015	Oct NEWA
AB		EQ 60MG BASE	A090780	003	Oct 28, 2015	Oct NEWA
AB	INVENTIA HLTHCARE	EQ 20MG BASE	A202336	001	Oct 28, 2015	Oct NEWA
AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Oct NEWA
AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Oct NEWA

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

>A> AB	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Nov NEWA
>A> AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	Nov NEWA
>A> AB	APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Nov NEWA
>A> AB	BANNER PHARMACAPS	0.5MG	A200899	001	Nov 20, 2015	Nov NEWA
>A> AB	BRECKENRIDGE PHARM	0.5MG	A204705	001	Nov 20, 2015	Nov NEWA
>A> AB	RISING PHARMS INC	0.5MG	A202530	001	Nov 20, 2015	Nov NEWA
>A> AB	ROXANE	0.5MG	A202204	001	Nov 23, 2015	Nov NEWA
>A> AB	SANDOZ INC	0.5MG	A202660	001	Nov 20, 2015	Nov NEWA
>A> AB	STRIDES ARCOLAB LTD	0.5MG	A204262	001	Nov 20, 2015	Nov NEWA
>A> AB	VINTAGE PHARMS LLC	0.5MG	A202421	001	Nov 20, 2015	Nov NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

>A> AB	ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975	001	Nov 20, 2015	Nov NEWA
--------	---------------------	-------------	---------	-----	--------------	----------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

DAIICHI SANKYO

	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
	EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
+	EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

+ MYLAN INSTITUTIONAL 10MG/ML

A088873	001	Aug 06, 1985	Mar CRLD
---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+ NOVARTIS PHARMS CORP EQ 25MG ACID/PACKET

N207027	001	Aug 24, 2015	Aug NEWA
---------	-----	--------------	----------

TABLET; ORAL

PROMACTA

NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
	EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN

TABLET; ORAL						
PROMACTA						
	EQ 50MG ACID		N022291	002	Nov 20, 2008	May CRLD
+	EQ 50MG ACID		N022291	002	Nov 20, 2008	Mar CAHN
+	EQ 75MG ACID		N022291	003	Sep 08, 2009	May CRLD
	EQ 75MG ACID		N022291	003	Sep 08, 2009	Mar CAHN
+	EQ 100MG ACID		N022291	005	Nov 16, 2012	May CRLD
	EQ 100MG ACID		N022291	005	Nov 16, 2012	Mar CAHN
<u>ELUXADOLINE</u>						
TABLET; ORAL						
VIBERZI						
	FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
+		100MG	N206940	002	May 27, 2015	Jul CAHN
	FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
+		100MG	N206940	002	May 27, 2015	May NEWA
<u>EMPAGLIFLOZIN; LINAGLIPTIN</u>						
TABLET; ORAL						
GLYXAMBI						
	BOEHRINGER INGELHEIM	10MG; 5MG	N206073	001	Jan 30, 2015	Jan NEWA
+		25MG; 5MG	N206073	002	Jan 30, 2015	Jan NEWA
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE</u>						
TABLET; ORAL						
SYNJARDY						
	BOEHRINGER INGELHEIM	5MG; 500MG	N206111	001	Aug 26, 2015	Aug NEWA
		5MG; 1GM	N206111	002	Aug 26, 2015	Aug NEWA
		12.5MG; 500MG	N206111	003	Aug 26, 2015	Aug NEWA
+		12.5MG; 1GM	N206111	004	Aug 26, 2015	Aug NEWA
<u>ENALAPRIL MALEATE</u>						
TABLET; ORAL						
ENALAPRIL MALEATE						
AB	SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB		5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB		10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB		20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@ SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@	5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@	10MG	A075556	003	Aug 22, 2000	Apr CAHN
	@	20MG	A075556	004	Aug 22, 2000	Apr CAHN
VASOTEC						
AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
AB		5MG	N018998	001	Dec 24, 1985	Apr CAHN
AB		10MG	N018998	002	Dec 24, 1985	Apr CAHN
AB	+	20MG	N018998	003	Dec 24, 1985	Apr CAHN
<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>						
TABLET; ORAL						
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE						
AB	G AND W LABS INC	5MG; 12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
AB		10MG; 25MG	A075727	002	Sep 18, 2001	Apr CAHN
<u>ENTACAPONE</u>						
TABLET; ORAL						
ENTACAPONE						
AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA
<u>ENTECAVIR</u>						
TABLET; ORAL						
ENTECAVIR						
AB	AMNEAL PHARMS	0.5MG	A206652	001	Nov 12, 2015	Oct NEWA
AB		1MG	A206652	002	Nov 12, 2015	Oct NEWA
AB	AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015	Aug NEWA
AB		1MG	A206217	002	Aug 26, 2015	Aug NEWA
AB	HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015	Aug NEWA
AB		1MG	A205740	002	Aug 21, 2015	Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

+ PAR STERILE PRODUCTS EQ 1MG BASE/ML (EQ 1MG BASE/ML) N204200 001 Dec 07, 2012 Jul CAIN
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

+ PAR STERILE PRODUCTS EQ 30MG BASE/30ML (EQ 1MG BASE/ML) N204640 001 Dec 18, 2013 Jul CAIN

EPINEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION), INTRAOCULAR
EPINEPHRINE

BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 Oct CDFR

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@ EUROHLTH INTL SARL 0.01MG/ML;1% A080406 001 Sep CAHN
@ 0.01MG/ML;2% A080406 002 Sep CAHN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
TEVETEN HCT

@ ABBVIE 600MG;12.5MG N021268 001 Nov 01, 2001 Jun DISC
@ 600MG;25MG N021268 002 Nov 01, 2001 Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

>A> AP AUROBINDO PHARMA LTD 2MG/ML A206127 001 Dec 08, 2015 Nov NEWA
>A> AP 75MG/100ML A206127 002 Dec 08, 2015 Nov NEWA
AP TEVA PHARMS USA 2MG/ML A090854 001 Jun 12, 2015 Jun NEWA
AP 75MG/100ML A091555 001 Jun 05, 2015 May NEWA
INTEGRILIN
AP + SCHERING 2MG/ML N020718 001 May 18, 1998 Jun CTEC
AP + 75MG/100ML N020718 002 May 18, 1998 May CFTG

ERGOALCICIFEROL

CAPSULE;ORAL
VITAMIN D

AA BANNER LIFE SCIENCES 50,000 IU A080704 001 Jan CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOSTAT

@ WATSON LABS INC 2MG A088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

@ MYLAN PHARMS INC EQ 25MG BASE A091002 001 Jun 11, 2014 Sep DISC
@ EQ 100MG BASE A091002 002 Jun 11, 2014 Sep DISC
@ EQ 150MG BASE A091002 003 Jun 11, 2014 Sep DISC
@ TEVA PHARMS USA EQ 100MG BASE A091059 002 Aug 28, 2015 Oct DISC
AB EQ 100MG BASE A091059 002 Aug 28, 2015 Aug NEWA
@ EQ 150MG BASE A091059 003 Aug 28, 2015 Oct DISC
AB EQ 150MG BASE A091059 003 Aug 28, 2015 Aug NEWA
TARCEVA
OSI PHARMS EQ 25MG BASE N021743 001 Nov 18, 2004 Sep CTEC
EQ 100MG BASE N021743 002 Nov 18, 2004 Oct CTEC
+ EQ 150MG BASE N021743 003 Nov 18, 2004 Oct CTEC

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL
ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC EQ 125MG BASE/5ML A062169 001 Oct 17, 1990 Apr CAHN
@ EQ 250MG BASE/5ML A062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ANI PHARMS INC

EQ 200MG BASE/5ML

A062055 001

Jul CAHN

SUSPENSION;ORAL

>D> E.E.S. 200

>D> AB ARBOR PHARMS LLC

EQ 200MG BASE/5ML

A061639 001

Nov DISC

>A> @

EQ 200MG BASE/5ML

A061639 001

Nov DISC

>D> E.E.S. 400

>D> AB + ARBOR PHARMS LLC

EQ 400MG BASE/5ML

A061639 002

Nov DISC

>A> @

EQ 400MG BASE/5ML

A061639 002

Nov DISC

>D> PEDIAMYCIN

>D> AB ARBOR PHARMS LLC

EQ 200MG BASE/5ML

A062304 001

Nov DISC

>A> @

EQ 200MG BASE/5ML

A062304 001

Nov DISC

>D> PEDIAMYCIN 400

>D> AB ARBOR PHARMS LLC

EQ 400MG BASE/5ML

A062304 002

Nov DISC

>A> @

EQ 400MG BASE/5ML

A062304 002

Nov DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015

May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015

Apr NEWA

AB

EQ 10MG BASE

A077550 002 May 14, 2015

Apr NEWA

AB

EQ 20MG BASE

A077550 003 May 14, 2015

Apr NEWA

AB PRINSTON INC

EQ 5MG BASE

A078032 001 Aug 28, 2015

Aug NEWA

AB

EQ 10MG BASE

A078032 002 Aug 28, 2015

Aug NEWA

AB

EQ 20MG BASE

A078032 003 Aug 28, 2015

Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP AUROBINDO PHARMA LTD

10MG/ML

A205520 001 Jul 23, 2015

Jul NEWA

AP LUITPOLD

10MG/ML

A201126 001 Feb 20, 2015

Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB DR REDDYS LABS LTD

EQ 20MG BASE

A078279 001 Sep 25, 2015

Sep NEWA

AB

EQ 40MG BASE

A078279 002 Sep 25, 2015

Sep NEWA

AB HETERO LABS LTD III

EQ 20MG BASE

A202784 001 Sep 21, 2015

Sep NEWA

AB

EQ 40MG BASE

A202784 002 Sep 21, 2015

Sep NEWA

AB IVAX SUB TEVA PHARMS

EQ 20MG BASE

A078003 001 Jan 26, 2015

Jan NEWA

AB

EQ 40MG BASE

A078003 002 Jan 26, 2015

Jan NEWA

AB MYLAN LABS LTD

EQ 20MG BASE

A078936 001 Aug 02, 2015

Jul NEWA

AB

EQ 40MG BASE

A078936 002 Aug 03, 2015

Jul NEWA

AB MYLAN PHARMS INC

EQ 20MG BASE

A078936 001 Aug 02, 2015

Sep CAHN

AB

EQ 40MG BASE

A078936 002 Aug 03, 2015

Sep CAHN

AB TORRENT PHARMS LTD

EQ 20MG BASE

A203636 001 Oct 19, 2015

Oct NEWA

AB

EQ 40MG BASE

A203636 002 Oct 19, 2015

Oct NEWA

NEXIUM

AB ASTRAZENECA PHARMS

EQ 20MG BASE

N021153 001 Feb 20, 2001

Jan CFTG

AB +

EQ 40MG BASE

N021153 002 Feb 20, 2001

Jan CFTG

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

ESOMEPRAZOLE SODIUM

AP ACCORD HLTHCARE

EQ 40MG BASE/VIAL

A205379 001 Sep 25, 2015

Sep NEWA

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

HANMI PHARM CO LTD

24.65MG

N202342 001 Aug 06, 2013

Aug CPOT

+

49.3MG

N202342 002 Aug 06, 2013

Aug CPOT

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN

MINIVELLE

NOVEN

0.025MG/24HR

N203752 005 Sep 23, 2014 Jan NEWA

TABLET;ORAL

ESTRADIOL

@ EPIC PHARMA INC

0.5MG

A040275 001 Dec 29, 1998 Oct CAHN

@

1MG

A040275 002 Dec 29, 1998 Oct CAHN

@

2MG

A040275 003 Dec 29, 1998 Oct CAHN

TABLET;VAGINAL

ESTRADIOL

@ AMNEAL PHARMS

10MCG

A205256 001 May 29, 2015 May DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECIN

AP	+ ATON	EQ 50MG BASE/VIAL	N016093	001		Jul CFTG
----	--------	-------------------	---------	-----	--	----------

ETHACRYNATE SODIUM

AP	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul NEWA
----	----------------------	-------------------	---------	-----	--------------	----------

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb NEWA
----	-------------------	--------------------------	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar NEWA
----	-------------------	---------------	---------	-----	--------------	----------

AB	GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun NEWA
----	---------------------	---------------	---------	-----	--------------	----------

>A> AB	HAUPT PHARMA	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Nov NEWA
--------	--------------	---------------	---------	-----	--------------	----------

AB	+ WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar CTEC
----	---------------	---------------	---------	-----	--------------	----------

TABLET;ORAL-28

>A> ELIFEMME

>A> AB	SANDOZ INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Nov NEWA
--------	------------	---	---------	-----	--------------	----------

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A> AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Nov NEWA
--------	-----------	---	---------	-----	--------------	----------

LEVORA 0.15/30-28

AB	+ WATSON LABS	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CRLD
----	---------------	---------------	---------	-----	--------------	----------

VIENVA

AB1	SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA
-----	------------	--------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

XULANE

AB	+ MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD
----	----------------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

@ ACTAVIS LABS UT INC

0.035MG;0.5MG

N017566 001 Mar CAHN

NORINYL 1+35 21-DAY

AB	ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001		Feb CAHN
----	---------------------	-------------	---------	-----	--	----------

TABLET;ORAL-21

TRI-NORINYL 21-DAY

@	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	001	Apr 13, 1984	Feb CAHN
---	---------------------	---	---------	-----	--------------	----------

TABLET;ORAL-28

BREVICON 28-DAY

AB	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001		Mar CAHN
>A>	CYCLAFEM 0.5/35					
>A> AB	VINTAGE PHARMS	0.035MG;0.5MG	A203413	001	Dec 16, 2015	Nov NEWA
	NORETHINDRONE AND ETHINYL ESTRADIOL					
AB	FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Apr NEWA
AB	+ JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015	Jul CRLD
AB		0.035MG;0.5MG	A200488	001	Oct 21, 2015	Oct NEWA
AB		0.035MG;1MG	A200489	001	Oct 21, 2015	Oct NEWA
	+ NORINYL 1+35 28-DAY	0.05MG;1MG	A203006	001	Aug 05, 2013	Jul CTEC
AB	ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002		Feb CAHN
	TRI-NORINYL 28-DAY					
AB	+ ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	002	Apr 13, 1984	Feb CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

BLISOVI 24 FE

AB	LUPIN LTD	0.02MG;1MG	A091398	001	Oct 28, 2015	Oct NEWA
	FEMHRT					
AB	WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Mar CTEC
	FYAVOLV					
>A> AB	LUPIN LTD	0.005MG;1MG	A204213	002	Dec 10, 2015	Nov NEWA
>A> AB		0.0025MG;0.5MG	A204213	001	Dec 10, 2015	Nov NEWA
	LARIN 24 FE					
AB	NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015	Feb NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
AB	+ BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009	Mar CTEC
AB	GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015	Mar NEWA
AB		0.005MG;1MG	A203038	002	Apr 02, 2015	Mar NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	+ AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009	Jan CRLD
	TABLET;ORAL-28					
	BLISOVI FE 1.5/30					
>A> AB	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015	Nov NEWA
	BLISOVI FE 1/20					
>A> AB	LUPIN LTD	0.02MG;1MG	A201584	001	Nov 18, 2015	Nov NEWA

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	HAUPT PHARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.2 15MG,0.25MG	A203870	001	Nov 12, 2015	Oct NEWA
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015	Oct NEWA
AB	JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A202132	001	Sep 09, 2015	Aug NEWA
AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.2 15MG;0.25MG	A200383	001	Apr 07, 2015	Mar NEWA
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Mar NEWA
	TRI LO SPRINTEC					
>D>	@ BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A076784	001	Jun 29, 2009	Nov CMFD
>A> AB		0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A076784	001	Jun 29, 2009	Nov CMFD
	TRI-LO-ESTARYLLA					
AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A091232	001	Jun 29, 2015	Jun NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	Feb CMFD
----	-------------	--------------	---------	-----	--------------	----------

ETHOSUXIMIDECAPSULE;ORAL
ETHOSUXIMIDE

AB	BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002	Jan CAHN
AB	HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012	Sep CAHN

ETODOLACTABLET;ORAL
ETODOLAC

@	LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997	Sep CAHN
---	---------------	-------	---------	-----	--------------	----------

ETONOGESTRELIMPLANT;IMPLANTATION
IMPLANON

@	ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006	Jun DISC
---	-----------------	--------------	---------	-----	--------------	----------

EZETIMIBETABLET;ORAL
EZETIMIBE

@	GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015	Jun DISC
AB		10MG	A078560	001	Jun 26, 2015	Jun NEWA
	ZETIA					
+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002	Jun CTEC
AB	+	10MG	N021445	001	Oct 25, 2002	Jun CFTG

FAMOTIDINEINJECTABLE;INJECTION
FAMOTIDINE

AP	+	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001	Jun CAHN
	@		10MG/ML	A075799	001	Apr 30, 2002	Sep CAHN
		FAMOTIDINE PRESERVATIVE FREE					
AP	+	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001	Jun CAHN
		TABLET;ORAL					
		PEPCID					
AB		VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
AB	+		40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELBAMATETABLET;ORAL
FELBAMATE

AB	COREPHARMA	400MG	A202284	001	Nov 04, 2015	Oct NEWA
AB		600MG	A202284	002	Nov 04, 2015	Oct NEWA

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA	
AB		5MG	A203032	002	May 21, 2015	May NEWA	
AB		10MG	A203032	003	May 21, 2015	May NEWA	
AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN	
AB		5MG	A091200	002	Dec 13, 2013	Apr CAHN	
AB		10MG	A091200	003	Dec 13, 2013	Apr CAHN	
>D>	PLENDIL						
>D>	AB	ASTRAZENECA	2.5MG	N019834	004	Sep 22, 1994	Nov DISC
>A>	@	2.5MG	N019834	004	Sep 22, 1994	Nov DISC	
>D>	AB	5MG	N019834	001	Jul 25, 1991	Nov DISC	
>A>	@	5MG	N019834	001	Jul 25, 1991	Nov DISC	
>D>	AB	10MG	N019834	002	Jul 25, 1991	Nov DISC	
>A>	@	10MG	N019834	002	Jul 25, 1991	Nov DISC	

FENOFIBRATECAPSULE;ORAL
FENOFIBRATE

AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
AB		130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL
FENOFIBRATE

AB	LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug NEWA
AB		160MG	A204019	002	Aug 17, 2015	Aug NEWA
AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
		107MG	A076635	002	Oct 31, 2005	Apr CAHN

TABLET;ORAL
FENOFIBRATE

AB		160MG	A076635	003	Oct 31, 2005	Apr CAHN
AB	VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
AB		145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACID

TABLET;ORAL
FIBRICOR

	TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL
FENTANYL-100

AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
----	---------------------	-----------	---------	-----	--------------	----------

FENTANYL-12

AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA
----	------------------	------------	---------	-----	--------------	----------

FENTANYL-25

AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL-50

AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL-75

AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN
----	---------------------	----------	---------	-----	--------------	----------

FENTANYL CITRATE

FILM;BUCCAL
ONSOLIS

@	BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
@		EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
@		EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
@		EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
@		EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
----	---	--------------------	-------------------	---------	-----	--------------	----------

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

@	THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATE

TABLET;ORAL
AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA
---	-----------------	---------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATE

SOLUTION;IV (INFUSION)
TRIFERIC

+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA
		272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Oct NEWA

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

>A>	AB	ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Nov NEWA
>A>	AB		8MG	A204827	002	Dec 10, 2015	Nov NEWA

TOVIAZ

>D>		PFIZER	4MG	N022030	001	Oct 31, 2008	Nov CFTG
>A>	AB		4MG	N022030	001	Oct 31, 2008	Nov CFTG
>D>	+		8MG	N022030	002	Oct 31, 2008	Nov CFTG
>A>	AB	+	8MG	N022030	002	Oct 31, 2008	Nov CFTG

FIDAXOMICIN

TABLET;ORAL
DIFICID

+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB		100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB		150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB		100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB		150MG	A202821	003	Jul 08, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr CAHN

FLIBANSERIN

TABLET; ORAL

ADDYI

+	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug NEWA
---	---------------	-------	---------	-----	--------------	----------

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB		100MG	A078423	002	Mar 07, 2011	May CMFD
AB		150MG	A078423	003	Mar 07, 2011	May CMFD
AB		200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	3D IMAGING DRUG	20-300mCi/ML	A203778	001	Oct 30, 2015	Oct NEWA	
>A>	AP	CARDINAL HEALTH 414	20-300mCi/ML	A203603	001	Nov 13, 2015	Nov NEWA
AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug NEWA	
AP	KETTERING MEDCTR	4-40mCi/ML	A204759	001	Oct 27, 2015	Oct NEWA	
AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA	
>A>	AP	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	Nov NEWA
AP	MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug NEWA	
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA	
	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug NEWA	
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA	
AP	+ UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Oct CTEC	
AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul NEWA	

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN

FLUOCINOLONE ACETONIDE

OIL;TOPICAL							
FLUOCINOLONE ACETONIDE							
AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun	NEWA
SOLUTION;TOPICAL							
FLUOCINOLONE ACETONIDE							
AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug	NEWA

FLUOCINONIDE

GEL;TOPICAL							
FLUOCINONIDE							
AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

CREAM;TOPICAL							
CARAC							
AB	+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
	+	0.5%	N020985	001	Oct 27, 2000	Feb	CAHN
FLUOROURACIL							
AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA
TOLAK							
	+ HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL							
FLUOXETINE HYDROCHLORIDE							
	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
	+ MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

OINTMENT;TOPICAL							
CORDRAN							
	+ AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
		0.05%	N012806	001		May	CMFD
TAPE;TOPICAL							
CORDRAN							
	+ ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLURBIPROFEN

TABLET;ORAL							
ANSAID							
	@ PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct	DISC
	@	100MG	N018766	003	Oct 31, 1988	Oct	DISC
FLURBIPROFEN							
AB	+ MYLAN	100MG	A074358	002	Jun 20, 1994	Oct	CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION							
BREO ELLIPTA							
	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FLUTICASONE PROPIONATE

CREAM;TOPICAL							
FLUTICASONE PROPIONATE							
AB	+ PERRIGO NEW YORK	0.05%	A076793	001	May 14, 2004	Oct	CRLD

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL							
FLUVASTATIN SODIUM							
AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug	NEWA
LESCOL XL							
AB	+ NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug	CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul CAHN
	@	25MG	A075898	001	Mar 12, 2001	Jul CAHN
AB		50MG	A075897	002	Jan 25, 2001	Jul CAHN
	@	50MG	A075898	002	Mar 12, 2001	Jul CAHN
AB		100MG	A075897	003	Jan 25, 2001	Jul CAHN
	@	100MG	A075898	003	Mar 12, 2001	Jul CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug CAHN
AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr CAHN
AB		20MG;12.5MG	A076739	002	Dec 17, 2004	Apr CAHN

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

	@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
	@	10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET; ORAL

GABAPENTIN

	@ HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
	@	800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN
OPTIMARK IN PLASTIC CONTAINER						
+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GEFITINIB

TABLET; ORAL

IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA
---	--------------------	-------	---------	-----	--------------	----------

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA
----	----------------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

TABLET; ORAL

FACTIVE

AB	+ LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
AB	GEMIFLOXACIN MESYLATE					
AB	ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>A>	@ BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982	Nov	DISC
>A> AP		EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 2MG BASE/ML	A062373	009	Sep 07, 1982	Nov	CTNA
>A>	@	EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982	Nov	DISC
>A> AP		EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982	Nov	CTNA
>A>	@	EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982	Nov	DISC
>A> AP		EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982	Nov	CTNA
>A>	@	EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982	Nov	DISC
>A> AP		EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982	Nov	CTNA
>A> AP		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982	Nov	CTNA

ISOTONIC GENTAMICIN SULFATE IN PLASTIC CONTAINER

>D> AP	BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373	001	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 2MG BASE/ML	A062373	009	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 2.4MG BASE/ML	A062373	010	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 40MG BASE/100ML	A062373	003	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 60MG BASE/100ML	A062373	004	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982	Nov	CTNA
>D> AP		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982	Nov	CTNA

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
		GLATOPIA						
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@ HIKMA PHARMS
@
@

1MG
2MG
4MG

A078952 001 Aug 01, 2013 Apr DISC
A078952 002 Aug 01, 2013 Apr DISC
A078952 003 Aug 01, 2013 Apr DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

@ ANI PHARMS INC
AB
@
AB

5MG
5MG
10MG
10MG

A074387 001 Mar 04, 1996 Aug CAHN
A074497 001 Aug 31, 1995 Oct CAHN
A074387 002 Mar 04, 1996 Aug CAHN
A074497 002 Aug 31, 1995 Oct CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB MYLAN PHARMS INC
AB
AB

2.5MG
5MG
10MG

A202298 001 May 19, 2015 May NEWA
A202298 002 May 19, 2015 May NEWA
A202298 003 May 19, 2015 May NEWA

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+ FRESENIUS KABI USA EQ 1MG BASE/VIAL

N201849 001 May 08, 2015 May NEWA

GLYBURIDE

TABLET;ORAL

DIABETA

AB2 SANOFI AVENTIS US
AB2
AB2 +

1.25MG
2.5MG
5MG

N017532 001 May 01, 1984 Sep CFTG
N017532 002 May 01, 1984 Sep CFTG
N017532 003 May 01, 1984 Sep CFTG

GLYBURIDE

AB1 AUROBINDO PHARMA
AB1
AB1

1.25MG
2.5MG
5MG

A077537 001 Oct 18, 2007 Sep CTEC
A077537 002 Oct 18, 2007 Sep CTEC
A077537 003 Oct 18, 2007 Sep CTEC

TABLET;ORAL

GLYBURIDE

AB1	COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep CTEC
AB2		1.25MG	A206079	001	Sep 30, 2015	Sep NEWA
AB1		2.5MG	A076257	002	Jun 27, 2002	Sep CTEC
AB2		2.5MG	A206079	002	Sep 30, 2015	Sep NEWA
AB1		5MG	A076257	003	Jun 27, 2002	Sep CTEC
AB2		5MG	A206079	003	Sep 30, 2015	Sep NEWA
AB1	HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep CTEC
AB1		2.5MG	A090937	002	Feb 28, 2011	Sep CTEC
AB1		5MG	A090937	003	Feb 28, 2011	Sep CTEC
AB1	TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep CTEC
AB1		2.5MG	A074388	002	Aug 29, 1995	Sep CTEC
AB1	+	5MG	A074388	003	Aug 29, 1995	Sep CTEC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLUCOVANCE

@	BRISTOL MYERS SQUIBB	1.25MG;250MG	N021178	001	Jul 31, 2000	Oct DISC
---	----------------------	--------------	---------	-----	--------------	----------

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN
---	---------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

INJECTABLE;INJECTION

ROBINUL

AP	+	EUROHLTH INTL SARL	0.2MG/ML	N017558	001	Jun CAHN
----	---	--------------------	----------	---------	-----	----------

POWDER;INHALATION

SEEBRI

+	NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015	Oct NEWA
---	----------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

GLYCOPYRROLATE

AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
AA		2MG	A040844	002	Aug 18, 2009	Apr CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

+	NOVARTIS PHARMS CORP	15.6MCG/INH;27.5MCG/INH	N207930	001	Oct 29, 2015	Oct NEWA
---	----------------------	-------------------------	---------	-----	--------------	----------

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE				
AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GRISEOFULVIN, MICROSIZE

TABLET;ORAL

GRIFULVIN V

>D>	AB	+	VALEANT LUXEMBOURG	500MG	A062279	003		Nov	DISC
>A>			@	500MG	A062279	003		Nov	DISC
			GRISEOFULVIN						
>D>	AB		SANDOZ INC	500MG	A091592	002	Aug 07, 2013	Nov	CRLD
>A>	AB	+		500MG	A091592	002	Aug 07, 2013	Nov	CRLD

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

	MIKART INC	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
	MISSION PHARMACAL CO	200MG/5ML;2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May	NEWA
---	------------	--------------------------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Oct	NEWA
AB		EQ 2MG BASE	A202238	002	Oct 20, 2015	Oct	NEWA
AB		EQ 3MG BASE	A202238	003	Oct 20, 2015	Oct	NEWA
AB		EQ 4MG BASE	A202238	004	Oct 20, 2015	Oct	NEWA
AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May	NEWA
AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May	NEWA
AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May	NEWA
AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May	NEWA
AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May	NEWA
AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May	NEWA
AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May	NEWA
AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May	NEWA
AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May	NEWA
AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May	NEWA
AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May	NEWA
AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May	NEWA
AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May	NEWA
AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May	NEWA
AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May	NEWA
AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May	NEWA

HALOBETASOL PROPIONATE

>A> LOTION; TOPICAL

>A> ULTRAVATE

>A>	+	FERNDAL LABS INC	0.05%	N208183	001	Nov 06, 2015	Nov	NEWA
-----	---	------------------	-------	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May	CAHN
@		1MG	A071129	001	Feb 17, 1987	Jun	CAHN
@		5MG	A071131	001	Feb 17, 1987	Jun	CAHN
@		10MG	A071132	001	May 12, 1987	Jun	CAHN
@		20MG	A071133	001	May 12, 1987	May	CAHN
@	ROXANE	2MG	A071130	001	Feb 17, 1987	Jun	CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May	CAHN
---	------------------	----------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

HALOPERIDOL

@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr	CAHN
@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP	+	EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug	CAHN
			1,000 UNITS/ML	N017037	001		Jun	CAHN
	@		2,500 UNITS/ML	N017007	007		Aug	CAHN
	@		5,000 UNITS/ML	N017007	002		Aug	CAHN
	@		5,000 UNITS/0.5ML	N017007	010		Aug	CAHN
AP	+		5,000 UNITS/ML	N017037	002		Jun	CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun	CAHN
	@		7,500 UNITS/ML	N017007	003		Aug	CAHN
	@		10,000 UNITS/ML	N017007	004		Aug	CAHN
AP	+		10,000 UNITS/ML	N017037	003		Jun	CAHN
	@		15,000 UNITS/ML	N017007	005		Aug	CAHN
	@		20,000 UNITS/ML	N017007	006		Aug	CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@ HERITAGE PHARMS INC 10MG

A040858 001 Feb 26, 2010 Sep CAHN

@ 25MG

A040858 002 Feb 26, 2010 Sep CAHN

@ 50MG

A040858 003 Feb 26, 2010 Sep CAHN

@ 100MG

A040858 004 Feb 26, 2010 Sep CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS INC 12.5MG

A090651 001 Apr 07, 2014 Aug DISC

MICROZIDE

AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN
----	---	---------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD 12.5MG; 10MG

A076007 001 Jul 01, 2002 Apr CAHN

AB 12.5MG; 20MG

A076007 002 Jul 01, 2002 Apr CAHN

AB 25MG; 20MG

A076007 003 Jul 01, 2002 Apr CAHN

ZESTORETIC

AB ALVOGEN IPCO SARL 12.5MG; 10MG

N019888 003 Nov 18, 1993 Feb CAHN

AB + 12.5MG; 20MG

N019888 001 Sep 20, 1990 Feb CAHN

AB + 25MG; 20MG

N019888 002 Jul 20, 1989 Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

CONCORDIA PHARMS INC 12.5MG; EQ 25MG TARTRATE

N021956 001 Aug 28, 2006 Jun CAHN

12.5MG; EQ 50MG TARTRATE

N021956 002 Aug 28, 2006 Jun CAHN

+ 12.5MG; EQ 100MG TARTRATE

N021956 003 Aug 28, 2006 Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERIDE-40/25

@ WYETH PHARMS INC 25MG; 40MG

N018031 001 Oct DISC

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 25MG; 40MG

A070704 001 Oct 01, 1986 Jul CAHN

AB 25MG; 40MG

A072042 001 Mar 14, 1988 Aug CAHN

@ 25MG; 80MG

A070705 001 Oct 01, 1986 Jul CAHN

AB 25MG; 80MG

A072043 001 Mar 14, 1988 Aug CAHN

AB + MYLAN 25MG; 40MG

A070947 002 Mar 04, 1987 Oct CRLD

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD 12.5MG; EQ 10MG BASE

A078211 001 Mar 04, 2009 Apr CAHN

AB 12.5MG; EQ 20MG BASE

A078211 002 Mar 04, 2009 Apr CAHN

AB 25MG; EQ 20MG BASE

A078211 003 Mar 04, 2009 Apr CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB MACLEODS PHARMS LTD 12.5MG; 40MG

A204169 001 Nov 02, 2015 Oct NEWA

AB 12.5MG; 80MG

A204169 002 Nov 02, 2015 Oct NEWA

AB 25MG; 80MG

A204169 003 Nov 02, 2015 Oct NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC 25MG; 37.5MG

A074970 001 Jan 06, 1998 Aug CAHN

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB ANI PHARMS INC 50MG; 75MG

A073467 001 Jan 31, 1996 Aug CAHN

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER

+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr CAHN
		15MG	N202880	002	Oct 25, 2013	Apr CAHN
		20MG	N202880	003	Oct 25, 2013	Apr CAHN
		30MG	N202880	004	Oct 25, 2013	Apr CAHN
		40MG	N202880	005	Oct 25, 2013	Apr CAHN
		50MG	N202880	006	Oct 25, 2013	Apr CAHN
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun CAHN
		15MG	N202880	002	Oct 25, 2013	Jun CAHN
		20MG	N202880	003	Oct 25, 2013	Jun CAHN
		30MG	N202880	004	Oct 25, 2013	Jun CAHN
		40MG	N202880	005	Oct 25, 2013	Jun CAHN
		50MG	N202880	006	Oct 25, 2013	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL
HYSINGLA

+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar CRLD
---	------------------	------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> AA	COASTAL PHARMS	5MG/5ML;60MG/5ML	A205658	001	Nov 17, 2015	Nov NEWA
--------	----------------	------------------	---------	-----	--------------	----------

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar CAHN
----	-------------------	------	---------	-----	--------------	----------

POWDER;FOR RX COMPOUNDING

HYDRO-RX

@ X GEN PHARMS	100%	A085982	001			Apr DISC
----------------	------	---------	-----	--	--	----------

TABLET;ORAL

HYDROCORTISONE

AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb NEWA
AB		10MG	A083365	003	Feb 23, 2015	Feb NEWA
AB		20MG	A083365	001		Feb CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

@ X GEN PHARMS	100%	A085981	001			Apr DISC
----------------	------	---------	-----	--	--	----------

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

@ G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr CAHN
--------------------	------	---------	-----	--------------	----------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001	Jun CMS2
----	---	-------------------	-------------------------------------	---------	-----	----------

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

DILAUDID-HP

@ PURDUE PHARM PRODS	250MG/VIAL	N019034	002	Aug 04, 1994	Oct DISC
----------------------	------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar NEWA
AB		12MG	A204278	002	Apr 06, 2015	Mar NEWA
AB		16MG	A204278	003	Apr 06, 2015	Mar NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

@ SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr CAHN
+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL
PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG		N009768	001		Jun	CAHN
----	---	----------------------	-------	--	---------	-----	--	-----	------

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION
HYDROXYPROGESTERONE CAPROATE

@	ACTAVIS LABS UT INC	125MG/ML
@		250MG/ML
+	MCGUFF	250MG/ML

N017439	001		Mar	CAHN
N017439	002		Mar	CAHN
A200271	001	Aug 24, 2015	Aug	NEWA

HYDROXYZINE HYDROCHLORIDETABLET; ORAL
HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun	CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun	CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun	CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD
	@	MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul	DISC
	@		25MG	A089382	001	May 19, 1986	Jul	DISC
	@		50MG	A089383	001	May 19, 1986	Jul	DISC
	@	WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul	DISC
	@		25MG	A088349	001	Sep 15, 1983	Jul	DISC
	@		50MG	A088350	001	Sep 15, 1983	Jul	DISC

HYDROXYZINE PAMOATECAPSULE; ORAL
HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS
IBANDRONATE SODIUM

AP		APOTEX INC	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015	Oct	NEWA
AP		AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug	NEWA

IBUPROFENTABLET; ORAL
IBUPROFEN

AB		GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug	NEWA
AB			600MG	A091625	002	Sep 15, 2015	Aug	NEWA
AB			800MG	A091625	003	Sep 15, 2015	Aug	NEWA
	@	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul	DISC
	@		400MG	A071231	001	Oct 22, 1986	Jul	DISC
	@		600MG	A071232	001	Oct 22, 1986	Jul	DISC
	@		800MG	A072004	001	Nov 18, 1987	Jul	DISC

ILOPERIDONETABLET; ORAL
FANAPT

+ VANDA PHARMS INC

1MG	N022192	001	May 06, 2009	Jan	CAHN
2MG	N022192	002	May 06, 2009	Jan	CAHN
4MG	N022192	003	May 06, 2009	Jan	CAHN
6MG	N022192	004	May 06, 2009	Jan	CAHN
8MG	N022192	005	May 06, 2009	Jan	CAHN
10MG	N022192	006	May 06, 2009	Jan	CAHN
12MG	N022192	007	May 06, 2009	Jan	CAHN

IMATINIB MESYLATETABLET; ORAL
GLEEVEC

>D>		NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Nov	CFTG
>A>	AB		EQ 100MG BASE	N021588	001	Apr 18, 2003	Nov	CFTG
>D>	+		EQ 400MG BASE	N021588	002	Apr 18, 2003	Nov	CFTG

		TABLET;ORAL							
		GLEEVEC							
>A>	AB	+	EQ 400MG BASE		N021588	002	Apr 18, 2003	Nov	CFTG
>A>		IMATINIB MESYLATE							
>A>	AB	SUN PHARMA GLOBAL	EQ 100MG BASE		A078340	001	Dec 03, 2015	Nov	NEWA
>A>	AB		EQ 400MG BASE		A078340	002	Dec 03, 2015	Nov	NEWA
<u>IMIQUIMOD</u>									
		CREAM;TOPICAL							
		IMIQUIMOD							
AB		G AND W LABS INC	5%		A200481	001	Apr 18, 2011	Apr	CAHN
<u>INDAPAMIDE</u>									
		TABLET;ORAL							
		INDAPAMIDE							
AB		ANI PHARMS INC	1.25MG		A074299	002	Apr 29, 1996	Jul	CAHN
		@	1.25MG		A074498	002	Feb 12, 1998	Jul	CAHN
AB			2.5MG		A074299	001	Jul 27, 1995	Jul	CAHN
		@	2.5MG		A074498	001	Oct 31, 1996	Jul	CAHN
<u>INDOMETHACIN</u>									
		CAPSULE, EXTENDED RELEASE;ORAL							
		INDOMETHACIN							
AB		JUBILANT GENERICS	75MG		A202706	001	Oct 05, 2015	Sep	NEWA
<u>INGENOL MEBUTATE</u>									
		GEL;TOPICAL							
		PICATO							
+		LEO PHARMA AS	0.015%		N202833	001	Jan 23, 2012	May	CRLD
<u>INSULIN DEGLUDEC</u>									
		SOLUTION;SUBCUTANEOUS							
		TRESIBA							
		NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)		N203314	001	Sep 25, 2015	Sep	NEWA
+			600 UNITS/3ML (200 UNITS/ML)		N203314	002	Sep 25, 2015	Sep	NEWA
<u>INSULIN GLARGINE RECOMBINANT</u>									
		SOLUTION;SUBCUTANEOUS							
		TOUJEO SOLOSTAR							
+		SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)		N206538	001	Feb 25, 2015	Feb	NEWA
<u>INSULIN LISPRO RECOMBINANT</u>									
		SOLUTION;SUBCUTANEOUS							
		HUMALOG KWIKPEN							
+		ELI LILLY AND CO	200 UNITS/ML		N205747	001	May 26, 2015	May	NEWA
<u>INSULIN RECOMBINANT HUMAN</u>									
		POWDER;INHALATION							
		AFREZZA							
		SANOFI AVENTIS	12 UNITS/INH		N022472	003	Apr 17, 2015	Apr	NEWA
<u>IOHEXOL</u>									
		FOR SOLUTION;ORAL							
		ORALTAG							
		INTERPHARMA PRAHA AS	9.7GM/BOT		N205383	001	Mar 26, 2015	Mar	NEWA
<u>IOPAMIDOL</u>									
		INJECTABLE;INJECTION							
		IOPAMIDOL-250							
		@ FRESENIUS KABI USA	51%		A074679	001	Apr 02, 1997	Jan	DISC
		IOPAMIDOL-300							
		@ FRESENIUS KABI USA	61%		A074679	002	Apr 02, 1997	Jan	DISC
		IOPAMIDOL-370							
		@ FRESENIUS KABI USA	76%		A074679	003	Apr 02, 1997	Jan	DISC
		ISOVUE-200							
+		BRACCO	41%		N018735	006	Jul 07, 1987	Feb	CTEC
		ISOVUE-250							
+		BRACCO	51%		N018735	007	Jul 06, 1992	Feb	CTEC
+			51%		N020327	002	Oct 12, 1994	Feb	CTEC
		ISOVUE-300							
+		BRACCO	61%		N020327	003	Oct 12, 1994	Feb	CTEC

INJECTABLE; INJECTION
ISOVUE-370

	+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb CTEC
		SCANLUX-300					
AP		MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010	Aug CAHN
		SCANLUX-370					
AP		MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010	Aug CAHN

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION
CONRAY

	+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb CAHN
		CONRAY 30					
	+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb CAHN
		CONRAY 43					
	+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb CAHN
		SOLUTION; INTRAVESICAL					
		CYSTO-CONRAY II					
		LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb CAHN

IOVERSOL

INJECTABLE; INJECTION
OPTIRAY 160

	@	LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb CAHN
		OPTIRAY 240					
	+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb CAHN
	@		51%	N020923	001	May 28, 1998	Feb CAHN
		OPTIRAY 300					
	+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb CAHN
	+		64%	N020923	004	May 13, 1999	Feb CAHN
		OPTIRAY 320					
	+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb CAHN
	+		68%	N020923	002	May 29, 1998	Oct CMFD
	@		68%	N020923	002	May 29, 1998	Feb CAHN
		OPTIRAY 350					
	+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb CAHN
	+		74%	N020923	003	May 28, 1998	Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION
HEXABRIX

	@	GUERBET	39.3%; 19.6%	N018905	002	Jul 26, 1985	May DISC
--	---	---------	--------------	---------	-----	--------------	----------

IRBESARTAN

TABLET; ORAL

IRBESARTAN

>A>	AB	AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Nov NEWA
>A>	AB		150MG	A203685	002	Dec 10, 2015	Nov NEWA
>A>	AB		300MG	A203685	003	Dec 10, 2015	Nov NEWA
	AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb NEWA
	AB		150MG	A203534	002	Feb 23, 2015	Feb NEWA
	AB		300MG	A203534	003	Feb 23, 2015	Feb NEWA
>A>	AB	SCIEGEN PHARMS INC	75MG	A204774	001	Dec 07, 2015	Nov NEWA
>A>	AB		150MG	A204774	002	Dec 07, 2015	Nov NEWA
>A>	AB		300MG	A204774	003	Dec 07, 2015	Nov NEWA
>A>	AB	UNICHEM LABS LTD	75MG	A203020	001	Dec 07, 2015	Nov NEWA
>A>	AB		150MG	A203020	002	Dec 07, 2015	Nov NEWA
>A>	AB		300MG	A203020	003	Dec 07, 2015	Nov NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

>A>	AP	ACTAVIS TOTOWA	500MG/25ML (20MG/ML)	A078589	003	Nov 18, 2015	Nov NEWA
		INJECTABLE, LIPOSOMAL; IV (INFUSION)					
		ONIVYDE					
	+	MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Oct NEWA

IRON DEXTRANINJECTABLE; INJECTION
INFED

BP	+	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN
----	---	---------------------	-----------------	---------	-----	--	-----	------

ISAVUCONAZONIUM SULFATECAPSULE; ORAL
CRESEMBA

	+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
--	---	----------	-------	---------	-----	--------------	-----	------

POWDER; IV (INFUSION)
CRESEMBA

	+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA
--	---	----------	-------	---------	-----	--------------	-----	------

ISOSORBIDE DINITRATETABLET; ORAL
ISORDIL

AB		VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb	CAHN
	+		40MG	N012093	001	Jul 29, 1988	Feb	CAHN

ISOTRETINOINCAPSULE; ORAL
ABSORICA

		RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb	NEWA
--	--	---------	------	---------	-----	--------------	-----	------

			35MG	N021951	006	Aug 15, 2014	Feb	NEWA
--	--	--	------	---------	-----	--------------	-----	------

MYORISAN

AB		DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug	NEWA
----	--	----------------	------	---------	-----	--------------	-----	------

SOTRET

AB		SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr	CAHN
----	--	--------------------	------	---------	-----	--------------	-----	------

AB			20MG	A076041	002	Dec 24, 2002	Apr	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			30MG	A076503	001	Jun 20, 2003	Apr	CAHN
----	--	--	------	---------	-----	--------------	-----	------

AB			40MG	A076041	003	Dec 24, 2002	Apr	CAHN
----	--	--	------	---------	-----	--------------	-----	------

ZENATANE

AB		DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb	NEWA
----	--	--------------------	------	---------	-----	--------------	-----	------

ISRADIPINECAPSULE; ORAL
ISRADIPINE

AB		ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

AB			5MG	A077169	002	Apr 24, 2006	Mar	CAHN
----	--	--	-----	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

>A>		ISRADIPINE						
-----	--	------------	--	--	--	--	--	--

>A>		MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015	Nov	NEWA
-----	--	------------------	-----	---------	-----	--------------	-----	------

>A>			10MG	A201067	002	Nov 27, 2015	Nov	NEWA
-----	--	--	------	---------	-----	--------------	-----	------

ITRACONAZOLESOLUTION; ORAL
ITRACONAZOLE

AA		AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Oct	NEWA
----	--	---------------	---------	---------	-----	--------------	-----	------

SPORANOX

AA	+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Oct	CFTG
----	---	----------------	---------	---------	-----	--------------	-----	------

IVABRADINE HYDROCHLORIDETABLET; ORAL
CORLANOR

		AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr	NEWA
--	--	-----------	-------------	---------	-----	--------------	-----	------

	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr	NEWA
--	---	--	---------------	---------	-----	--------------	-----	------

IVACAFTORGRANULE; ORAL
KALYDECO

		VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar	NEWA
--	--	-------------------	-------------	---------	-----	--------------	-----	------

	+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar	NEWA
--	---	--	-------------	---------	-----	--------------	-----	------

IVACAFTOR; LUMACFTORTABLET; ORAL
ORKAMBI

	+	VERTEX PHARMS INC	125MG; 200MG	N206038	001	Jul 02, 2015	Jul	NEWA
--	---	-------------------	--------------	---------	-----	--------------	-----	------

IXABEPILONE

INJECTABLE;IV (INFUSION)
IXEMPRA KIT

+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

>A> IXAZOMIB CITRATE

CAPSULE;ORAL
NINLARO

>A>	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462	001	Nov 20, 2015	Nov NEWA
>A>		EQ 3MG BASE	N208462	002	Nov 20, 2015	Nov NEWA
>A>	+	EQ 4MG BASE	N208462	003	Nov 20, 2015	Nov NEWA

KANAMYCIN SULFATE

INJECTABLE;INJECTION
KANAMYCIN

@	EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
@		EQ 500MG BASE/2ML	A062324	002		Jun CAHN
@		EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION
KETOROLAC TROMETHAMINE

AP	BD RX	15MG/ML	A203242	001	Oct 07, 2015	Sep NEWA
AP		30MG/ML	A203242	002	Oct 07, 2015	Sep NEWA
	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@ EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED;NASAL
SPRIX

+	EGALET US INC	15.75MG/SPRAY	N022382	001	May 14, 2010	Jan CAHN
---	---------------	---------------	---------	-----	--------------	----------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION
OMIDRIA

+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	Feb CPOT
---	--------	-------------------------------------	---------	-----	--------------	----------

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE

@	CLARIS PHARMASERVICE	5MG/ML	A076051	001	Jul 05, 2002	Apr CAHN
---	----------------------	--------	---------	-----	--------------	----------

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	MUTUAL PHARM	100MG	A075215	001	Jul 29, 1999	Jan CMFD
AB		200MG	A075215	002	Jul 29, 1999	Jan CMFD
AB		300MG	A075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

SOLUTION;ORAL, RECTAL
LACTULOSE

AA	BIO-PHARM INC	10GM/15ML	A203762	001	Mar 27, 2015	Mar NEWA
----	---------------	-----------	---------	-----	--------------	----------

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL
DUTREBIS

@	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Aug DISC
+		150MG;EQ 300MG BASE	N206510	001	Feb 06, 2015	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	HETERO LABS LTD III	150MG;300MG	A079124	001	Sep 17, 2015	Aug NEWA
AB	STRIDES ARCOLAB LTD	150MG;300MG	A079128	001	May 13, 2015	Apr NEWA
AB	STRIDES PHARMA	150MG;300MG	A079128	001	May 13, 2015	Aug CAHN

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

@	HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	May DISC
@		100MG	A078134	002	Apr 19, 2011	May DISC
@		150MG	A078134	003	Apr 19, 2011	May DISC
@		200MG	A078134	004	Apr 19, 2011	May DISC

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB	PAR PHARM	25MG	A204158	001	Oct 27, 2015	Oct NEWA
AB		50MG	A204158	002	Oct 27, 2015	Oct NEWA
AB		100MG	A204158	003	Oct 27, 2015	Oct NEWA
AB		200MG	A204158	004	Oct 27, 2015	Oct NEWA

LAPATINIB DITOSYLATE

TABLET; ORAL

TYKERB

+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N022059	001	Mar 13, 2007	Mar CAHN
---	----------------------	---------------	---------	-----	--------------	----------

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

	EISAI INC	EQ 4MG BASE	N206947	001	Feb 13, 2015	Feb NEWA
+		EQ 10MG BASE	N206947	002	Feb 13, 2015	Feb NEWA

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul NEWA
----	--------------------	----------------------	---------	-----	--------------	----------

SOLUTION; ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May NEWA
----	-------------	----------	---------	-----	--------------	----------

TABLET; ORAL

LEVETIRACETAM

>A>	AB	SECAN PHARMS	250MG	A205102	001	Dec 16, 2015	Nov NEWA
>A>	AB		750MG	A205102	002	Dec 16, 2015	Nov NEWA
>A>	AB		1GM	A205102	003	Dec 16, 2015	Nov NEWA

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul NEWA
		500MG	N207958	002	Jul 31, 2015	Jul NEWA
		750MG	N207958	003	Jul 31, 2015	Jul NEWA
		1GM	N207958	004	Jul 31, 2015	Jul NEWA

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

	AB	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb NEWA
	AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug NEWA
	AB		750MG	A202167	002	Sep 04, 2015	Aug NEWA
>A>	AB	MYLAN PHARMS INC	1GM	A200475	003	Dec 07, 2015	Nov NEWA
	AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug CAHN
	AB		750MG	A201464	002	May 25, 2012	Aug CAHN
	AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May NEWA
	AB		750MG	A203468	002	May 21, 2015	May NEWA

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

@	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr DISC
---	-----------------	----------	---------	-----	--------------	----------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul NEWA

INJECTABLE;INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul CRLD
	TABLET;ORAL					
	LEVOFLOXACIN					
AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Oct NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Oct NEWA
	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb NEWA
AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct CTEC
		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb NEWA
AP	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct CTEC
	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb NEWA
--	--------------	------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

	+ SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr CAHN
--	-----------------------	-----	---------	-----	--------------	----------

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

>D>	+	FRESENIUS KABI USA	200MCG/VIAL	N202231	002	Jun 24, 2011	Nov CFTG
>A>	AP		200MCG/VIAL	N202231	002	Jun 24, 2011	Nov CFTG
>A>	AP	PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Nov NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul NEWA
	@ BELMORA LLC	5%	A080210	001		Sep CAHN

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar CAHN
AB	MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

	@ EUROHLTH INTL SARL	1%	A080407	001		Mar CAHN
	@	2%	A080407	002		Mar CAHN
AP	LUITPOLD	1%	A091564	001	Aug 14, 2015	Aug NEWA
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ EUROHLTH INTL SARL	1%	A084625	001		Feb CAHN
	@	2%	A084625	002		Feb CAHN

JELLY;TOPICAL

ANESTACON

	@ BANNER LIFE SCIENCES	2%	A080429	001		Jan CAHN
--	------------------------	----	---------	-----	--	----------

JELLY;TOPICAL									
LIDOCAINE HYDROCHLORIDE									
	@ G AND W LABS INC	2%		A081318	001	Apr 29, 1993	Apr	CAHN	
<u>LIDOCAINE; PRILOCAINE</u>									
CREAM;TOPICAL									
EMLA									
AB	+ ACTAVIS LABS UT INC	2.5%;2.5%		N019941	001	Dec 30, 1992	Feb	CAHN	
<u>LINACLOTIDE</u>									
CAPSULE;ORAL									
LINZESS									
	FOREST LABS LLC	145MCG		N202811	001	Aug 30, 2012	Mar	CAHN	
	+	290MCG		N202811	002	Aug 30, 2012	Mar	CAHN	
<u>LINCOMYCIN HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
LINCOCIN									
AP	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML		N050317	001		May	CFTG	
LINCOMYCIN									
AP	X-GEN PHARMS INC	EQ 300MG BASE/ML		A201746	001	Jun 04, 2015	May	NEWA	
<u>LINEZOLID</u>									
FOR SUSPENSION;ORAL									
LINEZOLID									
AB	ROXANE	100MG/5ML		A200068	001	Jun 03, 2015	May	NEWA	
ZYVOX									
AB	+ PHARMACIA AND UPJOHN	100MG/5ML		N021132	001	Apr 18, 2000	May	CFTG	
SOLUTION;IV (INFUSION)									
LINEZOLID									
AP	HOSPIRA INC	600MG/300ML (2MG/ML)		A205442	001	Jul 07, 2015	Jun	NEWA	
AP	SANDOZ INC	200MG/100ML (2MG/ML)		A200904	001	Jul 16, 2015	Jul	NEWA	
AP		600MG/300ML (2MG/ML)		A200904	002	Jul 16, 2015	Jul	NEWA	
AP	TEVA PHARMS	600MG/300ML (2MG/ML)		A200222	001	Jun 27, 2012	May	CDFR	
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
	+ HOSPIRA INC	600MG/300ML (2MG/ML)		N206473	001	Jun 18, 2015	Jun	NEWA	
ZYVOX									
AP	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)		N021131	001	Apr 18, 2000	Jul	CTEC	
		200MG/100ML (2MG/ML)		N021131	001	Apr 18, 2000	May	CDFR	
		400MG/200ML (2MG/ML)		N021131	002	Apr 18, 2000	May	NEWA	
AP	+	600MG/300ML (2MG/ML)		N021131	003	Apr 18, 2000	May	NEWA	
TABLET;ORAL									
LINEZOLID									
AB	TEVA PHARMS USA	600MG		A078061	001	May 18, 2015	May	NEWA	
ZYVOX									
AB	+ PHARMACIA AND UPJOHN	600MG		N021130	002	Apr 18, 2000	May	CFTG	
<u>LISINOPRIL</u>									
TABLET;ORAL									
LISINOPRIL									
AB	SUN PHARM INDS LTD	2.5MG		A075944	001	Jul 01, 2002	Apr	CAHN	
AB		5MG		A075944	002	Jul 01, 2002	Apr	CAHN	
AB		10MG		A075944	003	Jul 01, 2002	Apr	CAHN	
AB		20MG		A075944	004	Jul 01, 2002	Apr	CAHN	
AB		30MG		A075944	006	Feb 11, 2003	Apr	CAHN	
AB		40MG		A075944	005	Jul 01, 2002	Apr	CAHN	
ZESTRIL									
AB	ALVOGEN IPCO SARL	2.5MG		N019777	005	Apr 29, 1993	Feb	CAHN	
AB		5MG		N019777	001	May 19, 1988	Feb	CAHN	
AB		10MG		N019777	002	May 19, 1988	Feb	CAHN	
AB		20MG		N019777	003	May 19, 1988	Feb	CAHN	
AB		30MG		N019777	006	Jan 20, 1999	Feb	CAHN	
AB	+	40MG		N019777	004	May 19, 1988	Feb	CAHN	
<u>LITHIUM CARBONATE</u>									
TABLET, EXTENDED RELEASE;ORAL									
LITHIUM CARBONATE									
AB	ALEMBIC PHARMS LTD	300MG		A204445	001	Jun 10, 2015	May	NEWA	
	@ HIKMA INTL PHARMS	450MG		A076490	001	Jun 17, 2003	Feb	DISC	
AB	UNIQUE PHARM LABS	300MG		A204779	001	Jul 27, 2015	Jul	NEWA	

LOMITAPIDE MESYLATECAPSULE;ORAL
JUXTAPID

AEGERION

EQ 30MG BASE
EQ 40MG BASE
EQ 60MG BASEN203858 004 Apr 23, 2015 Apr NEWA
N203858 005 Apr 23, 2015 Apr NEWA
N203858 006 Apr 23, 2015 Apr NEWALOMUSTINE

CAPSULE;ORAL

GLEOSTINE

CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014 Jan NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

AB + @ J AND J CONSUMER INC

2MG
2MGN017690 001 Jul CAHN
N017694 001 Jul CAHNLOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

@ ABBVIE

133.3MG;33.3MG

N021226 001 Sep 15, 2000 Jun DISC

LORAZEPAM

INJECTABLE;INJECTION

ATIVAN

AP + EUROHLTH INTL SARL
AP +2MG/ML
4MG/MLN018140 001 Jun CAHN
N018140 002 Jun CAHN

TABLET;ORAL

LORAZEPAM

AB ANI PHARMS INC
AB
AB
AB SUN PHARM INDS LTD
AB
AB
AB0.5MG
1MG
2MG
0.5MG
1MG
2MGA077396 001 Dec 13, 2006 Oct CAHN
A077396 002 Dec 13, 2006 Oct CAHN
A077396 003 Dec 13, 2006 Oct CAHN
A076045 001 Aug 29, 2001 Apr CAHN
A076045 002 Aug 29, 2001 Apr CAHN
A076045 003 Aug 29, 2001 Apr CAHNLOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB HETERO LABS LTD V
AB
AB
AB UNICHEM LABS LTD
AB
AB
AB
AB WATSON LABS
AB
AB
AB25MG
50MG
100MG
25MG
50MG
100MG
25MG
50MG
100MGA203835 001 Aug 12, 2015 Jul NEWA
A203835 002 Aug 12, 2015 Jul NEWA
A203835 003 Aug 12, 2015 Jul NEWA
A203030 001 Oct 14, 2015 Oct NEWA
A203030 002 Oct 14, 2015 Oct NEWA
A203030 003 Oct 14, 2015 Oct NEWA
A091129 001 Oct 06, 2010 Feb CMFD
A091129 002 Oct 06, 2010 Feb CMFD
A091129 003 Oct 06, 2010 Feb CMFDLOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@ COVIS PHARMA SARL

10MG
20MG
40MG
60MGN021316 001 Jun 26, 2002 May CAHN
N021316 002 Jun 26, 2002 May CAHN
N021316 003 Jun 26, 2002 May CAHN
N021316 004 Jun 26, 2002 May CAHNLOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@ ACTAVIS LABS UT INC

EQ 25MG BASE/ML

N017658 001 Mar CAHN

INJECTABLE;INJECTION

LOXITANE IM

@ ACTAVIS LABS UT INC

EQ 50MG BASE/ML

N018039 001 Mar CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May CAHN

LOXITANE

@	ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar CAHN
@		EQ 10MG BASE	N017525	002		Mar CAHN
@		EQ 25MG BASE	N017525	003		Mar CAHN
@		EQ 50MG BASE	N017525	004		Mar CAHN

TABLET; ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar CAHN
@		EQ 25MG BASE	N017525	007		Mar CAHN
@		EQ 50MG BASE	N017525	008		Mar CAHN

LUCINACTANT

SUSPENSION; INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May DISC
---	----------------	-------	---------	-----	--------------	----------

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML; 128MG/100ML; 234MG/100ML	N019047	001	Jun 15, 1984	Mar DISC
---	-----------------	--------------------------------------	---------	-----	--------------	----------

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
AP	+ FRESenius KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESenius KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr NEWA
---	--------------------	--------------------	---------	-----	--------------	----------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

@	BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A, N/A, N/A, N/A, N/A, 210GM, 0.74GM, 2.86GM, 5.6GM	N203595	001	Jan 18, 2013	Aug DISC
---	----------------	---	---------	-----	--------------	----------

MANNITOL

INJECTABLE; INJECTION

MANNITOL 25%

@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar CAHN
@		12.5GM/50ML	A089240	001	May 06, 1987	Mar CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@	ANI PHARMS INC	12.5MG	A084975	001		Aug CAHN
@		25MG	A084657	001		Aug CAHN
@	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun DISC
@		25MG	A040179	002	Jan 30, 1997	Jun DISC

MELOXICAM

CAPSULE; ORAL

VIVLODEX

	IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015	Oct NEWA
+		10MG	N207233	002	Oct 22, 2015	Oct NEWA

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR

FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
	14MG	N022525	002	Jun 21, 2010	Mar CAHN
	21MG	N022525	003	Jun 21, 2010	Mar CAHN
+	28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

>A> AA	BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Nov NEWA
AA	MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015	Sep NEWA
AA	SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015	Sep NEWA
NAMENDA						
AA	+ FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
	+	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
AB		10MG	A090058	002	May 05, 2010	Mar CMFD
MEMANTINE HYDROCHLORIDE						
>A> AB	AJANTA PHARMA LTD	5MG	A206528	001	Nov 30, 2015	Nov NEWA
>A> AB		10MG	A206528	002	Nov 30, 2015	Nov NEWA
AB	ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200891	002	Oct 13, 2015	Sep NEWA
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar NEWA
AB	AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep NEWA
AB		10MG	A203175	002	Oct 13, 2015	Sep NEWA
AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep NEWA
AB		10MG	A091585	002	Oct 13, 2015	Sep NEWA
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar NEWA
AB	MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep NEWA
AB		10MG	A202840	002	Oct 13, 2015	Sep NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
	@	5MG	A079225	001	Jan 30, 2015	Mar DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun CMFD
	@	10MG	A079225	002	Jan 30, 2015	Mar DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan NEWA
>A> AB	PURACAP PHARM LLC	5MG	A206855	001	Nov 17, 2015	Nov NEWA
>A> AB		10MG	A206855	002	Nov 17, 2015	Nov NEWA
AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct CTNA
AB		10MG	A090058	002	May 05, 2010	Oct CTNA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
AB		10MG	A090052	002	Oct 25, 2011	May CMFD
AB	TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200155	002	Oct 13, 2015	Sep NEWA
AB	UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200022	002	Oct 13, 2015	Sep NEWA
AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul NEWA
AB		10MG	A090043	002	Jul 31, 2015	Jul NEWA
AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug NEWA
AB		10MG	A090073	002	Sep 04, 2015	Aug NEWA
NAMENDA						
AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

@ FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC
-----------	-----------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP		50MG/ML	A080445	002		Feb CAHN
AP		75MG/ML	A080445	003		Feb CAHN
AP		100MG/ML	A080445	004		Feb CAHN

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@	EUROHLTH INTL SARL	25MG/ML; 25MG/ML	N011730	001		Jun CAHN
---	--------------------	------------------	---------	-----	--	----------

MEROPENEM

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B	BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr NEWA
		1GM/VIAL	N202106	002	Apr 30, 2015	Apr NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul CAHN
---	---------------------	-------	---------	-----	--------------	----------

ENEMA; RECTAL

MESALAMINE

AB	G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Aug CAHN
----	------------------	----------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL

CANASA

>D>	+	@ FOREST LABS LLC	500MG	N021252	001	Jan 05, 2001	Aug CAHN
>A>	AB	+	1GM	N021252	002	Nov 05, 2004	Nov CFTG
		+	1GM	N021252	002	Nov 05, 2004	Nov CFTG
		+	1GM	N021252	002	Nov 05, 2004	Aug CAHN

MESALAMINE

>A>	AB	MYLAN PHARMS INC	1GM	A204354	001	Nov 24, 2015	Nov NEWA
-----	----	------------------	-----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

ASACOL

@	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Oct DISC
---	---------------------	-------	---------	-----	--------------	----------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

@	ACTAVIS LABS UT INC	0.1MG; 2MG	N013625	004		Mar CAHN
---	---------------------	------------	---------	-----	--	----------

TABLET; ORAL-21

NORINYL 1+50 21-DAY

@	ACTAVIS LABS UT INC	0.05MG; 1MG	N013625	002		Mar CAHN
---	---------------------	-------------	---------	-----	--	----------

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+	ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001		Mar CAHN
---	---------------------	-------------	---------	-----	--	----------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr DISC
@		0.6%	A070804	001	Aug 17, 1987	Apr DISC
@	WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr DISC
@		0.6%	A075586	002	May 30, 2002	Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@	G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr CAHN
@		10MG/5ML	A073034	001	Aug 30, 1991	Apr CAHN

METAXALONE

TABLET; ORAL

METAXALONE

>D>		COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
>A>			640MG	N022503	001	Jun 01, 2015	Nov DISC
	@		640MG	N022503	001	Jun 01, 2015	Nov DISC
			640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

RIOMET

+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN
---	--------------------	-----------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	500MG;EQ 15MG BASE	A204802	001	Nov 05, 2015	Oct NEWA
AB		850MG;EQ 15MG BASE	A204802	002	Nov 05, 2015	Oct NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

AB	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
AB	+	500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun NEWA
AB		500MG;2MG	A200624	002	Jul 15, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO

500MG;EQ 2MG BASE

N021410 002 Oct 10, 2002 May DISC

@

500MG;EQ 4MG BASE

N021410 003 Oct 10, 2002 May DISC

@

1GM;EQ 2MG BASE

N021410 004 Aug 25, 2003 May DISC

@

1GM;EQ 4MG BASE

N021410 005 Aug 25, 2003 May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 2MG BASE

A077337 001 May 07, 2014 May CTEC

500MG;EQ 4MG BASE

A077337 002 May 07, 2014 May CTEC

+

1GM;EQ 4MG BASE

A077337 004 May 07, 2014 May CRLD

1GM;EQ 2MG BASE

A077337 003 May 07, 2014 May CTEC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
AA		10MG	A203502	002	Aug 31, 2015	Aug NEWA
AA	COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
AA		10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE HYDROCHLORIDE

>A> AA	ROXANE	5MG	A203846	001	Nov 17, 2015	Nov NEWA
--------	--------	-----	---------	-----	--------------	----------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001	Jun CAHN
----	---	--------------------	---------------------	---------	-----	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD
----	--------------------	-----------------	---------	-----	--------------	----------

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
----	-------------	------	---------	-----	--------------	----------

METHYLNALTREXONE BROMIDE

>D>	INJECTABLE;SUBCUTANEOUS						
>D>	RELISTOR						
>D>	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Nov	CDFR
>D>	+	12MG/0.6ML (12MG/0.6ML)	N021964	003	Apr 24, 2008	Nov	CDFR
>A>	SOLUTION;SUBCUTANEOUS						
>A>	RELISTOR						
>A>	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Nov	CDFR
>A>	+	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Nov	CDFR

METHYLPHENIDATE HYDROCHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL						
	APTENSIO XR						
	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
		15MG	N205831	002	Apr 17, 2015	Apr	NEWA
		20MG	N205831	003	Apr 17, 2015	Apr	NEWA
		30MG	N205831	004	Apr 17, 2015	Apr	NEWA
		40MG	N205831	005	Apr 17, 2015	Apr	NEWA
		50MG	N205831	006	Apr 17, 2015	Apr	NEWA
	+	60MG	N205831	007	Apr 17, 2015	Apr	NEWA
	METHYLPHENIDATE HYDROCHLORIDE						
AB2	MALLINCKRODT INC	10MG	A203583	001	Sep 29, 2015	Sep	NEWA
AB2		20MG	A203583	002	Sep 29, 2015	Sep	NEWA
AB2		30MG	A203583	003	Sep 29, 2015	Sep	NEWA
AB2		40MG	A203583	004	Sep 29, 2015	Sep	NEWA
AB2		50MG	A203583	005	Sep 29, 2015	Sep	NEWA
AB2		60MG	A203583	006	Sep 29, 2015	Sep	NEWA
	RITALIN LA						
AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
	+	60MG	N021284	005	Oct 27, 2014	Feb	CRLD
	SOLUTION;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug	NEWA
AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug	NEWA
	TABLET;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB	ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015	Sep	NEWA
AB		10MG	A207416	002	Sep 22, 2015	Sep	NEWA
AB		20MG	A207416	003	Sep 22, 2015	Sep	NEWA
>A> AB	NOVEL LABS INC	5MG	A207884	001	Nov 13, 2015	Nov	NEWA
>A> AB		10MG	A207884	002	Nov 13, 2015	Nov	NEWA
>A> AB		20MG	A207884	003	Nov 13, 2015	Nov	NEWA
	TABLET, CHEWABLE;ORAL						
>D>	METHYLIN						
>D> AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Nov	DISC
>A>	@	2.5MG	N021475	001	Apr 15, 2003	Nov	DISC
	AB	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
>D> AB		5MG	N021475	002	Apr 15, 2003	Nov	DISC
>A>	@	5MG	N021475	002	Apr 15, 2003	Nov	DISC
	AB	5MG	N021475	002	Apr 15, 2003	Feb	CFTG
>D> AB	+	10MG	N021475	003	Apr 15, 2003	Nov	DISC
>A>	@	10MG	N021475	003	Apr 15, 2003	Nov	DISC
	AB	10MG	N021475	003	Apr 15, 2003	Feb	CFTG
	METHYLPHENIDATE HYDROCHLORIDE						
>D> AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Nov	CTEC
>A>		2.5MG	A204115	001	Feb 25, 2015	Nov	CTEC
	AB	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
>D> AB		5MG	A204115	002	Feb 25, 2015	Nov	CTEC
>A>		5MG	A204115	002	Feb 25, 2015	Nov	CTEC
	AB	5MG	A204115	002	Feb 25, 2015	Feb	NEWA
>D> AB		10MG	A204115	003	Feb 25, 2015	Nov	CRLD
>A>	+	10MG	A204115	003	Feb 25, 2015	Nov	CRLD
	AB	10MG	A204115	003	Feb 25, 2015	Feb	NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	METHYLIN ER						
AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
	METHYLPHENIDATE HYDROCHLORIDE						
AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
AB		20MG	A207488	002	Jun 09, 2015	May	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015	Nov NEWA
>A>	AP		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015	Nov NEWA
>A>	AP		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015	Nov NEWA
>A>	AP		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015	Nov NEWA

METHYLTESTOSTERONE

CAPSULE;ORAL

METHYLTESTOSTERONE

AB		IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015	Sep NEWA
		TESTRED					
AB	+	VALEANT PHARM INTL	10MG	A083976	001		Sep CTEC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AP	HOSPIRA	EQ 5MG BASE/ML	A073118	001	Jan 17, 1991	Nov CRLD
>A>	AP	+	EQ 5MG BASE/ML	A073118	001	Jan 17, 1991	Nov CRLD
>D>		REGLAN					
>D>	AP	+	BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	N017862	001	Nov CAHN
>D>		@	EQ 10MG BASE/ML	N017862	004	May 28, 1987	Nov CAHN
>A>		@	EUROHLTH INTL SARL	EQ 5MG BASE/ML	N017862	001	Nov DISC
>A>	AP	+	EQ 5MG BASE/ML	N017862	001		Nov CAHN
>A>		@	EQ 10MG BASE/ML	N017862	004	May 28, 1987	Nov CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION

METOPROLOL TARTRATE

AP		CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr CAHN
		TABLET;ORAL					
		METOPROLOL TARTRATE					
		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar NEWA
			75MG	A076704	005	Mar 18, 2015	Mar NEWA

METRONIDAZOLE

CREAM;TOPICAL

NORITATE

+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb CAHN
---	----------------------	----	---------	-----	--------------	----------

GEL;VAGINAL

METRONIDAZOLE

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CAHN
---	---------------------	------	---------	-----	--------------	----------

NUVESSA

+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb CTNA
---	---------------------	------	---------	-----	--------------	----------

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

>D>	AP	+	PFIZER	500MG/100ML	N018353	002	Nov DISC
>A>		@		500MG/100ML	N018353	002	Nov DISC

METRONIDAZOLE

@ EUROHLTH INTL SARL 500MG/100ML

N018907	001	Mar 30, 1984	Aug CAHN
---------	-----	--------------	----------

METRONIDAZOLE IN PLASTIC CONTAINER

AP		CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr CAHN
----	--	----------------------	-------------	---------	-----	--------------	----------

TABLET;ORAL

METRONIDAZOLE

AB		APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep NEWA
AB			500MG	A205245	002	Sep 23, 2015	Sep NEWA
AB		AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May NEWA
AB			500MG	A203974	002	May 29, 2015	May NEWA

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

@ IDT AUSTRALIA LTD 150MG

A074450	001	May 16, 1996	Oct CAHN
---------	-----	--------------	----------

@ 200MG

A074450	002	May 16, 1996	Oct CAHN
---------	-----	--------------	----------

@ 250MG

A074450	003	May 16, 1996	Oct CAHN
---------	-----	--------------	----------

MICONAZOLETABLET;BUCCAL
ORAVIG

+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	------------------	------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr CAHN
----	--------------------	----------------	---------	-----	--------------	----------

MIGLITOLTABLET;ORAL
GLYSET

AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb CFTG

MIGLITOL

AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATEINJECTABLE;INJECTION
MILRINONE LACTATE

AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep CAHN
AP	+	HIKMA FARMACEUTICA	A077966	001	Dec 03, 2010	Jan CRLD

MINOCYCLINE HYDROCHLORIDECAPSULE;ORAL
MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr CAHN
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr CAHN
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	+	SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep CRLD
AB		SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
AB			EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
AB			EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
AB			EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB			EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
SOLODYN							
MEDICIS							
			EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
AB			EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
AB	+		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD
<u>MIVACURIUM CHLORIDE</u>							
SOLUTION; INTRAVENOUS							
MIVACRON							
		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
	+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA
<u>MOLINDONE HYDROCHLORIDE</u>							
TABLET;ORAL							
MOLINDONE HYDROCHLORIDE							
		COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
			10MG	A090453	002	Mar 20, 2015	Mar NEWA
	+		25MG	A090453	003	Mar 20, 2015	Mar NEWA
<u>MONTELUKAST SODIUM</u>							
GRANULE;ORAL							
MONTELUKAST SODIUM							
AB		AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA
TABLET;ORAL							
MONTELUKAST SODIUM							
AB		AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
AB		AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
AB		UNICHEM LABS LTD	EQ 10MG BASE	A204290	001	Oct 08, 2015	Sep NEWA
TABLET, CHEWABLE;ORAL							
MONTELUKAST SODIUM							
AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
AB			EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
AB		ANBISON LAB CO LTD	EQ 4MG BASE	A205695	001	Nov 05, 2015	Oct NEWA
AB			EQ 5MG BASE	A205695	002	Nov 05, 2015	Oct NEWA
AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
AB			EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA
<u>MORPHINE SULFATE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
AVINZA							
		@ KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Sep DISC
		@	45MG	N021260	005	Dec 18, 2008	Sep DISC
		@	60MG	N021260	002	Mar 20, 2002	Sep DISC
		@	75MG	N021260	006	Dec 18, 2008	Sep DISC
		@	90MG	N021260	003	Mar 20, 2002	Sep DISC
		@	120MG	N021260	004	Mar 20, 2002	Sep DISC
KADIAN							
AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN

CAPSULE, EXTENDED RELEASE;ORAL
KADIAN

		130MG	N020616	011	Jul 09, 2012	Mar CAHN
		150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+	200MG	N020616	007	Feb 27, 2007	Mar CAHN
	MORPHINE SULFATE					
	ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013	Sep CTEC
		45MG	A079040	002	Jan 16, 2013	Sep CTEC
		60MG	A079040	003	Jan 16, 2013	Sep CTEC
		75MG	A079040	004	Jan 16, 2013	Sep CTEC
		90MG	A079040	005	Jan 16, 2013	Sep CTEC
	+	120MG	A079040	006	Jan 16, 2013	Sep CTEC
AB1	TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
AB1		70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE;INJECTION
DURAMORPH PF

AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN
	INFUMORPH						
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN
	MORPHINE SULFATE						
AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

SOLUTION;ORAL

MORPHINE SULFATE

AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May NEWA
AA			100MG/5ML	A203518	002	May 12, 2015	May NEWA
>A> AA		VINTAGE PHARMS LLC	10MG/5ML	A202309	001	Nov 25, 2015	Nov NEWA
AA			20MG/5ML	A202310	001	Oct 30, 2015	Oct NEWA

TABLET, EXTENDED RELEASE;ORAL

MORPHABOND

IDT

	IDT	15MG	N206544	001	Oct 02, 2015	Oct NEWA
		30MG	N206544	002	Oct 02, 2015	Oct NEWA
		60MG	N206544	003	Oct 02, 2015	Oct NEWA
+		100MG	N206544	004	Oct 02, 2015	Oct NEWA
	MORPHINE SULFATE					
AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar NEWA
AB		30MG	A203849	002	Apr 06, 2015	Mar NEWA
AB		60MG	A203849	003	Apr 06, 2015	Mar NEWA
AB		100MG	A203849	004	Apr 06, 2015	Mar NEWA
AB		200MG	A203849	005	Apr 06, 2015	Mar NEWA
AB	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Nov NEWA
AB		30MG	A203602	002	Dec 16, 2015	Nov NEWA
AB		60MG	A203602	003	Dec 16, 2015	Nov NEWA
AB		100MG	A203602	004	Dec 16, 2015	Nov NEWA
AB		200MG	A203602	005	Dec 16, 2015	Nov NEWA
AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr CAHN
AB		30MG	A078761	002	May 11, 2012	Apr CAHN
AB		60MG	A078761	003	May 11, 2012	Apr CAHN
AB		100MG	A078761	004	May 11, 2012	Apr CAHN
AB		200MG	A078761	005	May 11, 2012	Apr CAHN

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

	+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr NEWA
--	---	--------------------	--	---------	-----	--------------	----------

SOLUTION/DROPS;OPHTHALMIC

MOXEZA

AT2	+	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May CFTG
	MOXIFLOXACIN HYDROCHLORIDE						
AT1		LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May CTEC
AT2			EQ 0.5% BASE	A204079	001	May 28, 2015	May NEWA
AT1		WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May CTEC
AT			EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb NEWA
	VIGAMOX						
AT1	+	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May CTEC

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug NEWA
----	------------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL

MYCOPHENOLATE MOFETIL

@	DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct DISC
---	--------------------	-------	---------	-----	--------------	----------

NADOLOL

TABLET;ORAL

CORCARD

AB	US WORLD MEDS LLC	20MG	N018063	005	Oct 28, 1986	Oct CAHN
AB		40MG	N018063	001		Oct CAHN
AB	+	80MG	N018063	002		Oct CAHN
	@	120MG	N018063	003		Oct CAHN
	@	160MG	N018063	004		Oct CAHN

NADOLOL

AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug NEWA
AB		80MG	A201893	002	Sep 16, 2015	Aug NEWA

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

NALBUPHINE HYDROCHLORIDE

@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072071	001	Apr 10, 1989	Mar CAHN
@		10MG/ML	A072072	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072073	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072074	001	Apr 10, 1989	Mar CAHN
@		20MG/ML	A072075	001	Apr 10, 1989	Mar CAHN

NALMEFENE HYDROCHLORIDE

INJECTABLE;INJECTION

REVEX

@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun CAHN
@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar CAHN
---	--------------------	----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE

@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar CAHN
@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar CAHN
@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072091	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072092	001	Apr 11, 1989	Mar CAHN
@		1MG/ML	A072093	001	Apr 11, 1989	Mar CAHN

NARCAN

@	ADAPT	0.02MG/ML	N016636	002		Aug CAHN
@		0.4MG/ML	N016636	001		Aug CAHN
@		1MG/ML	N016636	003	Jun 14, 1982	Aug CAHN

SPRAY, METERED;NASAL

NARCAN

>A>	+	ADAPT PHARMA	4MG/SPRAY	N208411	001	Nov 18, 2015	Nov NEWA
-----	---	--------------	-----------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000	Apr CAHN
----	--------------------	----------------------------	---------	-----	--------------	----------

NAPROXENSUSPENSION;ORAL
NAPROSYN

AB	+	PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Apr CAHN
----	---	----------------	---------	---------	-----	--------------	----------

NAPROXEN SODIUMTABLET, EXTENDED RELEASE;ORAL
NAPRELAN

AB		ALVOGEN MALTA	EQ 375MG BASE	N020353	001	Jan 05, 1996	Oct CAHN
AB			EQ 500MG BASE	N020353	002	Jan 05, 1996	Oct CAHN
	+		EQ 750MG BASE	N020353	003	Jan 05, 1996	Oct CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET;ORAL
TREXIMET

		PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Jun NEWA
--	--	--------------------	-------------------	---------	-----	--------------	----------

NATEGLINIDETABLET;ORAL
NATEGLINIDE

>A>	AB	ALVOGEN MALTA	60MG	A205055	001	Dec 11, 2015	Nov NEWA
>A>	AB		120MG	A205055	002	Dec 11, 2015	Nov NEWA

NEBIVOLOL HYDROCHLORIDETABLET;ORAL
NEBIVOLOL HYDROCHLORIDE

		@ ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun DISC
			EQ 2.5MG BASE	A203741	001	Jun 24, 2015	Jun NEWA
		@	EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun DISC
			EQ 5MG BASE	A203741	002	Jun 24, 2015	Jun NEWA
		@	EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun DISC
			EQ 10MG BASE	A203741	003	Jun 24, 2015	Jun NEWA
		@	EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun DISC
			EQ 20MG BASE	A203741	004	Jun 24, 2015	Jun NEWA
		@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Apr DISC
AB			EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Mar NEWA
		@	EQ 5MG BASE	A203659	002	Apr 16, 2015	Apr DISC
AB			EQ 5MG BASE	A203659	002	Apr 16, 2015	Mar NEWA
		@	EQ 10MG BASE	A203659	003	Apr 16, 2015	Apr DISC
AB			EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
		@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB			EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA
		@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul DISC
			EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul NEWA
		@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul DISC
			EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul NEWA
		@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul DISC
			EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul NEWA
		@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul DISC
			EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul NEWA
>A>		@ WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015	Nov DISC
>A>			EQ 2.5MG BASE	A203683	001	Nov 27, 2015	Nov NEWA
>A>		@	EQ 5MG BASE	A203683	002	Nov 27, 2015	Nov DISC
>A>			EQ 5MG BASE	A203683	002	Nov 27, 2015	Nov NEWA
>A>		@	EQ 10MG BASE	A203683	003	Nov 27, 2015	Nov DISC
>A>			EQ 10MG BASE	A203683	003	Nov 27, 2015	Nov NEWA
>A>		@	EQ 20MG BASE	A203683	004	Nov 27, 2015	Nov DISC
>A>			EQ 20MG BASE	A203683	004	Nov 27, 2015	Nov NEWA

NEFAZODONE HYDROCHLORIDETABLET;ORAL
NEFAZODONE HYDROCHLORIDE

		@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
		@	100MG	A076072	002	Sep 16, 2003	Apr CAHN
		@	150MG	A076072	003	Sep 16, 2003	Apr CAHN
		@	200MG	A076072	004	Sep 16, 2003	Apr CAHN
		@	250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB		SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB			100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB			150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB			200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB			250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)
ARRANON

+ NOVARTIS PHARMS CORP 250MG/50ML (5MG/ML) N021877 001 Oct 28, 2005 Mar CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

FRESENIUS KABI USA 5MG/10ML (0.5MG/ML) N203629 001 Jan 08, 2015 Jan NEWA
10MG/10ML (1MG/ML) N203629 002 Jan 08, 2015 Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL
NEVIRAPINE

AB ALVOGEN MALTA 100MG A204621 002 Nov 09, 2015 Oct NEWA
AB 100MG A204621 002 Nov 09, 2015 Oct CAHN
AB 400MG A204621 001 Jul 10, 2015 Oct CAHN
AB ALVOGEN PINE BROOK 400MG A204621 001 Jul 10, 2015 Jun NEWA
AB CIPLA LTD 400MG A206448 001 Oct 15, 2015 Oct NEWA
AB MYLAN PHARMS INC 100MG A206271 001 Nov 09, 2015 Oct NEWA
VIRAMUNE XR
AB BOEHRINGER INGELHEIM 100MG N201152 002 Nov 08, 2012 Oct CFTG

NIACIN

TABLET, EXTENDED RELEASE;ORAL
NIACIN

AB AMNEAL PHARMS 500MG A203578 001 Jul 24, 2015 Jul NEWA
>A> AB 750MG A204178 001 Dec 11, 2015 Nov NEWA
AB 1GM A203578 002 Jul 24, 2015 Jul NEWA

NIFEDIPINE

CAPSULE;ORAL
NIFEDIPINE

AB HERITAGE PHARMA 10MG A202644 001 Apr 25, 2013 Mar CAHN
AB 20MG A202644 002 Apr 25, 2013 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE

AB2 VALEANT PHARMS NORTH 30MG A075289 002 Feb 06, 2001 Aug CAHN
AB2 60MG A075289 001 Sep 27, 2000 Aug CAHN

NILUTAMIDE

TABLET;ORAL
NILANDRON

@ CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996 Apr CAHN
+ 150MG N020169 002 Apr 30, 1999 Apr CAHN

NIMODIPINE

CAPSULE;ORAL
NIMODIPINE

AB + BANNER LIFE SCIENCES 30MG A076740 001 Jan 17, 2008 Jan CAHN
AB SOFGEN PHARMS 30MG A201832 001 Jul 24, 2015 Jul NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL
OFEV

BOEHRINGER INGELHEIM EQ 100MG BASE N205832 001 Oct 15, 2014 Mar CAIN
+ EQ 150MG BASE N205832 002 Oct 15, 2014 Mar CAIN

NITRIC OXIDE

GAS;INHALATION
INOMAX

@ INO 100PPM N020845 002 Dec 23, 1999 Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL
MACRODANTIN

AB ALVOGEN INC 25MG N016620 003 Jun CTEC
AB ALVOGEN MALTA 25MG N016620 003 Oct CAHN
AB 50MG N016620 001 Oct CAHN
AB + 100MG N016620 002 Oct CAHN

CAPSULE;ORAL					
NITROFURANTOIN					
AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015 Jun NEWA
AB		50MG	A091095	002	Jun 18, 2015 Jun NEWA
AB		100MG	A091095	003	Jun 18, 2015 Jun NEWA
<u>NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE</u>					
CAPSULE;ORAL					
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015 Jun NEWA
<u>NORETHINDRONE</u>					
TABLET;ORAL-28					
NOR-QD					
AB1	+ ACTAVIS LABS UT INC	0.35MG	N017060	001	Mar CAHN
<u>NORGESTREL</u>					
TABLET;ORAL					
OVRETTE					
	@ LABORATOIRE HRA	0.075MG	N017031	001	Jun CAHN
<u>NYSTATIN</u>					
CREAM;TOPICAL					
NYSTATIN					
AT	G AND W LABS INC	100,000 UNITS/GM	A061966	001	Jun CMFD
SUSPENSION;ORAL					
NYSTATIN					
AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982 Apr CAHN
	@	100,000 UNITS/ML	A062776	001	Dec 17, 1987 Apr CAHN
<u>NYSTATIN; TRIAMCINOLONE ACETONIDE</u>					
CREAM;TOPICAL					
MYKACET					
AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985 Mar CMFD
OINTMENT;TOPICAL					
MYKACET					
AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987 Mar CMFD
<u>OFLOXACIN</u>					
TABLET;ORAL					
OFLOXACIN					
AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003 Jul CMFD
<u>OLANZAPINE</u>					
TABLET;ORAL					
OLANZAPINE					
AB	ALKEM LABS LTD	2.5MG	A202295	001	Oct 20, 2015 Oct NEWA
AB		5MG	A202295	002	Oct 20, 2015 Oct NEWA
AB		7.5MG	A202295	003	Oct 20, 2015 Oct NEWA
AB		10MG	A202295	004	Oct 20, 2015 Oct NEWA
AB		15MG	A202295	005	Oct 20, 2015 Oct NEWA
AB		20MG	A202295	006	Oct 20, 2015 Oct NEWA
AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015 Apr NEWA
TABLET, ORALLY DISINTEGRATING;ORAL					
OLANZAPINE					
AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015 Feb NEWA
AB		10MG	A203044	002	Feb 20, 2015 Feb NEWA
AB		15MG	A203044	003	Feb 20, 2015 Feb NEWA
AB		20MG	A203044	004	Feb 20, 2015 Feb NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015 Feb NEWA
AB		10MG	A202937	002	Mar 02, 2015 Feb NEWA
AB		15MG	A202937	003	Mar 02, 2015 Feb NEWA
AB		20MG	A202937	004	Mar 02, 2015 Feb NEWA
<u>OLAPARIB</u>					
CAPSULE;ORAL					
LYNPARZA					
	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014 Jan CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION
STIOLTO RESPIMAT

+ BOEHRINGER INGELHEIM EQ 0.0025MG BASE/INH; EQ 0.0025MG BASE/INH N206756 001 May 21, 2015 May NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

>A> AT APOTEX INC EQ 0.1% BASE A078350 001 Dec 07, 2015 Nov NEWA
AT BARR LABS INC EQ 0.2% BASE A090848 001 Jul 13, 2015 Jun NEWA
>A> AT NOVEL LABS INC EQ 0.1% BASE A206306 001 Dec 07, 2015 Nov NEWA
>A> AT USV NORTH AMERICA EQ 0.1% BASE A203152 001 Dec 07, 2015 Nov NEWA
>A> AT ZACH SYSTEM SPA EQ 0.1% BASE A204706 001 Dec 07, 2015 Nov NEWA
PATADAY
AT + ALCON PHARMS LTD EQ 0.2% BASE N021545 001 Dec 22, 2004 Jun CFTG
PATANOL
>D> + ALCON EQ 0.1% BASE N020688 001 Dec 18, 1996 Nov CFTG
>A> AT + EQ 0.1% BASE N020688 001 Dec 18, 1996 Nov CFTG
PAZEO
+ ALCON RES LTD EQ 0.7% BASE N206276 001 Jan 30, 2015 Jan NEWA

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET; ORAL
TECHNIVIE

+ ABBVIE INC 12.5MG; 75MG; 50MG N207931 001 Jul 24, 2015 Aug CMS1
+ 12.5MG; 75MG; 50MG N207931 001 Jul 25, 2015 Jul NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

>A> AB AMNEAL PHARMS 1 GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS A204940 001 Nov 27, 2015 Nov NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL
OMEPRAZOLE

AB AUROBINDO PHARMA USA 10MG A203270 001 Aug 19, 2015 Aug NEWA
AB 20MG A203270 002 Aug 19, 2015 Aug NEWA
AB 40MG A203270 003 Aug 19, 2015 Aug NEWA
AB LUPIN LTD 40MG A202384 001 Aug 25, 2015 Aug NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL
ONDANSETRON

AB SUN PHARM INDS LTD 4MG A078602 001 Feb 24, 2011 Apr CAHN
AB 8MG A078602 002 Feb 24, 2011 Apr CAHN
ZOFTRAN ODT
AB NOVARTIS PHARMS CORP 4MG N020781 001 Jan 27, 1999 Mar CAHN
AB + 8MG N020781 002 Jan 27, 1999 Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDE

AP ACCORD HLTHCARE EQ 2MG BASE/ML A206846 001 Jul 13, 2015 Jun NEWA
AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078288 001 Feb 22, 2013 Apr CAHN
AP EUROHLTH INTL SARL EQ 2MG BASE/ML A077365 001 Dec 26, 2006 Jun CAHN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
AP CLARIS PHARMASERVICE EQ 2MG BASE/ML A078287 001 Feb 22, 2013 Apr CAHN
AP EUROHLTH INTL SARL EQ 2MG BASE/ML A077541 001 Dec 26, 2006 Jun CAHN
@ TARO PHARMS IRELAND EQ 2MG BASE/ML A078014 001 Mar 21, 2008 Jan DISC
ZOFTRAN
AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 001 Jan 04, 1991 Mar CAHN
ZOFTRAN PRESERVATIVE FREE
AP + NOVARTIS PHARMS CORP EQ 2MG BASE/ML N020007 003 Dec 10, 1993 Mar CAHN
SOLUTION; ORAL
ZOFTRAN
AA + NOVARTIS PHARMS CORP EQ 4MG BASE/5ML N020605 001 Jan 24, 1997 Mar CAHN

TABLET;ORAL									
ZOFTRAN									
AB		NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar	CAHN	
AB			EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar	CAHN	
AB	+		EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar	CAHN	
<u>ORPHENADRINE CITRATE</u>									
INJECTABLE;INJECTION									
NORFLEX									
		@ IGI LABS INC	30MG/ML	N013055	001		Apr	CAHN	
		@ MEDICIS	30MG/ML	N013055	001		Mar	DISC	
ORPHENADRINE CITRATE									
AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar	CRLD	
>A> <u>OSIMERTINIB MESYLATE</u>									
>A> TABLET;ORAL									
>A> TAGRISSO									
>A>		ASTRAZENECA PHARMS	EQ 40MG BASE	N208065	001	Nov 13, 2015	Nov	NEWA	
>A>	+		EQ 80MG BASE	N208065	002	Nov 13, 2015	Nov	NEWA	
<u>OXACILLIN SODIUM</u>									
CAPSULE;ORAL									
OXACILLIN SODIUM									
		@ ANI PHARMS INC	EQ 250MG BASE	A062222	001		Aug	CAHN	
		@	EQ 500MG BASE	A062222	002		Aug	CAHN	
INJECTABLE;INJECTION									
OXACILLIN SODIUM									
>A> AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015	Nov	NEWA	
>A> AP			EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015	Nov	NEWA	
<u>OXANDROLONE</u>									
TABLET;ORAL									
OXANDRIN									
AB		GEMINI LABS LLC	2.5MG	N013718	001		Aug	CAHN	
AB	+		10MG	N013718	002	Nov 05, 2001	Aug	CAHN	
<u>OXCARBAZEPINE</u>									
SUSPENSION;ORAL									
OXCARBAZEPINE									
AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr	CAHN	
<u>OXYBUTYNIN</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
OXYTROL									
AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar	CAHN	
GEL, METERED;TRANSDERMAL									
GELNIQUE 3%									
	+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar	CAHN	
<u>OXYBUTYNIN CHLORIDE</u>									
GEL;TRANSDERMAL									
GELNIQUE									
	+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
OXYBUTYNIN CHLORIDE									
>A> AB		AMNEAL PHARMS	5MG	A204010	001	Nov 23, 2015	Nov	NEWA	
>A> AB			10MG	A204010	002	Nov 23, 2015	Nov	NEWA	
>A> AB			15MG	A204010	003	Nov 23, 2015	Nov	NEWA	
<u>OXYCODONE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
OXYCODONE HYDROCHLORIDE									
AB		AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug	NEWA	
AB		NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug	NEWA	
SOLUTION;ORAL									
OXYCODONE HYDROCHLORIDE									
AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May	NEWA	
AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr	NEWA	
AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun	NEWA	

TABLET; ORAL

OXAYDO

	ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
		7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
	EGALET LTD	5MG	N202080	001	Jun 17, 2011	May CAHN
		7.5MG	N202080	002	Jun 17, 2011	May CAHN
	EGALET US INC	5MG	N202080	001	Jun 17, 2011	Jul CAHN
		7.5MG	N202080	002	Jun 17, 2011	Jul CAHN
	OXYCODONE HYDROCHLORIDE					
AB	ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
AB	EPIC PHARMA LLC	5MG	A202662	001	Sep 22, 2015	Sep NEWA
AB		10MG	A202662	002	Sep 22, 2015	Sep NEWA
AB		15MG	A202662	003	Sep 22, 2015	Sep NEWA
AB		30MG	A202662	004	Sep 22, 2015	Sep NEWA
AB	VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
AB		20MG	A077712	005	Apr 13, 2015	Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYMORPHONE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
AB		7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
AB		10MG	A203506	003	Apr 24, 2015	Apr NEWA
AB		15MG	A203506	004	Apr 24, 2015	Apr NEWA
AB		20MG	A203506	005	Apr 24, 2015	Apr NEWA
AB		30MG	A203506	006	Apr 24, 2015	Apr NEWA
AB		40MG	A203506	007	Apr 24, 2015	Apr NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001	Feb CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007 Feb CAHN

PALBOCICLIB

CAPSULE; ORAL

IBRANCE

	PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb NEWA
		100MG	N207103	002	Feb 03, 2015	Feb NEWA
	+	125MG	N207103	003	Feb 03, 2015	Feb NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

AB	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul CFTG
AB		3MG	N021999	001	Dec 19, 2006	Jul CFTG
AB	+	6MG	N021999	002	Dec 19, 2006	Jul CFTG
AB		9MG	N021999	003	Dec 19, 2006	Jul CFTG
	PALIPERIDONE					
AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul NEWA
AB		3MG	A202645	002	Aug 03, 2015	Jul NEWA
AB		6MG	A202645	003	Aug 03, 2015	Jul NEWA
AB		9MG	A202645	004	Aug 03, 2015	Jul NEWA
AB	MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015	Sep NEWA
AB		3MG	A203802	002	Sep 24, 2015	Sep NEWA
AB		6MG	A203802	003	Sep 24, 2015	Sep NEWA
AB		9MG	A203802	004	Sep 24, 2015	Sep NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May NEWA
	+	819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

AP	+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008 Sep CFTG
AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003 Sep CFTG

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

AP	SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015	Sep NEWA
AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015	Sep NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015	Sep NEWA

PANCURONIUM BROMIDEINJECTABLE; INJECTION
PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar CAHN

PANOBINOSTATCAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
		15MG	N205353	002	Feb 23, 2015	Feb NEWA
+		20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATECAPSULE; ORAL
FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAIN
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUMINJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
		TABLET, DELAYED RELEASE; ORAL				
		PANTOPRAZOLE SODIUM				
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAROXETINE HYDROCHLORIDETABLET; ORAL
PAROXETINE HYDROCHLORIDE

>A>	AB	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Nov NEWA
>A>	AB		EQ 20MG BASE	A205528	002	Nov 27, 2015	Nov NEWA
>A>	AB		EQ 30MG BASE	A205528	003	Nov 27, 2015	Nov NEWA
>A>	AB		EQ 40MG BASE	A205528	004	Nov 27, 2015	Nov NEWA

PATIROMER SORBITE CALCIUMPOWDER; ORAL
VELTASSA

	RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Oct NEWA
		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Oct NEWA
+		EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Oct NEWA

PAZOPANIB HYDROCHLORIDETABLET;ORAL
VOTRIENT+ NOVARTIS PHARMS CORP EQ 200MG BASE
@ EQ 400MG BASE
EQ 400MG BASEN022465 001 Oct 19, 2009 Mar CAHN
N022465 002 Oct 19, 2009 Aug DISC
N022465 002 Oct 19, 2009 Mar CAHNPENTOXIFYLLINETABLET, EXTENDED RELEASE;ORAL
PENTOXIFYLLINE

AB VALEANT PHARMS 400MG

A075028 001 Jul 20, 1998 Feb CAHN

PERPHENAZINETABLET;ORAL
PERPHENAZINE>A> AB INDICUS PHARMA 2MG
>A> AB 4MG
>A> AB 8MG
>A> AB 16MGA205973 001 Dec 17, 2015 Nov NEWA
A205973 002 Dec 17, 2015 Nov NEWA
A205973 003 Dec 17, 2015 Nov NEWA
A205973 004 Dec 17, 2015 Nov NEWAPHENDIMETRAZINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
BONTRIL@ VALEANT 105MG
PHENDIMETRAZINE TARTRATE
+ SANDOZ 105MGA088021 001 Sep 21, 1982 Jan DISC
N018074 001 Jan CTECPHENOXYBENZAMINE HYDROCHLORIDECAPSULE;ORAL
DIBENZYLINE

AB + CONCORDIA PHARMS INC 10MG

N008708 001 Jun CAHN

PHENTERMINE HYDROCHLORIDECAPSULE;ORAL
PHENTERMINE HYDROCHLORIDE

AA MIKAH PHARMA LLC 37.5MG

A040228 001 Jun 19, 1997 Jun CMFD

PHENYLEPHRINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE+ AKORN INC 2.5%
2.5%
+ 10%
10%
+ PARAGON BIOTECK 2.5%N207926 001 Jan 15, 2015 Sep CRLD
N207926 001 Jan 15, 2015 Jan NEWA
N207926 002 Jan 15, 2015 Sep CRLD
N207926 002 Jan 15, 2015 Jan NEWA
N203510 001 Mar 21, 2013 Sep CRLDPHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP;ORAL
PROMETH VC PLAIN

AA + G AND W LABS INC 5MG/5ML;6.25MG/5ML

A088761 001 Nov 08, 1984 Jul CAHN

PHENYTOIN SODIUMCAPSULE;ORAL
EXTENDED PHENYTOIN SODIUM@ WOCKHARDT 30MG EXTENDED
@ WOCKHARDT USA 100MG EXTENDED
PHENYTOIN SODIUM

AB AUROBINDO PHARMA LTD 100MG EXTENDED

A204309 001 Jun 10, 2015 May NEWA

INJECTABLE;INJECTION
PHENYTOIN SODIUM

AP + EUROHLTH INTL SARL 50MG/ML

A084307 001 Feb CAHN

PHYTONADIONEINJECTABLE;INJECTION
AQUAMEPHYTON@ IGI LABS INC 1MG/0.5ML
@ 10MG/MLN012223 002 Apr CAHN
N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE

	GEL;OPHTHALMIC								
	PILOPINE HS								
	@ ALCON	4%				N018796	001	Oct 01, 1984	Aug DISC
	TABLET;ORAL								
	PILOCARPINE HYDROCHLORIDE								
AB	ELAN PHARMA INTL LTD	5MG				A076746	001	Nov 16, 2004	Mar CAHN

PIMOZIDE

	TABLET;ORAL								
	ORAP								
AB	TEVA	1MG				N017473	003	Aug 27, 1997	Sep CFTG
AB	+	2MG				N017473	001	Jul 31, 1984	Sep CFTG
	PIMOZIDE								
AB	PAR PHARM	1MG				A204521	001	Sep 28, 2015	Sep NEWA
AB		2MG				A204521	002	Sep 28, 2015	Sep NEWA

PINDOLOL

	TABLET;ORAL								
	PINDOLOL								
	@ G AND W LABS INC	5MG				A073661	001	Oct 31, 1993	Apr CAHN
	@	5MG				A073687	001	Feb 26, 1993	Apr CAHN
	@	5MG				A074123	001	Apr 17, 1997	Apr CAHN
	@	10MG				A073661	002	Oct 31, 1993	Apr CAHN
	@	10MG				A073687	002	Feb 26, 1993	Apr CAHN
	@	10MG				A074123	002	Apr 17, 1997	Apr CAHN

PIRBUTEROL ACETATE

	AEROSOL, METERED;INHALATION								
	MAXAIR								
	@ MEDICIS	EQ 0.2MG BASE/INH				N020014	001	Nov 30, 1992	Jan DISC

PIRFENIDONE

	CAPSULE;ORAL								
	ESBRIET								
	+	GENENTECH INC	267MG			N022535	001	Oct 15, 2014	Feb CAHN

PIROXICAM

	CAPSULE;ORAL								
	PIROXICAM								
AB	MYLAN PHARMS INC	10MG				A074116	001	Jun 15, 1993	May CAHN
AB		20MG				A074118	001	Jun 15, 1993	May CAHN

PODOFILOX

	GEL;TOPICAL								
	CONDYLOX								
	+	ACTAVIS LABS UT INC	0.5%			N020529	001	Mar 13, 1997	Feb CAHN
	SOLUTION;TOPICAL								
	CONDYLOX								
AT	+	ACTAVIS LABS UT INC	0.5%			N019795	001	Dec 13, 1990	Jan CAHN
	PODOFILOX								
AT	BAUSCH AND LOMB INC	0.5%				A090184	001	Jul 21, 2010	May CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

	SOLUTION/DROPS;OPHTHALMIC								
	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE								
AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML				A064211	001	Apr 13, 1998	Jan CAHN

PONATINIB HYDROCHLORIDE

	TABLET;ORAL								
	ICLUSIG								
	ARIAD	EQ 30MG BASE				N203469	003	Apr 23, 2015	Apr NEWA

POTASSIUM CHLORIDE

	CAPSULE, EXTENDED RELEASE;ORAL								
	KLOR-CON								
AB	UPSHER SMITH	8MEQ				A203106	001	Jul 10, 2015	Jun NEWA
AB		10MEQ				A203106	002	Jul 10, 2015	Jun NEWA
	POTASSIUM CHLORIDE								
>A> AB	PHARMACEUTICS INTL	8MEQ				A205549	001	Dec 08, 2015	Nov NEWA

CAPSULE, EXTENDED RELEASE;ORAL									
POTASSIUM CHLORIDE									
>A>	AB	10MEQ		A205549	002	Dec 08, 2015	Nov	NEWA	
FOR SOLUTION;ORAL									
POTASSIUM CHLORIDE									
	PHARMA RES SOFTWARE	20MEQ		N208019	001	Aug 19, 2015	Aug	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
POTASSIUM CHLORIDE									
AB1	ADARE PHARMS INC	20MEQ		A076368	001	Aug 18, 2004	Jul	CAHN	
AB2	MYLAN PHARMS INC	8MEQ		A204662	001	Aug 21, 2014	Feb	CPOT	
AB2		10MEQ		A204662	002	Aug 21, 2014	Feb	CPOT	
AB2	PADDOCK LLC	8MEQ		A205993	001	Nov 05, 2015	Oct	NEWA	
AB2		10MEQ		A205993	002	Nov 05, 2015	Oct	NEWA	
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>									
TABLET;ORAL									
PRAMIPEXOLE DIHYDROCHLORIDE									
AB	GLENMARK GENERICS	0.75MG		A090781	006	Sep 11, 2015	Aug	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
PRAMIPEXOLE DIHYDROCHLORIDE									
AB	DR REDDYS LABS LTD	0.375MG		A203354	001	Aug 07, 2015	Jul	NEWA	
AB		0.75MG		A203354	002	Aug 07, 2015	Jul	NEWA	
AB		1.5MG		A203354	003	Aug 07, 2015	Jul	NEWA	
AB		3MG		A203354	004	Aug 07, 2015	Jul	NEWA	
AB		4.5MG		A203354	005	Aug 07, 2015	Jul	NEWA	
<u>PREDNICARBATE</u>									
OINTMENT;TOPICAL									
DERMATOP									
AB	+ VALEANT PHARMS NORTH	0.1%		N019568	001	Sep 23, 1991	Apr	CAHN	
<u>PREDNISOLONE ACETATE</u>									
>D>	SUSPENSION;ORAL								
>D>	FLO-PRED								
>D>	+ TARO	EQ 15MG BASE/5ML		N022067	002	Jan 17, 2008	Nov	DISC	
>A>	@	EQ 15MG BASE/5ML		N022067	002	Jan 17, 2008	Nov	DISC	
<u>PREDNISONE</u>									
TABLET;ORAL									
PREDNISONE									
	@ HIKMA PHARMS	1MG		A040890	001	Nov 01, 2010	Aug	DISC	
<u>PREGABALIN</u>									
CAPSULE;ORAL									
LYRICA									
	PF PRISM CV	25MG		N021446	001	Dec 30, 2004	Apr	CTEC	
		50MG		N021446	002	Dec 30, 2004	Apr	CTEC	
		75MG		N021446	003	Dec 30, 2004	Apr	CTEC	
		100MG		N021446	004	Dec 30, 2004	Apr	CTEC	
		150MG		N021446	005	Dec 30, 2004	Apr	CTEC	
		200MG		N021446	006	Dec 30, 2004	Apr	CTEC	
		225MG		N021446	007	Dec 30, 2004	Apr	CTEC	
	+	300MG		N021446	008	Dec 30, 2004	Apr	CTEC	
<u>PROCAINAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@ IDT AUSTRALIA LTD	250MG		A089219	001	Jul 01, 1986	Jun	CAHN	
	@	500MG		A089221	001	Jul 01, 1986	Jun	CAHN	
TABLET, EXTENDED RELEASE;ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@ IDT AUSTRALIA LTD	250MG		A089369	001	Aug 14, 1987	Jun	CAHN	
	@	500MG		A089370	001	Jan 09, 1987	Jun	CAHN	
	@	750MG		A089371	001	Aug 14, 1987	Jun	CAHN	
<u>PROCHLORPERAZINE EDISYLATE</u>									
INJECTABLE;INJECTION									
PROCHLORPERAZINE EDISYLATE									
AP	+ EUROHLTH INTL SARL	EQ 5MG BASE/ML		A089903	001	Aug 29, 1989	Feb	CAHN	

PROGESTERONECAPSULE; ORAL
PROGESTERONE

AB	BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013	Jan CAHN

GEL; VAGINAL
CRINONE

>D>	ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Nov CRLD
>A>	+	4%	N020701	001	Jul 31, 1997	Nov CRLD
		4%	N020701	001	Jul 31, 1997	Feb CAHN
	+	8%	N020701	002	Jul 31, 1997	Feb CAHN

INJECTABLE; INJECTION
PROGESTERONE

AO	+	ACTAVIS LABS UT INC	50MG/ML	N017362	002	Mar CAHN
----	---	---------------------	---------	---------	-----	----------

PROMETHAZINE HYDROCHLORIDEINJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	25MG/ML	A083312	001	Jun CAHN
AP	+		50MG/ML	A083312	002	Jun CAHN

SUPPOSITORY; RECTAL
PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N010926	002	Apr CAHN
@		25MG	N010926	001	Apr CAHN

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

AB	HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar CAHN
AB		25MG	A040673	002	Mar 05, 2008	Mar CAHN
AB		50MG	A040673	003	Mar 05, 2008	Mar CAHN

PROPAFENONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
PROPAFENONE HYDROCHLORIDE

AB	WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug NEWA
AB		325MG	A202688	002	Aug 24, 2015	Aug NEWA
AB		425MG	A202688	003	Aug 24, 2015	Aug NEWA

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

PYRIDOSTIGMINE BROMIDE

@	ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug CAHN
@		60MG	A040512	001	Oct 08, 2003	Aug CAHN
AB	ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA

TABLET, EXTENDED RELEASE; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	180MG	N011665	001	Jun CFTG	
		PYRIDOSTIGMINE BROMIDE					
AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	
AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

+	TURING PHARMS AG	25MG	N008578	001	Aug CAHN
---	------------------	------	---------	-----	----------

QUAZEPAM

TABLET; ORAL

DORAL

@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC
---	---------------------	------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

TABLET; ORAL

SEROQUEL

AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
	@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN
---	------------------	-------	---------	-----	--------------	----------

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@	CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
---	------------------	-------	---------	-----	--	----------

@		300MG	A085632	001		Jun CAHN
---	--	-------	---------	-----	--	----------

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE SULFATE

+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN
---	------------------	-------	---------	-----	--------------	----------

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

RABEPRAZOLE SODIUM

AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA
>A> AB	BRECKENRIDGE PHARM	20MG	A204237	001	Nov 18, 2015	Nov NEWA

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA

RAMELTEON

TABLET; ORAL

RAMELTEON

AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug NEWA
----	---------------------	-----	---------	-----	--------------	----------

RAMIPRIL

TABLET; ORAL

RAMIPRIL

>A>	APOTEX INC	1.25MG	A091069	001	Dec 02, 2015	Nov CTEC
>A> AB		1.25MG	A091069	001	Dec 02, 2015	Nov NEWA
>A>		2.5MG	A091069	002	Dec 02, 2015	Nov CTEC
>A> AB		2.5MG	A091069	002	Dec 02, 2015	Nov NEWA
>A>		5MG	A091069	003	Dec 02, 2015	Nov CTEC
>A> AB		5MG	A091069	003	Dec 02, 2015	Nov NEWA
>A>	+	10MG	A091069	004	Dec 02, 2015	Nov CRLD
>A> AB		10MG	A091069	004	Dec 02, 2015	Nov NEWA
>D> AB	MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011	Nov DISC
>A>	@	1.25MG	A090650	001	Jun 30, 2011	Nov DISC
>D> AB		2.5MG	A090650	002	Jun 30, 2011	Nov DISC
>A>	@	2.5MG	A090650	002	Jun 30, 2011	Nov DISC
>D> AB		5MG	A090650	003	Jun 30, 2011	Nov DISC
>A>	@	5MG	A090650	003	Jun 30, 2011	Nov DISC
>D> AB		10MG	A090650	004	Jun 30, 2011	Nov DISC
>A>	@	10MG	A090650	004	Jun 30, 2011	Nov DISC
>D> AB	ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009	Nov DISC
>A>	@	1.25MG	A090697	001	Sep 24, 2009	Nov DISC
>D> AB		2.5MG	A090697	002	Sep 24, 2009	Nov DISC
>A>	@	2.5MG	A090697	002	Sep 24, 2009	Nov DISC
>D> AB		5MG	A090697	003	Sep 24, 2009	Nov DISC
>A>	@	5MG	A090697	003	Sep 24, 2009	Nov DISC

TABLET;ORAL									
RAMIPRIL									
>D>	AB	10MG		A090697	004	Sep 24, 2009	Nov	DISC	
>A>	@	10MG		A090697	004	Sep 24, 2009	Nov	DISC	
<u>RANITIDINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
ZANTAC									
AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML		N019090	001	Oct 19, 1984	Jun	CAHN	
TABLET;ORAL									
RANITIDINE HYDROCHLORIDE									
	@ SUN PHARM INDS LTD	EQ 150MG BASE		A075439	001	Apr 19, 2000	Apr	CAHN	
	@	EQ 300MG BASE		A075439	002	Apr 19, 2000	Apr	CAHN	
<u>REPAGLINIDE</u>									
TABLET;ORAL									
REPAGLINIDE									
AB	STANDARD CHEM PHARM	0.5MG		A091517	001	Apr 24, 2015	Apr	NEWA	
AB		1MG		A091517	002	Apr 24, 2015	Apr	NEWA	
AB		2MG		A091517	003	Apr 24, 2015	Apr	NEWA	
<u>RIBAVIRIN</u>									
CAPSULE;ORAL									
REBETOL									
	@ MERCK SHARP DOHME	200MG		N020903	001	Jun 03, 1998	Jun	DISC	
<u>RISEDRONATE SODIUM</u>									
TABLET;ORAL									
RISEDRONATE SODIUM									
>A>	AB	APOTEX INC	35MG	A090877	001	Nov 30, 2015	Nov	NEWA	
>A>	AB	AUROBINDO PHARMA LTD	5MG	A200296	001	Nov 30, 2015	Nov	NEWA	
>A>	AB		30MG	A200296	002	Nov 30, 2015	Nov	NEWA	
>A>	AB		35MG	A200296	003	Nov 30, 2015	Nov	NEWA	
>A>	AB	MACLEODS PHARMS LTD	5MG	A203533	001	Dec 09, 2015	Nov	NEWA	
>A>	AB		30MG	A203533	002	Dec 09, 2015	Nov	NEWA	
>A>	AB	MYLAN PHARMS INC	5MG	A200477	001	Nov 30, 2015	Nov	NEWA	
>A>	AB		30MG	A200477	002	Nov 30, 2015	Nov	NEWA	
>A>	AB		35MG	A200477	003	Nov 30, 2015	Nov	NEWA	
>A>	AB	SUN PHARMA GLOBAL	5MG	A090886	001	Nov 30, 2015	Nov	NEWA	
>A>	AB		30MG	A090886	002	Nov 30, 2015	Nov	NEWA	
>A>	AB		35MG	A090886	003	Nov 30, 2015	Nov	NEWA	
TABLET, DELAYED RELEASE;ORAL									
ATELVIA									
AB	+ WARNER CHILCOTT LLC	35MG		N022560	001	Oct 08, 2010	May	CFTG	
RISEDRONATE SODIUM									
AB	TEVA PHARMS USA	35MG		A203217	001	May 18, 2015	May	NEWA	
<u>RISPERIDONE</u>									
TABLET, ORALLY DISINTEGRATING;ORAL									
RISPERIDONE									
>A>	AB	DR REDDYS LABS LTD	3MG	A077328	004	Nov 30, 2009	Nov	NEWA	
>A>	AB		4MG	A077328	005	Nov 30, 2009	Nov	NEWA	
	AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr	CAHN	
	AB		1MG	A077542	002	Aug 06, 2010	Apr	CAHN	
	AB		2MG	A077542	003	Aug 06, 2010	Apr	CAHN	
	AB		3MG	A078474	001	Aug 06, 2010	Apr	CAHN	
	AB		4MG	A078474	002	Aug 06, 2010	Apr	CAHN	
<u>RIVAROXABAN</u>									
TABLET;ORAL									
XARELTO									
	JANSSEN PHARMS	10MG		N022406	001	Jul 01, 2011	Apr	CRLD	
<u>RIVASTIGMINE</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
EXELON									
AB	NOVARTIS	4.6MG/24HR		N022083	001	Jul 06, 2007	Aug	CFTG	
AB	+	9.5MG/24HR		N022083	002	Jul 06, 2007	Aug	CFTG	
AB		13.3MG/24HR		N022083	005	Aug 31, 2012	Aug	CFTG	
RIVASTIGMINE									
AB	ALVOGEN INC	4.6MG/24HR		A204403	001	Sep 03, 2015	Aug	NEWA	
AB		9.5MG/24HR		A204403	002	Sep 03, 2015	Aug	NEWA	

FILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug NEWA
AB	ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL
RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL
RIZATRIPTAN BENZOATE

AB	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Oct NEWA
AB		EQ 10MG BASE	A203334	002	Oct 16, 2015	Oct NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION
ROCURONIUM BROMIDE

AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug CAHN

ROFLUMILAST

TABLET;ORAL
DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN
---	--------------------	--------	---------	-----	--------------	----------

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL
VARUBI

+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Sep NEWA
---	------------	--------------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL
ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL
ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul NEWA
		49MG;51MG	N207620	002	Jul 07, 2015	Jul NEWA
+		97MG;103MG	N207620	003	Jul 07, 2015	Jul NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL
KUVAN

	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Oct NEWA
--	----------------	--------------	---------	-----	--------------	----------

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL
SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	+	NOVARTIS	N017874	001		Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC 5MG
 @ 5MG
 @ 5MG

A074537 001 Aug 02, 1996 Apr CAHN
 A074744 001 Jan 27, 1997 Apr CAHN
 A074756 001 Nov 25, 1998 Apr CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

@ HIKMA PHARMS EQ 25MG BASE
 @ EQ 50MG BASE
 @ EQ 100MG BASE
 AB SUN PHARM INDS LTD EQ 25MG BASE
 AB EQ 50MG BASE
 AB EQ 100MG BASE
 EQ 150MG BASE
 EQ 200MG BASE

A077864 001 Aug 10, 2009 May DISC
 A077864 002 Aug 10, 2009 May DISC
 A077864 003 Aug 10, 2009 May DISC
 A077977 001 Feb 06, 2007 Apr CAHN
 A077977 002 Feb 06, 2007 Apr CAHN
 A077977 003 Feb 06, 2007 Apr CAHN
 A077977 004 Feb 06, 2007 Apr CAHN
 A077977 005 Feb 06, 2007 Apr CAHN

SEVOFLURANE

LIQUID; INHALATION

SEVOFLURANE

AN SHANGHAI HENGRUI 100%

A203793 001 Nov 03, 2015 Oct NEWA

SILDENAFIL CITRATE

SOLUTION; INTRAVENOUS

REVATIO

AP + PFIZER EQ 10MG BASE/12.5ML (EQ 0.8MG
 BASE/ML)

N022473 001 Nov 18, 2009 Mar CFTG

SILDENAFIL CITRATE

AP AUROBINDO PHARMA LTD EQ 10MG BASE/12.5ML (EQ 0.8MG
 BASE/ML)

A203988 001 Apr 01, 2015 Mar NEWA

TABLET; ORAL

SILDENAFIL CITRATE

>A> AB AUROBINDO PHARMA LTD EQ 20MG BASE

A203963 001 Nov 18, 2015 Nov NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

+ ACTAVIS LABS UT INC 4MG
 8MG

N022206 001 Oct 08, 2008 Mar CAHN
 N022206 002 Oct 08, 2008 Mar CAHN

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB BIOCON LIMITED 5MG
 AB 10MG
 AB 20MG
 AB 40MG
 AB 80MG
 AB SUN PHARM INDS LTD 5MG
 AB 10MG
 AB 20MG
 AB 40MG
 AB 80MG

A078034 001 Dec 20, 2006 Oct CAHN
 A078034 002 Dec 20, 2006 Oct CAHN
 A078034 003 Dec 20, 2006 Oct CAHN
 A078034 004 Dec 20, 2006 Oct CAHN
 A078034 005 Dec 20, 2006 Oct CAHN
 A076285 001 Dec 20, 2006 Apr CAHN
 A076285 002 Dec 20, 2006 Apr CAHN
 A076285 003 Dec 20, 2006 Apr CAHN
 A076285 004 Dec 20, 2006 Apr CAHN
 A076285 005 Jun 23, 2006 Apr CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP EUROHLTH INTL SARL 9MG/ML

A201850 001 Jan 20, 2012 Feb CAHN

SODIUM CHLORIDE 0.9%

EUROHLTH INTL SARL 9MG/ML

A201833 001 Sep 24, 2013 Feb CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ LIEBEL-FLARSHEIM 45MG/50ML (9MG/ML)
 112.5MG/125ML (9MG/ML)
 + 405MG/50ML (9MG/ML)
 1012.5MG/125ML (9MG/ML)

N021569 001 Jul 27, 2006 Feb CAHN
 N021569 002 Jul 27, 2006 Feb CAHN
 N021569 001 Jul 27, 2006 Feb CPOT
 N021569 002 Jul 27, 2006 Feb CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	3D IMAGING DRUG	10-200mCi/ML	A203777	001	Oct 19, 2015	Oct NEWA
AP	CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
AP	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
AP	IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug NEWA
>A> AP	MIDWEST MEDCL	10-200mCi/ML	A204440	001	Nov 17, 2015	Nov NEWA
AP	MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP	TRIAD ISOTOPES INC	10-200mCi/ML	A203968	001	Oct 23, 2015	Oct NEWA
>A> AP	UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015	Nov NEWA
AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+ CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+ @	200uCi	N018671	002	May 27, 1982	Apr CAHN
		400uCi	N018671	003	May 27, 1982	Apr CAHN

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 1.87GM/100ML

N016692	001		Sep DISC
---------	-----	--	----------

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN 1.87GM/100ML

N020004	001	Apr 21, 1992	Sep CTEC
---------	-----	--------------	----------

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

KVK TECH

15GM/BOT

A040905	002	Apr 03, 2015	Mar NEWA
---------	-----	--------------	----------

KAYEXALATE

AA	+ CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr CAHN
----	------------------------	-------------	---------	-----	--	----------

SODIUM TETRADECYL SULFATE

INJECTABLE;INJECTION

SOTRADECOL

+ MYLAN INSTITUTIONAL 20MG/2ML (10MG/ML)

A040541	001	Nov 12, 2004	Jul CRLD
---------	-----	--------------	----------

SOMATROPIN RECOMBINANT

INJECTABLE;INJECTION

NORDITROPIN FLEXPRO

NOVO NORDISK INC

30MG/3ML

N021148	011	Jan 23, 2015	Jan NEWA
---------	-----	--------------	----------

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC

30MG/3ML

N021148	007	Mar 10, 2009	Jul DISC
---------	-----	--------------	----------

30MG/3ML

N021148	007	Mar 10, 2009	Mar CMFD
---------	-----	--------------	----------

@

30MG/3ML

N021148	007	Mar 10, 2009	Jan DISC
---------	-----	--------------	----------

NUTROPIN

@ GENENTECH

5MG/VIAL

N020168	001	Nov 17, 1993	Jun DISC
---------	-----	--------------	----------

@

10MG/VIAL

N020168	002	Nov 17, 1993	Jun DISC
---------	-----	--------------	----------

BX	+ 10MG/VIAL		N020168	002	Nov 17, 1993	Mar CTEC
----	-------------	--	---------	-----	--------------	----------

NUTROPIN AQ

@ GENENTECH

10MG/2ML (5MG/ML)

N020522	001	Dec 29, 1995	Jun DISC
---------	-----	--------------	----------

NUTROPIN AQ NUSPIN

+ GENENTECH

5MG/2ML (2.5MG/ML)

N020522	003	Jan 03, 2008	Jun CTNA
---------	-----	--------------	----------

+ GENENTECH

10MG/2ML (5MG/ML)

N020522	005	Jan 03, 2008	Jun NEWA
---------	-----	--------------	----------

+ GENENTECH

20MG/2ML (10MG/ML)

N020522	004	Jan 03, 2008	Jun CTNA
---------	-----	--------------	----------

NUTROPIN AQ PEN

+ GENENTECH

20MG/2ML (10MG/ML)

N020522	006	Jan 03, 2008	Jun NEWA
---------	-----	--------------	----------

ZOMACTON

BX	+ FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar CTNA
----	-----------	----------	---------	-----	--------------	----------

BX		10MG/VIAL	N019774	003	Mar 07, 2012	Apr CRLD
----	--	-----------	---------	-----	--------------	----------

BX	+ 10MG/VIAL		N019774	003	Mar 07, 2012	Mar NEWA
----	-------------	--	---------	-----	--------------	----------

SONIDEGIB PHOSPHATECAPSULE;ORAL
ODOMZO

+ NOVARTIS PHARMS CORP EQ 200MG BASE N205266 001 Jul 24, 2015 Jul NEWA

SOTALOL HYDROCHLORIDESOLUTION;INTRAVENOUS
SOTALOL HYDROCHLORIDE

+ ALTATHERA PHARMS LLC 150MG/10ML (15MG/ML) N022306 001 Jul 02, 2009 Apr CAHN

TABLET;ORAL
BETAPACE

AB1	COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
AB1		120MG	N019865	005	Apr 20, 1994	Mar	CAHN
AB1	+	160MG	N019865	002	Oct 30, 1992	Mar	CAHN
AB1		240MG	N019865	003	Oct 30, 1992	Mar	CAHN
	@	320MG	N019865	004	Oct 30, 1992	Mar	CAHN

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

AP EUROHLTH INTL SARL 100% A206369 001 Sep 02, 2015 Aug NEWA

SUCCINYLCHOLINE CHLORIDEINJECTABLE;INJECTION
QUELICIN PRESERVATIVE FREE

@ HOSPIRA 100MG/ML N008845 004 Jun DISC

SUCRALFATETABLET;ORAL
SUCRALFATE

AB MYLAN PHARMS INC 1GM A074415 001 Jun 08, 1998 May CAHN

SUFENTANIL CITRATEINJECTABLE;INJECTION
SUFENTANIL CITRATE

AP EUROHLTH INTL SARL EQ 0.05MG BASE/ML A074413 001 Dec 15, 1995 Jun CAHN

SULFACETAMIDE SODIUMLOTION;TOPICAL
KLARON

AB + VALEANT PHARMS NORTH 10% N019931 001 Dec 23, 1996 Mar CAHN

OINTMENT;OPHTHALMIC
CETAMIDE

@ ALCON 10% A080021 001 Oct DISC

SULFACETAMIDE SODIUM

+ PERRIGO CO TENNESSEE 10% A080029 001 Oct CRLD

SOLUTION/DROPS;OPHTHALMIC
SULFACETAMIDE SODIUM

AT AKORN 10% A040215 001 May 25, 1999 Mar CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ ANI PHARMS INC 200MG/5ML;40MG/5ML A070028 001 Jun 02, 1987 Jul CAHN

SULFANILAMIDE

CREAM;VAGINAL

SULFANILAMIDE

@ G AND W LABS INC 15% A088718 001 Sep 19, 1985 Apr CAHN

SULFISOXAZOLE

TABLET;ORAL

SULFISOXAZOLE

@ ANI PHARMS INC 500MG A080142 001 Oct CAHN

SULINDACTABLET; ORAL
SULINDAC

@ ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992	Aug CAHN
@	200MG	A072973	001	Feb 28, 1992	Aug CAHN

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS
IMITREX STATDOSE

>D> BX	+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	Nov CTEC
>A> AB	+		EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	Nov CTEC
>D> AB	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Nov CTEC
>A> AB	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Nov CTEC

SUMATRIPTAN SUCCINATE

>A> AB		ANTARES PHARMA INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	A078319	001	Dec 10, 2015	Nov NEWA
>A> AB			EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A078319	002	Dec 10, 2015	Nov NEWA

TABLET; ORAL

SUMATRIPTAN SUCCINATE

		@ SANDOZ	EQ 25MG BASE	A076976	001	Aug 10, 2009	Sep DISC
		@	EQ 50MG BASE	A076976	002	Aug 10, 2009	Sep DISC
		@	EQ 100MG BASE	A076976	003	Aug 10, 2009	Sep DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr CAHN
AB			EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr CAHN
AB			EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE; ORAL

ENVARISUS XR

		VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul NEWA
			EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul NEWA
	+		EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+		DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May CAHN
---	--	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

NUCYNTA

		DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May CAHN
			EQ 75MG BASE	N022304	002	Nov 20, 2008	May CAHN
	+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May CAHN

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

		DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May CAHN
			EQ 100MG BASE	N200533	002	Aug 25, 2011	May CAHN
			EQ 150MG BASE	N200533	003	Aug 25, 2011	May CAHN
			EQ 200MG BASE	N200533	004	Aug 25, 2011	May CAHN
	+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May CAHN

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+		CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN
---	--	-------------------	------------	---------	-----	--------------	----------

TABLET; ORAL

SIVEXTRO

+		CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014	Sep CAHN
---	--	-------------------	-------	---------	-----	--------------	----------

TELAPREVIR

TABLET; ORAL

INCIVEK

@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
-----------------	-------	---------	-----	--------------	----------

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB		AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug NEWA
AB			40MG	A204415	002	Sep 08, 2015	Aug NEWA
AB			80MG	A204415	003	Sep 08, 2015	Aug NEWA

TABLET;ORAL							
TELMISARTAN							
AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug	NEWA
AB		40MG	A206511	002	Sep 03, 2015	Aug	NEWA
AB		80MG	A206511	003	Sep 03, 2015	Aug	NEWA
AB	INVENTIA HLTHCARE	20MG	A205150	001	Oct 30, 2015	Oct	NEWA
AB		40MG	A205150	002	Oct 30, 2015	Oct	NEWA
AB		80MG	A205150	003	Oct 30, 2015	Oct	NEWA
<u>TEMAZEPAM</u>							
CAPSULE;ORAL							
TEMAZEPAM							
AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
AB		30MG	A201781	004	Jun 04, 2015	May	NEWA
<u>TEMOZOLOMIDE</u>							
CAPSULE;ORAL							
TEMOZOLOMIDE							
AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
AB		250MG	A203691	006	May 08, 2015	Apr	NEWA
<u>TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET;ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA
VIREAD							
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG
<u>TERBINAFINE</u>							
GEL;TOPICAL							
LAMISIL							
	@ GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug	CAHN
<u>TERBINAFINE HYDROCHLORIDE</u>							
SOLUTION;TOPICAL							
LAMISIL							
	@ GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug	CAHN
TABLET;ORAL							
TERBINAFINE HYDROCHLORIDE							
	@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC
<u>TERCONAZOLE</u>							
SUPPOSITORY;VAGINAL							
TERCONAZOLE							
AB	TARO	80MG	A077553	001	Mar 09, 2007	Sep	CMFD
<u>TESTOSTERONE</u>							
GEL;TRANSDERMAL							
ANDROGEL							
AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+ TESTIM	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC
AB2	+ AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
TESTOSTERONE							
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug	CMFD
AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug	CMFD
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC

GEL;TRANSDERMAL
VOGELXO

AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC
GEL, METERED;TRANSDERMAL ANDROGEL						
AB	+ ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul CFTG
AB	+ FORTESTA					
AB	+ ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG
	TESTOSTERONE					
AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA
AB		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA
AB	PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE						
AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
AB		25MG	A206129	002	Aug 17, 2015	Aug NEWA
XENAZINE						
AB	VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
		12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
AB	+	25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+	25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ACHROMYCIN V						
AB	+ HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD
TETRACYCLINE HYDROCHLORIDE						
	@ CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep CAHN
	@	500MG	A062752	002	Aug 12, 1988	Sep CAHN
	@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
	@	500MG	A060704	002		Apr DISC

THEOPHYLLINE

TABLET;ORAL

THEOLAIR						
	@ MEDICIS	125MG	A086399	001		Mar DISC
	@	250MG	A086399	002		Mar DISC
TABLET, EXTENDED RELEASE;ORAL THEOPHYLLINE						
>A> AB	MYLAN PHARMS INC	400MG	A040560	003	Apr 21, 2006	Nov CMS1
AB	+	600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA						
	+ EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD

TICAGRELOR

TABLET;ORAL

BRILINTA						
	ASTRAZENECA LP	60MG	N022433	002	Sep 03, 2015	Sep NEWA

TIGECYCLINE

INJECTABLE;IV (INFUSION)

TIGECYCLINE						
AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA
TYGACIL						
AP	+ PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

ISTALOL						
AT2	+ BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG
TIMOLOL MALEATE						
AT1	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
AT1		EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
AT1	ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC

SOLUTION/DROPS;OPHTHALMIC							
TIMOLOL MALEATE							
AT1	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr	CTEC
AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr	CTEC
AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr	CTEC
AT1	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr	CTEC
TIMOPTIC							
AT1	+ ATON	EQ 0.5% BASE	N018086	002		Apr	CTEC
<u>TINIDAZOLE</u>							
TABLET;ORAL							
TINIDAZOLE							
AB	EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul	NEWA
AB		500MG	A203808	002	Aug 04, 2015	Jul	NEWA
<u>TIOTROPIUM BROMIDE</u>							
SPRAY, METERED;INHALATION							
SPIRIVA RESPIMAT							
	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Sep	NEWA
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE</u>							
TABLET;ORAL							
LONSURF							
	TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Sep	NEWA
	+	EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Sep	NEWA
<u>TOBRAMYCIN</u>							
SOLUTION;INHALATION							
KITABIS PAK							
AN	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb	CTEC
TOBRAMYCIN							
AN	AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun	NEWA
SOLUTION/DROPS;OPHTHALMIC							
TOBREX							
AT	+ ALCON LABS INC	0.3%	N050541	001		Mar	CAHN
<u>TOBRAMYCIN SULFATE</u>							
INJECTABLE;INJECTION							
TOBRAMYCIN SULFATE							
	@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
	@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN
TOBRAMYCIN SULFATE (PHARMACY BULK)							
	+ FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CTEC
AP	+	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CRLD
<u>TOLAZAMIDE</u>							
TABLET;ORAL							
TOLAZAMIDE							
	@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
	@	250MG	N018894	002	Nov 02, 1984	Apr	CAHN
	@	500MG	N018894	003	Nov 02, 1984	Apr	CAHN
<u>TOLCAPONE</u>							
TABLET;ORAL							
TASMAR							
AB	+ VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG
TOLCAPONE							
AB	PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA
<u>TOLMETIN SODIUM</u>							
TABLET;ORAL							
TOLMETIN SODIUM							
	@ G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
	@	EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE;ORAL
TOLTERODINE TARTRATE

AB	TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul NEWA
AB		4MG	A203016	002	Aug 11, 2015	Jul NEWA
TABLET;ORAL						
TOLTERODINE TARTRATE						
AB	IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb NEWA
AB		2MG	A077006	002	Feb 23, 2015	Feb NEWA
AB	MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug NEWA
AB		2MG	A203409	002	Aug 31, 2015	Aug NEWA

TOPIRAMATETABLET;ORAL
TOPIRAMATE

AB	SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr CAHN
AB		100MG	A076327	002	Mar 27, 2009	Apr CAHN
AB		200MG	A076327	003	Mar 27, 2009	Apr CAHN
	@ WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr DISC
	@	50MG	A090353	002	Sep 01, 2010	Apr DISC
	@	100MG	A090353	003	Sep 01, 2010	Apr DISC
	@	200MG	A090353	004	Sep 01, 2010	Apr DISC
TOPIRAMATE						
	@ HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May DISC
	@	50MG	A091185	002	Nov 25, 2013	May DISC
	@	100MG	A091185	003	Nov 25, 2013	May DISC
	@	200MG	A091185	004	Nov 25, 2013	May DISC

TOPOTECAN HYDROCHLORIDECAPSULE;ORAL
HYCAMTIN

	NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar CAHN	
+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar CAHN	
	INJECTABLE;INJECTION						
	HYCAMTIN						
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar CAHN
	TOPOTECAN HYDROCHLORIDE						
AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May CAHN

TORSEMIDEINJECTABLE;INJECTION
TORSEMIDE

	EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan DISC
@		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan DISC
@	LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan DISC
@		50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan DISC

TRABECTEDINPOWDER;IV (INFUSION)
YONDELIS

+	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015	Oct NEWA
---	---------------	----------	---------	-----	--------------	----------

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE						
AB	MACLEODS PHARMS LTD	50MG	A205702	001	Sep 25, 2015	Sep NEWA
TABLET, EXTENDED RELEASE;ORAL						
TRAMADOL HYDROCHLORIDE						
AB1	AUROBINDO PHARMA LTD	100MG	A204421	001	Oct 20, 2015	Oct NEWA
AB1		200MG	A204421	002	Oct 20, 2015	Oct NEWA
AB1		300MG	A204421	003	Oct 20, 2015	Oct NEWA

TRAMETINIB DIMETHYL SULFOXIDETABLET;ORAL
MEKINIST

>D>	NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Nov CPOT
>A>		EQ 0.5MG	N204114	001	May 29, 2013	Nov CPOT
		EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar CAHN
>D>		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Nov CPOT
>A>		EQ 1MG	N204114	002	May 29, 2013	Nov CPOT
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar CAHN

		TABLET;ORAL							
		MEKINIST							
>D>	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Nov	CPOT	
>A>	+		EQ 2MG	N204114	003	May 29, 2013	Nov	CPOT	
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN	
<u>TRANEXAMIC ACID</u>									
		INJECTABLE;INJECTION							
		TRANEXAMIC ACID							
AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD	
		TABLET;ORAL							
		TRANEXAMIC ACID							
AB		MYLAN	650MG	A205133	001	Sep 21, 2015	Sep	NEWA	
<u>TRANLYCYPROMINE SULFATE</u>									
		TABLET;ORAL							
		PARNATE							
AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN	
<u>TRAVOPROST</u>									
		SOLUTION/DROPS;OPHTHALMIC							
		IZBA							
		@ ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul	DISC	
		TRAVATAN Z							
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC	
		TRAVOPROST							
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA	
<u>TRAZODONE HYDROCHLORIDE</u>									
		TABLET;ORAL							
		DESYREL							
		@ PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN	
		@	100MG	N018207	002		May	CAHN	
		@	150MG	N018207	003	Mar 25, 1985	May	CAHN	
		@	300MG	N018207	004	Nov 07, 1988	May	CAHN	
<u>TRETINOIN</u>									
		CREAM;TOPICAL							
		RENOVA							
	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN	
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN	
		RETIN-A							
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN	
		GEL;TOPICAL							
		ATRALIN							
AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul	CTEC	
		TRETINOIN							
AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul	NEWA	
<u>TRIAMCINOLONE ACETONIDE</u>									
		CREAM;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD	
AT			0.1%	A089798	001	May 31, 1991	Apr	CMFD	
		TRIDERM							
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA	
AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA	
		LOTION;TOPICAL							
		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD	
		OINTMENT;TOPICAL							
		KENALOG							
AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD	
AT			0.1%	N011600	001		Mar	CMFD	
		TRIAMCINOLONE ACETONIDE							
AT		G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug	CMFD	
AT			0.1%	A089796	001	Dec 23, 1988	Aug	CMFD	
		SPRAY;TOPICAL							
		KENALOG							
AT	+	RANBAXY	0.147MG/GM	N012104	001		Mar	CFTG	
AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Aug	CAHN	

SPRAY; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar	NEWA		
<u>TRIAMTERENE</u>									
CAPSULE; ORAL									
DYRENIUM									
	CONCORDIA PHARMS INC	50MG	N013174	001		Apr	CAHN		
+		100MG	N013174	002		Apr	CAHN		
<u>TRIMIPRAMINE MALEATE</u>									
CAPSULE; ORAL									
SURMONTIL									
AB	+	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun	CRLD	
AB			EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun	CRLD	
<u>TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)</u>									
CREAM; VAGINAL									
VAGILIA									
	@ G AND W LABS INC	3.7%; 2.86%; 3.42%	A088821	001	Nov 09, 1987	Jul	CAHN		
<u>TRIPTORELIN PAMOATE</u>									
INJECTABLE; INTRAMUSCULAR									
TRELSTAR									
+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan	CAHN		
+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan	CAHN		
+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan	CAHN		
<u>TROSPIUM CHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
TROSPIUM CHLORIDE									
AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD		
AB	+	60MG	A091289	001	Oct 12, 2012	May	CRLD		
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA		
TABLET; ORAL									
TROSPIUM CHLORIDE									
AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD		
AB	+	20MG	A091575	001	Aug 13, 2010	May	CRLD		
<u>UNOPROSTONE ISOPROPYL</u>									
SOLUTION/DROPS; OPHTHALMIC									
RESCULA									
+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN		
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN		
<u>URIDINE TRIACETATE</u>									
GRANULE; ORAL									
XURIDEN									
+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015	Sep	NEWA		
<u>URSODIOL</u>									
CAPSULE; ORAL									
ACTIGALL									
	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN		
AB	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN		
<u>VALACYCLOVIR HYDROCHLORIDE</u>									
TABLET; ORAL									
VALACYCLOVIR HYDROCHLORIDE									
AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA		
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA		
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr	CAHN		
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr	CAHN		
<u>VALPROIC ACID</u>									
CAPSULE; ORAL									
VALPROIC ACID									
AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN		
CAPSULE, DELAYED RELEASE; ORAL									
STAVZOR									
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN		

CAPSULE, DELAYED RELEASE;ORAL							
STAVZOR							
	@	250MG		N022152	002	Jul 29, 2008	Jan CAHN
	@	500MG		N022152	003	Jul 29, 2008	Jan CAHN
<u>VALSARTAN</u>							
TABLET;ORAL							
VALSARTAN							
AB	PRINSTON INC	40MG		A204821	001	Jun 09, 2015	May NEWA
AB		80MG		A204821	002	Jun 09, 2015	May NEWA
AB		160MG		A204821	003	Jun 09, 2015	May NEWA
AB		320MG		A204821	004	Jun 09, 2015	May NEWA
<u>VANCOMYCIN HYDROCHLORIDE</u>							
CAPSULE;ORAL							
VANCOMYCIN HYDROCHLORIDE							
AB	LUPIN LTD	EQ 125MG BASE		A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE		A090439	002	Jan 28, 2015	Jan NEWA
INJECTABLE;INJECTION							
VANCOLED							
	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL		A062682	001	Jul 22, 1986	Jun CAHN
	@	EQ 1GM BASE/VIAL		A062682	002	Mar 30, 1988	Jun CAHN
	@	EQ 2GM BASE/VIAL		A062682	003	May 11, 1988	Jun CAHN
	@	EQ 5GM BASE/VIAL		A062682	004	May 11, 1988	Jun CAHN
	@	EQ 10GM BASE/VIAL		A062682	005	May 11, 1988	Jun CAHN
VANCOMYCIN HYDROCHLORIDE							
AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL		A091377	001	Sep 09, 2015	Aug NEWA
AP		EQ 1GM BASE/VIAL		A091377	002	Sep 09, 2015	Aug NEWA
<u>VARDENAFIL HYDROCHLORIDE</u>							
TABLET, ORALLY DISINTEGRATING;ORAL							
STAXYN							
AB	+ BAYER HLTHCARE	10MG		N200179	001	Jun 17, 2010	Apr CFTG
VARDENAFIL HYDROCHLORIDE							
AB	WATSON LABS INC	10MG		A203689	001	Apr 22, 2015	Apr NEWA
<u>VENLAFAXINE HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE		A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE		A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE		A090071	003	Apr 15, 2011	Feb CAHN
TABLET;ORAL							
VENLAFAXINE HYDROCHLORIDE							
AB	YAOPHARMA CO LTD	EQ 25MG BASE		A202036	001	May 28, 2015	May NEWA
AB		EQ 37.5MG BASE		A202036	002	May 28, 2015	May NEWA
AB		EQ 50MG BASE		A202036	003	May 28, 2015	May NEWA
AB		EQ 75MG BASE		A202036	004	May 28, 2015	May NEWA
AB		EQ 100MG BASE		A202036	005	May 28, 2015	May NEWA
<u>VERAPAMIL HYDROCHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
VERELAN							
AB	RECRO GAINESVILLE	120MG		N019614	001	May 29, 1990	Apr CAHN
AB		180MG		N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG		N019614	002	May 29, 1990	Apr CAHN
	+ VERELAN PM	360MG		N019614	004	May 10, 1996	Apr CAHN
AB	RECRO GAINESVILLE	100MG		N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG		N020943	002	Nov 25, 1998	Apr CAHN
AB	+ VERELAN PM	300MG		N020943	003	Nov 25, 1998	Apr CAHN
INJECTABLE;INJECTION							
CALAN							
	@ EXELA PHARMA SCS LLC	2.5MG/ML		N018925	001	Mar 30, 1984	Aug CAHN
ISOPTIN							
	@ MT ADAMS	2.5MG/ML		N018485	001		Apr CAHN
TABLET;ORAL							
ISOPTIN							
	@ MT ADAMS	40MG		N018593	003	Nov 23, 1987	Apr CAHN
	@	80MG		N018593	001	Mar 08, 1982	Apr CAHN
	@	120MG		N018593	002	Mar 08, 1982	Apr CAHN

TABLET;ORAL							
VERAPAMIL HYDROCHLORIDE							
AB	HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015	Oct	NEWA
<u>VERTEPORFIN</u>							
INJECTABLE;INJECTION							
VISUDYNE							
+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar	CAHN
<u>VILAZODONE HYDROCHLORIDE</u>							
TABLET;ORAL							
VIIBRYD							
+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar	CAHN
		20MG	N022567	002	Jan 21, 2011	Mar	CAHN
		40MG	N022567	003	Jan 21, 2011	Mar	CAHN
<u>VINORELBINE TARTRATE</u>							
INJECTABLE;INJECTION							
VINORELBINE TARTRATE							
AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep	CAHN
<u>VORICONAZOLE</u>							
TABLET;ORAL							
VORICONAZOLE							
AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug	NEWA
AB		200MG	A203503	002	Sep 02, 2015	Aug	NEWA
<u>ZAFIRLUKAST</u>							
TABLET;ORAL							
ACCOLATE							
AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb	CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb	CAHN
<u>ZOLEDRONIC ACID</u>							
INJECTABLE;IV (INFUSION)							
ZOLEDRONIC ACID							
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul	CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT
<u>ZOLMITRIPTAN</u>							
TABLET;ORAL							
ZOLMITRIPTAN							
AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep	NEWA
AB		5MG	A204232	002	Sep 30, 2015	Sep	NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep	NEWA
AB		5MG	A203772	002	Sep 30, 2015	Sep	NEWA
TABLET, ORALLY DISINTEGRATING;ORAL							
ZOLMITRIPTAN							
AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep	NEWA
AB		5MG	A202956	002	Sep 17, 2015	Sep	NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct	NEWA
AB		5MG	A204336	002	Oct 22, 2015	Oct	NEWA
<u>ZOLPIDEM TARTRATE</u>							
SPRAY, METERED;ORAL							
ZOLPIMIST							
+	AMHERST PHARMS LLC	5MG/SPRAY	N022196	001	Dec 19, 2008	Sep	CAHN
TABLET;ORAL							
ZOLPIDEM TARTRATE							
	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar	DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar	DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr	CAHN
TABLET;SUBLINGUAL							
INTERMEZZO							
AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May	CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May	CFTG
ZOLPIDEM TARTRATE							
AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May	NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

@ J AND J CONSUMER INC 120MG

N017756 002

Aug CAHN

@ 650MG

N017756 001

Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG

A078569 001

Dec 14, 2011

Apr CAHN

@ 650MG

A090205 001

Nov 18, 2009

Apr CAHN

TYLENOL

+ J AND J CONSUMER INC 650MG

N019872 001

Jun 08, 1994

Aug CAHN

+ 650MG

N019872 002

Jan 11, 2001

Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001

Dec 07, 1992

Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003

Mar 23, 2015

Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001

Dec 07, 2001

Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001

Oct 16, 2000

Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 004

Jul 23, 2009

Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 002

Jul 23, 2009

Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML

N022155 002

Nov 16, 2007

Aug CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML

N022155 001

Nov 16, 2007

Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 5MG

A090760 001

Aug 05, 2015

Jul NEWA

10MG

A090760 003

Aug 05, 2015

Jul NEWA

SUN PHARM INDS LTD 5MG

A077498 001

Dec 27, 2007

Apr CAHN

10MG

A077498 002

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003

Dec 27, 2007

Apr CAHN

10MG

A077498 004

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 5MG

A090760 002

Aug 05, 2015

Jul NEWA

10MG

A090760 004

Aug 05, 2015

Jul NEWA

ZYRTEC ALLERGY

J AND J CONSUMER INC 5MG

N019835 003

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 004

Nov 16, 2007

Aug CAHN

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC 5MG

N019835 005

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 006

Nov 16, 2007

Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001

Feb 19, 2015

Feb NEWA

10MG

A091116 002

Feb 19, 2015

Feb NEWA

SANDOZ 5MG

A078692 001

Feb 14, 2008

Feb CTNA

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

+	10MG	A078692	002	Feb 14, 2008	Feb CTNA
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
	JUBILANT GENERICS 5MG	A091116	003	Feb 19, 2015	Feb NEWA
	10MG	A091116	004	Feb 19, 2015	Feb NEWA
	CHILDREN'S ZYRTEC ALLERGY				
	@ J AND J CONSUMER INC 5MG	N021621	003	Nov 16, 2007	Aug CAHN
	@ 10MG	N021621	004	Nov 16, 2007	Aug CAHN
	CHILDREN'S ZYRTEC HIVES RELIEF				
	@ J AND J CONSUMER INC 5MG	N021621	005	Nov 16, 2007	Aug CAHN
	@ 10MG	N021621	006	Nov 16, 2007	Aug CAHN
	TABLET, ORALLY DISINTEGRATING;ORAL				
	CETIRIZINE HYDROCHLORIDE ALLERGY				
	PAR PHARM INC 10MG	A205490	001	Sep 02, 2015	Aug NEWA
	ZYRTEC ALLERGY				
+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010	Aug CAHN

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ZYRTEC-D 12 HOUR

+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007	Aug CAHN
---	--------------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

	@ BAYER HEALTHCARE LLC 8MG	N007638	001		Mar CAHN
+	12MG	N007638	002		Mar CAHN

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001		Mar CAHN
---	--------------------------------	---------	-----	--	----------

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	@ ANI PHARMS INC 1.34MG	A073282	002	Dec 03, 1992	Jul CAHN
--	-------------------------	---------	-----	--------------	----------

CLOTTRIMAZOLE

CREAM;VAGINAL

GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990	Mar CAHN
	GYNE-LOTRIMIN 3				

+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998	Mar CAHN
---	-------------------------	---------	-----	--------------	----------

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN COMBINATION PACK

+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993	Mar CAHN
---	-------------------------------	---------	-----	--------------	----------

TABLET;VAGINAL

GYNE-LOTRIMIN

+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990	Mar CAHN
---	----------------------------	---------	-----	--------------	----------

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

	ACTAVIS LABS FL INC 30MG;600MG	A091070	001	Aug 31, 2015	Aug NEWA
	60MG;1.2GM	A091070	002	Aug 31, 2015	Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

	BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN
--	---	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

>A> TABLET, DELAYED RELEASE;ORAL

>A> NEXIUM 24HR

>A>	+	ASTRAZENECA LP EQ 20MG BASE	N207920	01	Nov 23, 2015	Nov NEWA
-----	---	-----------------------------	---------	----	--------------	----------

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr CAHN
	20MG	A090283	002	Nov 17, 2009	Apr CAHN
PEPCID AC					
J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995	Jul CAHN
+	20MG	N020325	002	Sep 23, 2003	Jul CAHN
PEPCID AC					
J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999	Aug CAHN
TABLET, CHEWABLE; ORAL					
PEPCID AC					
@ J AND J CONSUMER INC	10MG	N020801	001	Sep 24, 1998	Aug CAHN
+	20MG	N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug NEWA
	180MG	A204507	003	Sep 16, 2015	Aug NEWA
FEXOFENADINE HYDROCHLORIDE HIVES					
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug NEWA
	180MG	A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG; 120MG	A090818	001	Jan 29, 2015	Jan NEWA
-------------------	-------------	---------	-----	--------------	----------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug NEWA
---------------------	-------	---------	-----	--------------	----------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG; 60MG	A091071	001	May 27, 2015	May NEWA
	1.2GM; 120MG	A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
MIDOL LIQUID GELS					
+	BANNER LIFE SCIENCES 200MG	N021472	001	Oct 18, 2002	Jan CAHN
SUSPENSION; ORAL					
CHILDREN'S MOTRIN					
+	J AND J CONSUMER INC 100MG/5ML	N020516	001	Jun 16, 1995	Aug CAHN
SUSPENSION/DROPS; ORAL					
CHILDREN'S MOTRIN					
+	J AND J CONSUMER INC 40MG/ML	N020603	001	Jun 10, 1996	Aug CAHN
TABLET; ORAL					
IBUPROFEN					
@ ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987	Oct CAHN
@	200MG	A072901	001	Dec 19, 1991	Aug CAHN
@	200MG	A072903	001	Dec 19, 1991	Aug CAHN
JUNIOR STRENGTH MOTRIN					
J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug CAHN
MOTRIN IB					
+	J AND J CONSUMER INC 200MG	N019012	003	Dec 17, 1990	Aug CAHN
MOTRIN MIGRAINE PAIN					
+	J AND J CONSUMER INC 200MG	N019012	004	Feb 25, 2000	Aug CAHN
NUPRIN					
@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug CAHN
@	200MG	N019012	002	Jul 29, 1987	Aug CAHN
TABLET, CHEWABLE; ORAL					
CHILDREN'S MOTRIN					
J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug CAHN

TABLET, CHEWABLE;ORAL
JUNIOR STRENGTH MOTRIN

+ J AND J CONSUMER INC 100MG

N020601 003 Nov 15, 1996 Aug CAHN

IBUPROFEN SODIUM

TABLET;ORAL
IBUPROFEN SODIUM

PERRIGO R AND D EQ 200MG BASE

A206581 001 Aug 03, 2015 Jul NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL
CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC 100MG/5ML;15MG/5ML

N021128 001 Aug 01, 2000 Aug CAHN

TABLET;ORAL

SINE-AID IB

J AND J CONSUMER INC 200MG;30MG

N019899 001 Dec 31, 1992 Aug CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC
ALAWAY

BAUSCH AND LOMB EQ 0.035% BASE

N021996 002 Feb 11, 2015 Feb NEWA

LEVONORGESTREL

TABLET;ORAL
ATHENTIA NEXT

>A> AUROBINDO PHARMA LTD 1.5MG

A206867 001 Dec 08, 2015 Nov NEWA

LEVONORGESTREL

LOTUS PHARM CO LTD 1.5MG

A202246 001 Jun 05, 2015 May NEWA

OC PHARMA 1.5MG

A202380 001 May 29, 2015 May NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL
LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES 1MG

N021855 001 Aug 04, 2005 Jan CAHN

+ 2MG

N021855 002 Aug 04, 2005 Jan CAHN

SOLUTION;ORAL
IMODIUM A-D

+ J AND J CONSUMER INC 1MG/5ML

N019487 001 Mar 01, 1988 Aug CAHN

SUSPENSION;ORAL
IMODIUM A-D

+ J AND J CONSUMER INC 1MG/7.5ML

N019487 002 Jul 08, 2004 Aug CAHN

TABLET;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC 2MG

N019860 001 Nov 22, 1989 Aug CAHN

LOPERAMIDE HYDROCHLORIDE

>A> AUROBINDO PHARMA LTD 2MG

A206548 001 Dec 15, 2015 Nov NEWA

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997 Aug CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N021140 001 Nov 30, 2000 Aug CAHN

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD 2MG;125MG

A077500 001 Sep 06, 2006 Apr CAHN

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996 Aug CAHN

LORATADINE

CAPSULE;ORAL
CLARITIN

+ BAYER HEALTHCARE LLC 10MG

N021952 001 Jun 16, 2008 Mar CAHN

SYRUP;ORAL
CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML

N020641 002 Nov 27, 2002 Mar CAHN

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML

N020641 003 Nov 19, 2003 Mar CAHN

SYRUP;ORAL					
LORATADINE					
TARO	1MG/ML	A201865	001	Jul 31, 2015	Jul NEWA
TABLET;ORAL					
LORATADINE					
SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003	Apr CAHN
TABLET, CHEWABLE;ORAL					
CHILDREN'S CLARITIN					
+ BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar CAHN
TABLET, ORALLY DISINTEGRATING;ORAL					
CLARITIN REDITABS					
+ BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar CAHN
LORATADINE REDIDOSE					
SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL					
CLARITIN-D					
+ BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar CAHN
CLARITIN-D 24 HOUR					
+ BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar CAHN
LORATADINE AND PSEUDOEPHEDRINE SULFATE					
SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr CAHN

NAPROXEN SODIUM

CAPSULE;ORAL					
NAPROXEN SODIUM					
+ BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan CAHN
TABLET;ORAL					
NAPROXEN SODIUM					
SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL					
NICOTINE POLACRILEX					
@ IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar DISC
@	EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL					
OMEPRAZOLE MAGNESIUM					
PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015	Jul NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL					
ZEGERID OTC					
+ BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar CAHN
FOR SUSPENSION;ORAL					
ZEGERID OTC					
+ BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC					
OCUCLEAR					
BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL					
MIRALAX					
+ BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar CAHN
POLYETHYLENE GLYCOL 3350					
ANI PHARMS INC	17GM/SCOOPFUL	A202850	001	Dec 15, 2015	Nov NEWA
RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL					
PSEUDOEPHEDRINE HYDROCHLORIDE					
SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005	Apr CAHN
SUDAFED 24 HOUR					
+ J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992	Aug CAHN

>A>

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 75MG BASE
@ WOCKHARDT EQ 75MG BASE

A075132 001 Jan 14, 2000 Apr CAHN
A078884 001 Jul 31, 2008 Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER 2015

NO NOVEMBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO NOVEMBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	8664215	Dec 23, 2027	U-1493			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147 001	8062667	Mar 29, 2029	DP		NP	Oct 19, 2018
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREPITANT - EMEND</u>						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
>A>	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
>A>	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
>A>	9193685	Oct 24, 2033	DP U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	>A> 8071073	Jun 04, 2028	DP		>A> M-129	Aug 30, 2016
	>A> 8518919	Nov 22, 2025	U-1430		>A> NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
	>A> 9169238	Feb 25, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			
	>A> 9169238	Feb 25, 2030	DP			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	>A> 6753013	Jan 27, 2020	DP U-1761		NP	Oct 16, 2018
	9119781	Jun 10, 2031	DP U-1761			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88			
	6753013	Jan 27, 2020	DP U-193			
	6753013	Jan 27, 2020	DP U-1761			
	>A> 6787529	Jan 27, 2020	DP U-88			
	>A> 6787529	Jan 27, 2020	DP U-193			
	>A> 6787529	Jan 27, 2020	DP U-1761			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 002	>A> 6753013	Jan 27, 2020	DP U-1761			
	>A> 6787529	Jan 27, 2020	DP U-1761			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001					M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
	>A> 9155716	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BREXPIPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9144609	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - BUDESONIDE</u>						
A 201966 001					>A> PC	Jan 23, 2016
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9132093	Sep 07, 2031	DP			
	>A> 9192581	Sep 07, 2031	DP U-1325			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	>A> 6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	>A> 7579019	Jan 22, 2020	U-1769			
	>A> 8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	>A> 8629128	May 26, 2026	DP U-1280			
	>A> 8629128	May 26, 2026	DP U-1767			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	9089528	Jul 20, 2027	U-1469			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE</u>						
N 020958 001	>A> 5989588	Sep 30, 2017	DP U-349			
	>A> 5989588*PED	Mar 30, 2018				
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP ODE	Jan 09, 2018 Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CELECOXIB - CELECOXIB</u>						
A 078857	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857	004				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	002				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	003				PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562	004				PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323	001	6248363	Nov 23, 2019	DP U-1716		
		6383471	Apr 06, 2019	DP U-1716		
		9066942	Jan 03, 2032	U-1716		
		9107921	Jan 03, 2032	DP		
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768	001	8062667	Mar 29, 2029	DP		
		8790700	Mar 15, 2027	DP		
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	001				ODE	Mar 17, 2022
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750	002				ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658	002	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - ALVESCO</u>						
N 021658	003	8371292	Feb 01, 2028	U-1355		
<u>CICLESONIDE - OMNARIS</u>						
N 022004	001	8371292	Feb 01, 2028	U-1356		
<u>CICLESONIDE - ZETONNA</u>						
N 202129	001	8371292	Feb 01, 2028	U-1357		
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537	001	9149486	Sep 13, 2022	DP U-1578		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898	001				PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001	8962000	Aug 31, 2025	DP U-1410		
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395	001	5843946	Dec 01, 2015	DP U-1660		
		5843946*PED	Jun 01, 2016			
		7470506	Jun 23, 2019	U-1660		
		7470506*PED	Dec 23, 2019			
		7700645	Dec 26, 2026	DS DP		
		7700645*PED	Jun 26, 2027			
		8148374	Sep 03, 2029	DS DP U-1660		
		8518987	Feb 16, 2024	DS DP		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	>A> 5814639	Sep 29, 2015	DS DP		>A> NCE	Nov 05, 2020
	>A> 5814639*PED	Mar 29, 2017				
	>A> 5914331	Jul 02, 2017	DS			
	>A> 5914331*PED	Jan 02, 2018				
	>A> 6642245	Nov 04, 2020	U-257			
	>A> 6642245*PED	May 04, 2021				
	>A> 6703396	Mar 09, 2021	DS DP			
	>A> 7176220	Nov 20, 2023	DS DP U-257			
	>A> 7390791	May 07, 2022	DS DP			
	>A> 7635704	Oct 26, 2026	DS DP U-257			
	>A> 7800788	Feb 02, 2022	U-257			
	>A> 8148374	Sep 03, 2029	DS DP U-1279			
	>A> 8633219	Apr 24, 2030	DP U-257			
	>A> 8754065	Aug 15, 2032	DS DP U-257			
	>A> 8981103	Oct 26, 2026	DS DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	>A> 8633219	Apr 24, 2030	DP U-257		I-704	Dec 17, 2017
	8981103	Oct 26, 2026	DS DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 7803839	Feb 01, 2027	DS DP		>A> NCE	Nov 10, 2020
	>A> 8362002	Oct 05, 2026	U-1776			
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	>A> 9192590	Jan 26, 2027	U-1399			
	>A> 9198882	Jan 26, 2027	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	>A> 9192590	Jan 26, 2027	U-1399			
	>A> 9198882	Jan 26, 2027	U-1399			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	>A> 9192590	Jan 26, 2027	U-1399			
	>A> 9198882	Jan 26, 2027	U-1399			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9034822	Jan 20, 2031	U-1759		>A> M-168	Nov 20, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9034822	Jan 20, 2031	U-1759		>A> M-168	Nov 20, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	>A> 6087380	Feb 18, 2018	DS DP U-1089		>A> NS	Nov 20, 2018
	>A> 7866474	Aug 31, 2027	DP			
	>A> 7932273	Sep 07, 2025	DS DP			
	>A> 9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			
<u>DAKLINZA DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DAKLINZA DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001					M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002					M-157	Mar 11, 2018
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030		U-1687		
	9044480	Apr 10, 2031		U-1638		
	9139536	Nov 09, 2028		U-1753		
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021		U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021		U-735	NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP	U-735	ODE	Oct 14, 2016
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP	U-1690		
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025		U-1690		
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP	U-1412		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
>A>	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
>A>	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
>A>	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
>A>	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	>A> 9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	9155718	Jan 17, 2022	DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					M-166	Jul 30, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9107898	May 01, 2028	DP U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9107898	May 01, 2028	DP U-620			
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160	Jun 26, 2018
					M-161	Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160	Jun 26, 2018
					M-161	Jun 26, 2018
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
>A>	9173859	May 04, 2027	DP U-1772			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
>A>	9173859	May 04, 2027	DP U-1772			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
>A>	9173859	May 04, 2027	DP U-1772			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Aug 09, 2022	DS DP U-257			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					M-162	Sep 24, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	9107912	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001 >A>	9173847	Oct 01, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002 >A>	9173847	Oct 01, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001 >A>	5697896	Dec 16, 2016	DP			
	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	>A> 9095706	Feb 03, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001 >A>	9187405	Jun 25, 2027	U-1086			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001	7169401	Jul 18, 2023	DP		NP	Sep 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001 >A>	7270800	Apr 14, 2027	DS DP U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002 >A>	7270800	Apr 14, 2027	DS DP U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GEFITINIB - IRESSA</u>						
N 206995 001	5770599	May 05, 2017	DS DP U-1755		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
	9155776	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9095559	Mar 09, 2032	U-1383			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001 >A>	6521260	Jan 31, 2016	DP		>A> NP	Oct 29, 2018
	>A> 6528678	Apr 24, 2018	DP			
	>A> 7229607	Apr 09, 2021	U-1773			
	>A> 7736670	Jun 27, 2021	DP			
	>A> 8029768	Apr 09, 2021	U-1773			
	>A> 8048451	Jun 27, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	>A> 8182838	Oct 20, 2028	DP			
	>A> 8303991	Jun 27, 2021	DP			
	>A> 8435567	Jun 27, 2021	DP			
	>A> 8479730	Oct 11, 2028	DP			
	>A> 8580306	Jun 27, 2021	DP			
	>A> 8956661	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	>A> 6521260	Jan 31, 2016	DP		>A> NP	Oct 29, 2018
	>A> 6582678	Apr 24, 2018	DP			
	>A> 6878721	Oct 10, 2020	DS DP U-1773			
	>A> 7229607	Apr 09, 2021	U-1773			
	>A> 7736670	Jun 27, 2021	DP			
	>A> 7820694	Jun 02, 2020	DP U-1773			
	>A> 8029768	Apr 09, 2021	U-1773			
	>A> 8048451	Jun 27, 2021	DP			
	>A> 8067437	Jun 02, 2020	U-1773			
	>A> 8182838	Oct 20, 2028	DP			
	>A> 8283362	Jun 02, 2020	DP U-1773			
	>A> 8303991	Jun 27, 2021	DP			
	>A> 8435567	Jun 27, 2021	DP			
	>A> 8479730	Oct 11, 2028	DP			
	>A> 8580306	Jun 27, 2021	DP			
	>A> 8658673	Jun 02, 2020	DP U-1773			
	>A> 8796307	Jun 02, 2020	DP			
	>A> 8956661	Jun 27, 2021	DP			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001	>A> 8962028	Jun 19, 2033	DP U-1775			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9132096	Sep 12, 2034	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021			U-1556	
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027			U-1556	
	9095615	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
>A>	9181257	Dec 28, 2026	DS DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599		>A> D-152	Nov 20, 2018
	9012508	Sep 14, 2030	U-981		>A> NPP	Nov 20, 2018
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			
>A>	8796307	Jun 02, 2020	DS DP			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001 >A>	8377919	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002 >A>	8377919	Dec 18, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	7943572	Aug 10, 2026	U-1539			
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029	U-1537			
	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	>A> 8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	>A> 8329213	May 02, 2025	DS DP			
	>A> 8703181	May 02, 2025	U-1434			
	>A> 8992970	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE GAIN GAIN	Mar 06, 2022 Mar 06, 2025 Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001 >A>	7442830	Aug 06, 2027	DS DP U-1780		>A> NCE	Nov 20, 2020
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002 >A>	7442830	Aug 06, 2027	DS DP U-1780		>A> NCE	Nov 20, 2020
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003 >A>	7442830	Aug 06, 2027	DS DP U-1780		>A> NCE	Nov 20, 2020
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMDRIA</u>						
N 205388 001	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	>A> 5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	>A> 5905082*PED	Nov 18, 2016				
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	9144547	Sep 22, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
	>A> 9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
	>A> 9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9085573	Mar 21, 2028	DS DP U-1470		>A> D-153	Nov 12, 2018
					>A> I-718	Nov 12, 2018
					>A> I-719	Nov 12, 2018
					>A> I-720	Nov 12, 2018
					>A> NPP	Nov 12, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP	U-1666		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
	>A> 9173859	May 04, 2027	DP U-1503			
	>A> 9173859	May 04, 2027	DP U-1768			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP U-1503			
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
>A>	9169213	Dec 06, 2032	U-1762			
>A>	9169213	Dec 06, 2032	U-1763			
>A>	9169213	Dec 06, 2032	U-1764			
>A>	9169213	Dec 06, 2032	U-1765			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001 >A>	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002 >A>	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003 >A>	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004 >A>	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005 >A>	9174975	Jun 25, 2026	U-1770			
	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001					NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002					NP	Oct 22, 2018
<u>MESALAMINE - CANASA</u>						
N 021252 002 >A>	8217083	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	9089492	Nov 15, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001 >A>	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002 >A>	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003 >A>	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
>A>	9198858	Jun 28, 2032	U-1664			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028	U-1643			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP	U-1185		
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP	U-1185		
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	>A> 9211253	Mar 16, 2035	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP	U-1556		
	9056051	May 10, 2022	DP	U-1556		
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP	U-1556		
	9161937	May 10, 2022	DP	U-1556		
	9168252	May 10, 2022	DP	U-1556		
>A>	9205082	May 10, 2022	DP	U-1556		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP	U-1556		
	9056051	May 10, 2022	DP	U-1556		
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP	U-1556		
	9161937	May 10, 2022	DP	U-1556		
	9168252	May 10, 2022	DP	U-1556		
>A>	9205082	May 10, 2022	DP	U-1556		
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP	U-1556		
	9056051	May 10, 2022	DP	U-1556		
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP	U-1556		
	9161937	May 10, 2022	DP	U-1556		
	9168252	May 10, 2022	DP	U-1556		
>A>	9205082	May 10, 2022	DP	U-1556		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
	>A> 9186357	Nov 18, 2030	U-528			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1703			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
					PED	Jul 30, 2018
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	>A> 5840737	Jul 15, 2016	U-1025			
	>A> 6780882	Jul 15, 2016	DP			
	>A> 7399772	Jul 15, 2016	U-1025			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	9095577	Jul 13, 2030	DP			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	>A> 5840684	Nov 24, 2016	DS DP U-1569			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Aug 23, 2016	DS DP U-1113			
	5763483*PED	Feb 23, 2017				
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	>A> 8946235	Aug 08, 2032	DS DP U-1777		>A> NCE	Nov 13, 2020
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	>A> 8946235	Aug 08, 2032	DS DP U-1777		>A> NCE	Nov 13, 2020
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	>A> 7820788	Oct 27, 2024	DP U-1092			
	>A> 7820788	Oct 27, 2024	DP U-1290			
	>A> 7820788	Oct 27, 2024	DP U-1434			
	>A> 8853260	Oct 10, 2020	DP U-1092			
	>A> 8853260	Oct 10, 2020	DP U-1290			
	>A> 8853260	Oct 10, 2020	DP U-1434			
	9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
	9173942	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9125905	Jan 30, 2024	DP			
	9173942	Jan 30, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	>A> 7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	>A> 8147873	Mar 11, 2026	DP			
	>A> 8216560	Mar 14, 2027	U-1766			
	>A> 8282913	Mar 11, 2026	DP			
	>A> 8287847	Mar 30, 2024	U-1766			
	>A> 8337824	May 29, 2030	DS U-1766			
	>A> 8475780	Mar 30, 2024	U-1766			
	>A> 8778324	Mar 30, 2024	U-1766			
	>A> 8889115	Mar 30, 2024	U-1766			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	>A> 7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	>A> 8147873	Mar 11, 2026	DP			
	>A> 8216560	Mar 14, 2027	U-1766			
	>A> 8282913	Mar 11, 2026	DP			
	>A> 8287847	Mar 30, 2024	U-1766			
	>A> 8337824	May 29, 2030	DS U-1766			
	>A> 8475780	Mar 30, 2024	U-1766			
	>A> 8778324	Mar 30, 2024	U-1766			
	>A> 8889115	Mar 30, 2024	U-1766			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	>A> 7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	>A> 8147873	Mar 11, 2026	DP			
	>A> 8216560	Mar 14, 2027	U-1766			
	>A> 8282913	Mar 11, 2026	DP			
	>A> 8287847	Mar 30, 2024	U-1766			
	>A> 8337824	May 29, 2030	DS U-1766			
	>A> 8475780	Mar 30, 2024	U-1766			
	>A> 8778324	Mar 30, 2024	U-1766			
	>A> 8889115	Mar 30, 2024	U-1766			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	RE40640	Oct 14, 2016	DS DP	U-1462		
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
>A>	9186332	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
>A>	9186332	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
>A>	9186332	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Aug 09, 2022	DS DP U-1153		NPP	Aug 26, 2018
	7125879	Aug 09, 2022	DS DP U-1307			
	7125879	Aug 09, 2022	DS DP U-1740			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403 003					PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	>A> 7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	>A> 7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Oct 09, 2029	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	>A> 6858618	Dec 17, 2021	U-618		>A> NPP	Nov 20, 2018
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	>A> 6858618	Dec 17, 2021	U-618		>A> NPP	Nov 20, 2018
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	>A> 6858618	Dec 17, 2021	U-618		>A> NPP	Nov 20, 2018
	>A> 6858618	Dec 17, 2021	U-1032			
	>A> 6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					>A> NPP	Nov 20, 2018
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	>A> 7566714	Nov 17, 2024	U-1589			
	>A> 7566714*PED	May 17, 2025				
	>A> 7612073	Nov 17, 2024	U-1010			
	>A> 8067416	Nov 17, 2024	U-1589			
	>A> 8067416*PED	May 17, 2025				
	>A> RE43797	Nov 17, 2024	U-1590			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467		D-151 I-717	Oct 05, 2018 Oct 05, 2018
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPPO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUMATRIPTAN SUCCINATE - ZECURITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
>A>	9161907	Aug 30, 2024	DP U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
>A>	9161907	Aug 30, 2024	DP U-1752			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
>A>	9161907	Aug 30, 2024	DP U-1752			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1739			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
	>A> 9180194	Jun 02, 2026	U-1390			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-714	Sep 03, 2018
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171		NS	Sep 03, 2018
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 027981 001	5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	6479500	Mar 16, 2020	U-1751			
	7799783	Dec 16, 2026	U-1751			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 027981 002	5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	6479500	Mar 16, 2020	U-1751			
	7799783	Dec 16, 2026	U-1751			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001 >A>	8895557	Jan 07, 2028	DP		NCE	Oct 23, 2020
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
	>A> 9155706	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
	>A> 9155706	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP			
	9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001 >A>	9199908	May 24, 2024	U-1771			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002 >A>	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003 >A>	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004 >A>	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8512745	Jun 02, 2030	DP			
	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2018	DP		NCE ODE	Sep 04, 2020 Sep 04, 2022
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 11 - November 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003					NPP	Jun 12, 2018
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 004					NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>